{"matching_results": 31048, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1593, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1330}, {"key": "negative", "matching_results": 247}, {"key": "neutral", "matching_results": 16}]}]}, {"key": "thelincolnianonline.com", "matching_results": 813, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 666}, {"key": "negative", "matching_results": 147}]}]}, {"key": "watchlistnews.com", "matching_results": 812, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 676}, {"key": "negative", "matching_results": 136}]}]}, {"key": "tickerreport.com", "matching_results": 806, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 721}, {"key": "negative", "matching_results": 84}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 803, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 712}, {"key": "negative", "matching_results": 91}]}]}, {"key": "dailypolitical.com", "matching_results": 763, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 671}, {"key": "negative", "matching_results": 91}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 660, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 557}, {"key": "negative", "matching_results": 101}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "marketscreener.com", "matching_results": 539, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 366}, {"key": "negative", "matching_results": 169}, {"key": "neutral", "matching_results": 4}]}]}, {"key": "freelancer.com.co", "matching_results": 514, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 469}, {"key": "negative", "matching_results": 39}, {"key": "neutral", "matching_results": 6}]}]}, {"key": "zolmax.com", "matching_results": 443, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 383}, {"key": "negative", "matching_results": 60}]}]}]}], "results": [{"id": "v8980neB09_ngNvp6yxqFQA54JUQmRlrjtVy0N9uUGMeJ3wOyRkxEa8T6yp4EhAL", "result_metadata": {"score": 37.594555}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.421844, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Trade", "relevance": 0.838718, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Capitalism", "relevance": 0.751422, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}], "categories": [{"score": 0.61827, "label": "/health and fitness/disease/cancer"}, {"score": 0.458408, "label": "/health and fitness/disease/cholesterol"}, {"score": 0.421783, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Orally Disintegrating Tablets", "sentiment": {"score": -0.421844, "label": "negative"}, "relevance": 0.924441}, {"text": "Peptide-Based Therapeutics", "sentiment": {"score": -0.421844, "label": "negative"}, "relevance": 0.392614}, {"text": "Protein", "sentiment": {"score": -0.421844, "label": "negative"}, "relevance": 0.215008}]}, "crawl_date": "2018-11-06T20:41:11Z", "url": "https://www.findmarketresearch.org/2018/11/protein-and-peptide-based-therapeutics-trending-the-global-orally-disintegrating-tablets-market-2/", "host": "findmarketresearch.org", "text": "Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T05:27:00+05:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.469403, "label": "negative"}, "text": "Persistence Market Research", "relevance": 0.46327, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regional Forecast", "relevance": 0.160863, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": -0.54819, "label": "negative"}, "text": "North America", "relevance": 0.124478, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 3, "sentiment": {"score": -0.292714, "label": "negative"}, "text": "Hospital Pharmacies", "relevance": 0.120214, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.113745, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergy", "relevance": 0.109705, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Allergy", "dbpedia_resource": "http://dbpedia.org/resource/Allergy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.107436, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. Reddy\u2019s Laboratories Ltd", "relevance": 0.10501, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.100916, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.100756, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.223483, "label": "negative"}, "text": "Bayer AG", "relevance": 0.100055, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unichem Laboratories", "relevance": 0.0985544, "type": "Company", "disambiguation": {"subtype": [], "name": "Unichem Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Unichem_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zydus Cadila", "relevance": 0.0965412, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.0959078, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEOS Therapeutics, Inc.", "relevance": 0.0931936, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.0901789, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0897461, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0895244, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.238398, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.0885353, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant", "relevance": 0.0883053, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sun Pharmaceutical Industries Ltd.", "relevance": 0.0873689, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.0871349, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Services, Inc.", "relevance": 0.0857349, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0849841, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.0849805, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.0832016, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "F. Hoffmann-La Roche Ltd.", "relevance": 0.0826692, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan N.V.", "relevance": 0.07911, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glenmark", "relevance": 0.0782954, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0760106, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "eight year", "relevance": 0.0760106, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "13.2%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.5%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.7%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "15.7%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "49%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "55%", "relevance": 0.0760106, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0760106, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.478324, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a new report", "keywords": [{"text": "new report"}]}, "sentence": "In a new report titled \u2018Orally Disintegrating Tablets Market: Global Industry Analysis 2012 \u2013 2016 and Forecast 2017 \u2013 2025,\u2019 Persistence Market Research studies the performance of the global orally disintegrating tablets market over an eight year period from 2017 to 2025 and presents a detailed forecast of the market both for the historical period 2012 \u2013 2016 as well as for the forecasted period of 2017 \u2013 2025.", "object": {"text": "\u2018Orally Disintegrating Tablets Market", "keywords": [{"text": "\u2018Orally Disintegrating Tablets"}, {"text": "Market"}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}, {"subject": {"text": "tablets", "keywords": [{"text": "tablets"}]}, "sentence": " According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "action": {"verb": {"text": "disintegrate", "tense": "present"}, "text": "disintegrating", "normalized": "disintegrate"}}, {"subject": {"text": "orally disintegrating tablets", "keywords": [{"text": "orally disintegrating tablets"}]}, "sentence": " According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "object": {"text": "the scope for dosage errors", "keywords": [{"text": "dosage errors"}, {"text": "scope"}]}, "action": {"verb": {"text": "minimize", "tense": "present"}, "text": "minimize", "normalized": "minimize"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors are likely to boost revenue growth of the global orally disintegrating tablets market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value during the forecast period.", "object": {"text": "revenue growth of the global", "keywords": [{"text": "revenue growth"}], "entities": []}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "tablets market", "keywords": [{"text": "tablets market"}]}, "sentence": " These factors are likely to boost revenue growth of the global orally disintegrating tablets market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value during the forecast period.", "object": {"text": "anticipated to rise from an estimated US$ 11.4 Bn", "keywords": [{"text": "Bn"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a CAGR of 11.5% in terms of value", "keywords": [{"text": "CAGR"}, {"text": "terms"}, {"text": "value"}], "entities": [{"type": "Quantity", "text": "11.5"}]}, "sentence": " These factors are likely to boost revenue growth of the global orally disintegrating tablets market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value during the forecast period.", "action": {"verb": {"text": "witness", "tense": "present"}, "text": "witnessing", "normalized": "witness"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " In this report, Persistence Market Research segments the global orally disintegrating tablets market on the basis of drug class, disease indication, distribution channel, and region.", "object": {"text": "the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "segment", "tense": "present"}, "text": "segments", "normalized": "segment"}}, {"subject": {"text": "by Drug Class", "keywords": [{"text": "Drug Class"}]}, "sentence": " Global Orally Disintegrating Tablets Market, Forecast by Drug Class", "object": {"text": "Global Orally Disintegrating Tablets Market", "keywords": [{"text": "Orally Disintegrating Tablets"}, {"text": "Market"}], "entities": []}, "action": {"verb": {"text": "Forecast", "tense": "past"}, "text": "Forecast", "normalized": "Forecast"}}, {"subject": {"text": "the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "market"}], "entities": []}, "sentence": " In terms of drug class, the global orally disintegrating tablets market is further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, and Others.", "object": {"text": "further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS", "keywords": [{"text": "CNS Stimulants"}, {"text": "Anti-Parkinsonian Drugs"}, {"text": "NSAIDS"}, {"text": "Anti-Psychotics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "market"}], "entities": []}, "sentence": " In terms of drug class, the global orally disintegrating tablets market is further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, and Others.", "object": {"text": "into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS", "keywords": [{"text": "CNS Stimulants"}, {"text": "Anti-Parkinsonian Drugs"}, {"text": "NSAIDS"}, {"text": "Anti-Psychotics"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is further segmented", "normalized": "be further segment"}}, {"subject": {"text": "Anti-Psychotics drug class", "keywords": [{"text": "Anti-Psychotics drug class"}]}, "sentence": " Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20% revenue share of the global market by 2025 end.", "object": {"text": "the reigning segment", "keywords": [{"text": "segment"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Anti-Psychotics drug class", "keywords": [{"text": "Anti-Psychotics drug class"}]}, "sentence": " Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20% revenue share of the global market by 2025 end.", "object": {"text": "to hold about 20% revenue share of the global market by 2025 end", "keywords": [{"text": "revenue share"}, {"text": "global market"}, {"text": "end"}], "entities": [{"type": "Quantity", "text": "20"}]}, "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "anticipated", "normalized": "anticipate"}}, {"subject": {"text": "about 20% revenue share of the global market", "keywords": [{"text": "revenue share"}, {"text": "global market"}], "entities": [{"type": "Quantity", "text": "20"}]}, "sentence": " Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20% revenue share of the global market by 2025 end.", "action": {"verb": {"text": "hold", "tense": "future"}, "text": "anticipated to hold", "normalized": "anticipate to hold"}}, {"subject": {"text": "this segment", "keywords": [{"text": "segment"}]}, "sentence": " With a noteworthy 15.7% CAGR, this segment will retain its supremacy over other drug class segments during the eight year period.", "object": {"text": "its supremacy over other drug class segments", "keywords": [{"text": "drug class segments"}, {"text": "supremacy"}]}, "action": {"verb": {"text": "retain", "tense": "future"}, "text": "will retain", "normalized": "will retain"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "object": {"text": "segmented into Central Nervous System", "keywords": [{"text": "Central Nervous"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "object": {"text": "into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others", "keywords": [{"text": "Central Nervous"}, {"text": "GI"}, {"text": "Gastrointestinal"}, {"text": "Allergy"}], "entities": [{"type": "HealthCondition", "text": "Allergy", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Allergy", "dbpedia_resource": "http://dbpedia.org/resource/Allergy"}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "CNS Diseases segment", "keywords": [{"text": "CNS Diseases segment"}], "entities": []}, "sentence": " CNS Diseases segment will hold maximum revenue share in the global market, and Persistence Market Research forecasts indicate a 55% market share for this segment by the end of the forecast period in 2025.", "object": {"text": "maximum revenue share", "keywords": [{"text": "maximum revenue share"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "will hold", "normalized": "will hold"}}, {"subject": {"text": "Persistence Market Research forecasts", "keywords": [{"text": "Persistence Market Research"}, {"text": "forecasts"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " CNS Diseases segment will hold maximum revenue share in the global market, and Persistence Market Research forecasts indicate a 55% market share for this segment by the end of the forecast period in 2025.", "object": {"text": "a 55% market share for this segment by the end of the forecast period in 2025", "keywords": [{"text": "forecast period"}, {"text": "market share"}, {"text": "segment"}, {"text": "end"}], "entities": [{"type": "Quantity", "text": "55"}]}, "action": {"verb": {"text": "indicate", "tense": "present"}, "text": "indicate", "normalized": "indicate"}}, {"subject": {"text": "The CNS Diseases segment", "keywords": [{"text": "CNS Diseases segment"}]}, "sentence": " The CNS Diseases segment is forecasted to reach a market valuation of about US$ 15 Bn by 2025 end, registering a CAGR of 13.2%.", "object": {"text": "forecasted"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The CNS Diseases segment", "keywords": [{"text": "CNS Diseases segment"}]}, "sentence": " The CNS Diseases segment is forecasted to reach a market valuation of about US$ 15 Bn by 2025 end, registering a CAGR of 13.2%.", "object": {"text": "a market valuation of about US$ 15 Bn", "keywords": [{"text": "market valuation"}, {"text": "Bn"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is forecasted to reach", "normalized": "be forecast to reach"}}, {"subject": {"text": "This"}, "sentence": " This is slated to be the most dominant segment by disease indication in the global orally disintegrating tablets market.", "object": {"text": "to be the most dominant segment by disease indication in the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "dominant segment"}, {"text": "disease indication"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "slate", "tense": "past"}, "text": "slated", "normalized": "slate"}}, {"subject": {"text": "This"}, "sentence": " This is slated to be the most dominant segment by disease indication in the global orally disintegrating tablets market.", "object": {"text": "the most dominant segment", "keywords": [{"text": "dominant segment"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is slated to be", "normalized": "be slate to be"}}, {"subject": {"text": "by Distribution Channel", "keywords": [{"text": "Distribution Channel"}]}, "sentence": " Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel", "object": {"text": "Global Orally Disintegrating Tablets Market", "keywords": [{"text": "Orally Disintegrating Tablets"}, {"text": "Market"}], "entities": []}, "action": {"verb": {"text": "Forecast", "tense": "past"}, "text": "Forecast", "normalized": "Forecast"}}, {"subject": {"text": "Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies", "keywords": [{"text": "Hospital Pharmacies"}, {"text": "Retail Pharmacies"}, {"text": "Online Pharmacies"}, {"text": "Drug Stores"}], "entities": [{"type": "Company", "text": "Hospital Pharmacies"}, {"type": "Company", "text": "Hospital Pharmacies"}]}, "sentence": " Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "object": {"text": "the undisputed leader in terms of market share", "keywords": [{"text": "undisputed leader"}, {"text": "market share"}, {"text": "terms"}], "entities": [{"type": "Company", "text": "Hospital Pharmacies"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies", "keywords": [{"text": "Hospital Pharmacies"}, {"text": "Retail Pharmacies"}, {"text": "Online Pharmacies"}, {"text": "Drug Stores"}], "entities": [{"type": "Company", "text": "Hospital Pharmacies"}, {"type": "Company", "text": "Hospital Pharmacies"}]}, "sentence": " Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "object": {"text": "for nearly 49% value share", "keywords": [{"text": "value"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "49"}]}, "action": {"verb": {"text": "account", "tense": "future"}, "text": "anticipated to account", "normalized": "anticipate to account"}}, {"subject": {"text": "a 13.2% CAGR", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "13.2"}]}, "sentence": " A market valuation of about US$ 13 Bn by the end of 2025 with a 13.2% CAGR is likely to be in store for this segment.", "object": {"text": "in store", "keywords": [{"text": "store"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "to be", "normalized": "to be"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "object": {"text": "the performance of the global", "keywords": [{"text": "performance"}], "entities": []}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "tracks", "normalized": "track"}}, {"subject": {"text": "tablets market", "keywords": [{"text": "tablets market"}]}, "sentence": " Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "action": {"verb": {"text": "disintegrate", "tense": "present"}, "text": "disintegrating", "normalized": "disintegrate"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is slated to dominate the global market throughout the forecast period, with an estimated 35% market share and a market value of about US$ 9.7 Bn by the end of 2025.", "object": {"text": "to dominate the global market throughout the forecast period", "keywords": [{"text": "forecast period"}, {"text": "global market"}], "entities": []}, "action": {"verb": {"text": "slate", "tense": "past"}, "text": "slated", "normalized": "slate"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is slated to dominate the global market throughout the forecast period, with an estimated 35% market share and a market value of about US$ 9.7 Bn by the end of 2025.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "is slated to dominate", "normalized": "be slate to dominate"}}, {"subject": {"text": "This"}, "sentence": " This is reflective of a CAGR of 11.7% during the forecast period.", "object": {"text": "reflective of a CAGR of 11.7%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "11.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "object": {"text": "some of the leading companies operating", "keywords": [{"text": "leading companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "tablets market", "keywords": [{"text": "tablets market"}]}, "sentence": " The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "object": {"text": "Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories", "keywords": [{"text": "F. Hoffmann-La Roche"}, {"text": "Sun Pharmaceutical Industries"}, {"text": "Novartis AG"}, {"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Mylan N.V."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Johnson & Johnson Services, Inc."}, {"type": "Company", "text": "F. Hoffmann-La Roche Ltd."}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Valeant", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Sun Pharmaceutical Industries Ltd."}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Dr. Reddy\u2019s Laboratories Ltd"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Person", "text": "Zydus Cadila"}, {"type": "Company", "text": "NEOS Therapeutics, Inc."}, {"type": "Company", "text": "Glenmark"}, {"type": "Company", "text": "Unichem Laboratories", "disambiguation": {"subtype": [], "name": "Unichem Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Unichem_Laboratories"}}]}, "action": {"verb": {"text": "disintegrate", "tense": "present"}, "text": "disintegrating", "normalized": "disintegrate"}}], "concepts": [{"text": "Pharmaceutical industry", "relevance": 0.985571, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.950517, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmacology", "relevance": 0.832126, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Marketing", "relevance": 0.770259, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Pharmacy", "relevance": 0.733392, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.723336, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Pharmaceutical drug", "relevance": 0.523567, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5005, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Marketing research", "relevance": 0.498465, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}, {"text": "Distribution", "relevance": 0.479146, "dbpedia_resource": "http://dbpedia.org/resource/Distribution_(business)"}, {"text": "Central nervous system", "relevance": 0.457546, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "GlaxoSmithKline", "relevance": 0.456334, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Novartis", "relevance": 0.449572, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Years in the future", "relevance": 0.433765, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Generic drug", "relevance": 0.406678, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Hoffmann-La Roche", "relevance": 0.398497, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Benzodiazepine", "relevance": 0.382101, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Periodization", "relevance": 0.38104, "dbpedia_resource": "http://dbpedia.org/resource/Periodization"}, {"text": "Revenue", "relevance": 0.379283, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}], "categories": [{"score": 0.506141, "label": "/health and fitness"}, {"score": 0.503855, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.490004, "label": "/health and fitness/disease"}], "relations": [{"type": "partOf", "sentence": "In a new report titled \u02bbOrally Disintegrating Tablets Market: Global Industry Analysis 2012 - 2016 and Forecast 2017 - 2025,' Persistence Market Research studies the performance of the global orally disintegrating tablets market over an eight year period from 2017 to 2025 and presents a detailed forecast of the market both for the historical period 2012 - 2016 as well as for the forecasted period of 2017 - 2025. According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "score": 0.521024, "arguments": [{"text": "Global Industry Analysis", "location": [62, 86], "entities": [{"type": "Organization", "text": "Global Industry Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Disintegrating Tablets Market", "location": [31, 60], "entities": [{"type": "Organization", "text": "Disintegrating Tablets Market"}]}]}, {"type": "managerOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "score": 0.67108, "arguments": [{"text": "leader", "location": [2947, 2953], "entities": [{"type": "Person", "text": "Persistence Market"}]}, {"text": "Hospital Pharmacies", "location": [2904, 2923], "entities": [{"type": "Organization", "text": "Hospital Pharmacies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global Orally Disintegrating Tablets Market, Regional Forecast Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "score": 0.742459, "arguments": [{"text": "Persistence Market", "location": [3262, 3280], "entities": [{"type": "Person", "text": "Persistence Market"}]}, {"text": "Regional Forecast", "location": [3244, 3261], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Orally Disintegrating Tablets Market, Regional Forecast Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "score": 0.684628, "arguments": [{"text": "Asia", "location": [3432, 3436], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3437, 3444], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "employedBy", "sentence": "Request to Sample Report @ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.580883, "arguments": [{"text": "Sample Report", "location": [3729, 3742], "entities": [{"type": "Person", "text": "Sample Report"}]}, {"text": "Global Orally Disintegrating Tablets Market", "location": [3801, 3844], "entities": [{"type": "Organization", "text": "Global Orally Disintegrating Tablets Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Request to Sample Report @ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.499897, "arguments": [{"text": "Teva Pharmaceutical Industries Ltd.", "location": [3982, 4017], "entities": [{"type": "Organization", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3903, 3912], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Request to Sample Report @ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.505642, "arguments": [{"text": "Novartis AG", "location": [4019, 4030], "entities": [{"type": "Organization", "text": "Novartis AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3903, 3912], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Request to Sample Report @ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.338681, "arguments": [{"text": "Reddy", "location": [4254, 4259], "entities": [{"type": "Person", "text": "Reddy"}]}, {"text": "Laboratories Ltd", "location": [4262, 4278], "entities": [{"type": "Organization", "text": "Laboratories Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "In a new report titled \u02bbOrally Disintegrating Tablets Market: Global Industry Analysis 2012 - 2016 and Forecast 2017 - 2025,' Persistence Market Research studies the performance of the global orally disintegrating tablets market over an eight year period from 2017 to 2025 and presents a detailed forecast of the market both for the historical period 2012 - 2016 as well as for the forecasted period of 2017 - 2025. According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "score": 0.61113, "arguments": [{"text": "patients", "location": [807, 815], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "groups", "location": [827, 833], "entities": [{"type": "Person", "text": "groups"}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Drug Class In terms of drug class, the global orally disintegrating tablets market is further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, and Others.", "score": 0.429244, "arguments": [{"text": "Drug Class", "location": [1355, 1365], "entities": [{"type": "Organization", "text": "Drug Class", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Forecast", "location": [1343, 1351], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.558207, "arguments": [{"text": "Disease Indication", "location": [2021, 2039], "entities": [{"type": "Organization", "text": "Disease Indication"}]}, {"text": "Forecast", "location": [2009, 2017], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.500095, "arguments": [{"text": "CNS", "location": [2121, 2124], "entities": [{"type": "Organization", "text": "CNS Stimulants", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Central Nervous System", "location": [2097, 2119], "entities": [{"type": "Organization", "text": "Central Nervous System"}]}]}, {"type": "hasAttribute", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.837419, "arguments": [{"text": "Gastrointestinal", "location": [2136, 2152], "entities": [{"type": "Person", "text": "Gastrointestinal"}]}, {"text": "Diseases", "location": [2158, 2166], "entities": [{"type": "HealthCondition", "text": "Diseases"}]}]}, {"type": "hasAttribute", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.696635, "arguments": [{"text": "Gastrointestinal", "location": [2136, 2152], "entities": [{"type": "Person", "text": "Gastrointestinal"}]}, {"text": "Allergy", "location": [2199, 2206], "entities": [{"type": "HealthCondition", "text": "Allergy"}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.461439, "arguments": [{"text": "Cardiovascular", "location": [2168, 2182], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}, {"text": "CVS", "location": [2184, 2187], "entities": [{"type": "Organization", "text": "CVS", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "score": 0.497412, "arguments": [{"text": "Distribution Channel", "location": [2731, 2751], "entities": [{"type": "Organization", "text": "Distribution Channel", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Forecast", "location": [2719, 2727], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "orally disintegrating tablets", "sentiment": {"score": -0.505917, "label": "negative"}, "relevance": 0.97204}, {"text": "tablets market", "sentiment": {"score": -0.49123, "label": "negative"}, "relevance": 0.718847}, {"text": "Global Orally Disintegrating", "sentiment": {"score": -0.529513, "label": "negative"}, "relevance": 0.631166}, {"text": "Disintegrating Tablets Market", "sentiment": {"score": -0.529513, "label": "negative"}, "relevance": 0.616602}, {"text": "Persistence Market Research", "sentiment": {"score": -0.469403, "label": "negative"}, "relevance": 0.604573}, {"text": "forecast period", "sentiment": {"score": -0.0758052, "label": "negative"}, "relevance": 0.539635}, {"text": "drug class", "sentiment": {"score": -0.444069, "label": "negative"}, "relevance": 0.502408}, {"text": "CNS Diseases segment", "sentiment": {"score": -0.567536, "label": "negative"}, "relevance": 0.478776}, {"text": "global market", "sentiment": {"score": -0.496604, "label": "negative"}, "relevance": 0.478683}, {"text": "disease indication", "sentiment": {"score": -0.688221, "label": "negative"}, "relevance": 0.470032}, {"text": "Pharmaceutical Industries Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463455}, {"text": "market share", "sentiment": {"score": -0.509426, "label": "negative"}, "relevance": 0.461042}, {"text": "revenue share", "sentiment": {"score": -0.479519, "label": "negative"}, "relevance": 0.457905}, {"text": "market revenue share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457568}, {"text": "tablets viz.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457305}, {"text": "Global Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455013}, {"text": "market valuation", "sentiment": {"score": -0.579921, "label": "negative"}, "relevance": 0.447076}, {"text": "Anti-Psychotics drug class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442937}, {"text": "distribution channel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442873}, {"text": "maximum revenue share", "sentiment": {"score": -0.555152, "label": "negative"}, "relevance": 0.442633}, {"text": "drug class segments", "sentiment": {"score": -0.260101, "label": "negative"}, "relevance": 0.442468}, {"text": "Proton Pump Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440698}, {"text": "North America", "sentiment": {"score": -0.54819, "label": "negative"}, "relevance": 0.439472}, {"text": "Hospital Pharmacies", "sentiment": {"score": -0.292714, "label": "negative"}, "relevance": 0.438642}, {"text": "Teva Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438225}, {"text": "Regional Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438051}, {"text": "Hoffmann-La Roche Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437799}, {"text": "various distribution channels", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437642}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43751}, {"text": "Sun Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437094}, {"text": "market value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431608}, {"text": "dominant segment", "sentiment": {"score": -0.800445, "label": "negative"}, "relevance": 0.430573}, {"text": "end", "sentiment": {"score": -0.48724, "label": "negative"}, "relevance": 0.430205}, {"text": "Bn", "sentiment": {"score": -0.497123, "label": "negative"}, "relevance": 0.430108}, {"text": "historical period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429765}, {"text": "assessment period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429468}, {"text": "CNS Stimulants", "sentiment": {"score": -0.301306, "label": "negative"}, "relevance": 0.428127}, {"text": "revenue growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426419}, {"text": "new report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425637}, {"text": "age groups", "sentiment": {"score": -0.62341, "label": "negative"}, "relevance": 0.424752}, {"text": "Retail Pharmacies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424553}, {"text": "Online Pharmacies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424526}, {"text": "dosage errors", "sentiment": {"score": -0.62341, "label": "negative"}, "relevance": 0.423386}, {"text": "significant pace", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423328}, {"text": "CAGR", "sentiment": {"score": 0.453003, "label": "positive"}, "relevance": 0.422572}, {"text": "value share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422506}, {"text": "Anti-Allergy Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422488}, {"text": "undisputed leader", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421516}, {"text": "Central Nervous", "sentiment": {"score": -0.479188, "label": "negative"}, "relevance": 0.421502}, {"text": "Sample Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421426}]}, "extracted_metadata": {"sha1": "33d680ccf5819d56def9d6ecdc1dae254c539994", "filename": "1541536871911.zip-1a2ea52bd03c0cfd1498e446a422d019.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/14572", "https://www.persistencemarketresearch.com/market-research/orally-disintegrating-tablet-market.asp"], "title": "Protein and Peptide-Based Therapeutics Trending the Global Orally Disintegrating Tablets Market \u2013", "forum_title": "Research Insights \u2013 Page 36 \u2013 Find Market Research"}, {"id": "mQ9s1QRlCWGU4HpNCzvmNFM_FKaTVxFoUDuOHwqO7u282qQVJEs52dIvo4pVeB-U", "result_metadata": {"score": 37.011787}, "author": "Pr Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.227882, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.6599, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.515794, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.227882, "label": "negative"}, "relevance": 0.924296}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.852289}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264044}]}, "crawl_date": "2018-11-06T15:58:47Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45201071-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-amended-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.63547, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.546544, "label": "/real estate/buying and selling homes"}, {"score": 0.482893, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.470469, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.963268}, {"text": "POSITION DISCLOSURE/DEALING DISCLOSURE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.835375}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.729269}, {"text": "disclosure Dealing Disclosure02/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6707}, {"text": "RELEVANT SECURITIES REPRESENTING", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642298}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552319}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514888}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501531}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470999}, {"text": "possible cash offer", "sentiment": {"score": 0.403939, "label": "positive"}, "relevance": 0.464383}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392215}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321408}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313157}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310819}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291474}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281263}, {"text": "vehicle companies", "sentiment": {"score": -0.502585, "label": "negative"}, "relevance": 0.277052}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260288}, {"text": "YesShire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2488}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237089}]}, "extracted_metadata": {"sha1": "2c651e1ff086ee5f28d7139a6bde1ac91ac49c67", "filename": "1541519927901.zip-729076e90851e4812a3cf3dee7bcfd48.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd - Amended"}, {"id": "UYRuBBQg8_VcRBBtyR_osi5vw-RlugiZoOQHBDxEypacymV0okD5tjQZtnLSdzgN", "result_metadata": {"score": 36.13491}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.554414, "label": "negative"}, "text": "Ulcerative Colitis", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": -0.554414, "label": "negative"}, "text": "Japan", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.554414, "label": "negative"}, "text": "Treatment of Adult", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": -0.595306, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Launch of Entyvio\u00ae (vedolizumab)", "keywords": [{"text": "Launch"}, {"text": "Entyvio\u00ae"}, {"text": "vedolizumab"}]}, "sentence": "Takeda Pharmaceutical : Announces Launch of Entyvio\u00ae (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis in Japan | MarketScreener", "object": {"text": "for the Treatment of Adult Patients", "keywords": [{"text": "Adult Patients"}, {"text": "Treatment"}], "entities": [{"type": "Organization", "text": "Treatment of Adult"}]}, "action": {"verb": {"text": "Announces", "tense": "present"}, "text": "Announces", "normalized": "Announces"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.96094, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.4094, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Colitis", "relevance": 0.381568, "dbpedia_resource": "http://dbpedia.org/resource/Colitis"}], "categories": [{"score": 0.686387, "label": "/health and fitness/therapy"}, {"score": 0.489634, "label": "/health and fitness/disease"}, {"score": 0.322608, "label": "/health and fitness/disorders"}], "relations": [{"type": "employedBy", "sentence": "Takeda Pharmaceutical : Announces Launch of Entyvio\u00ae (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis in Japan | MarketScreener", "score": 0.449731, "arguments": [{"text": "Patients", "location": [94, 102], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "Adult", "location": [88, 93], "entities": [{"type": "Organization", "text": "Adult", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Takeda Pharmaceutical : Announces Launch of Entyvio\u00ae (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis in Japan | MarketScreener", "score": 0.453024, "arguments": [{"text": "Active Ulcerative Colitis", "location": [131, 156], "entities": [{"type": "Organization", "text": "Active Ulcerative Colitis"}]}, {"text": "Japan", "location": [160, 165], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "Severely Active Ulcerative", "sentiment": {"score": -0.554414, "label": "negative"}, "relevance": 0.915063}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.731589}, {"text": "Adult Patients", "sentiment": {"score": -0.554414, "label": "negative"}, "relevance": 0.556972}, {"text": "Colitis", "sentiment": {"score": -0.554414, "label": "negative"}, "relevance": 0.445801}, {"text": "Launch", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413628}, {"text": "Entyvio\u00ae", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335966}, {"text": "vedolizumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335505}, {"text": "Treatment", "sentiment": {"score": -0.554414, "label": "negative"}, "relevance": 0.335044}, {"text": "Japan", "sentiment": {"score": -0.554414, "label": "negative"}, "relevance": 0.333199}]}, "crawl_date": "2018-11-07T02:00:38Z", "url": "https://www.marketscreener.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Announces-Launch-of-Entyvio-vedolizumab-for-the-Treatment-of-Adult-Patien-27559394/", "host": "marketscreener.com", "text": "Media Contacts: JPBU Communications Ryoko Omichi ryoko.omichi@takeda.com +81 (0) 3-3278-2065 Media outside Japan Luke Willats TEL: +41-44-555-1145 Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T00:00:00Z", "enriched_text": {"entities": [{"count": 8, "sentiment": {"score": 0.159733, "label": "positive"}, "text": "Takeda", "relevance": 0.87688, "type": "Person"}, {"count": 5, "sentiment": {"score": 0.173638, "label": "positive"}, "text": "Takeda", "relevance": 0.682334, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.664376, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 10, "sentiment": {"score": -0.635827, "label": "negative"}, "text": "UC", "relevance": 0.596675, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "University of Canterbury", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Canterbury"}}, {"count": 6, "sentiment": {"score": -0.401992, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.595905, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Director of Takeda", "relevance": 0.468224, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.461603, "type": "Company"}, {"count": 5, "sentiment": {"score": -0.76911, "label": "negative"}, "text": "Entyvio", "relevance": 0.415927, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.383907, "label": "positive"}, "text": "Japan", "relevance": 0.366047, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": -0.718287, "label": "negative"}, "text": "bowel disease", "relevance": 0.289342, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.640742, "label": "negative"}, "text": "Japan Intractable Diseases Information Center", "relevance": 0.243865, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan Pharma Business Unit", "relevance": 0.241107, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Osaka", "relevance": 0.234172, "type": "Location", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"count": 1, "sentiment": {"score": 0.213238, "label": "positive"}, "text": "Masato Iwasaki", "relevance": 0.225808, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japanese Ministry of Health", "relevance": 0.219857, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.213998, "label": "negative"}, "text": "celiac disease", "relevance": 0.217109, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}, {"count": 1, "sentiment": {"score": 0.618363, "label": "positive"}, "text": "Luke Willats", "relevance": 0.206386, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Commitment to Gastroenterology", "relevance": 0.205411, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President", "relevance": 0.202915, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.191836, "type": "Crime"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ryoko Omichi", "relevance": 0.188454, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.213998, "label": "negative"}, "text": "Development team", "relevance": 0.182707, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IBD", "relevance": 0.182644, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPBU Communications", "relevance": 0.182459, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "300mg", "relevance": 0.182459, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ryoko.omichi@takeda.com", "relevance": 0.182459, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "25 years", "relevance": 0.182459, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "300 mg", "relevance": 0.182459, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8-week", "relevance": 0.182459, "type": "Quantity"}], "sentiment": {"document": {"score": -0.306494, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Limited ( TSE: 4502 ) ('Takeda')", "keywords": [{"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Osaka, Japan, November 7, 2018 --- Takeda Pharmaceutical Company Limited ( TSE: 4502 ) ('Takeda') today announced the launch of Entyvio \u00ae (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.", "object": {"text": "the launch of Entyvio \u00ae (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan", "keywords": [{"text": "active ulcerative colitis"}, {"text": "development code"}, {"text": "launch"}, {"text": "UC"}], "entities": [{"type": "Company", "text": "Entyvio"}, {"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "ulcerative colitis", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "University of Canterbury", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Canterbury"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "object": {"text": "a New Drug Application", "keywords": [{"text": "New Drug Application"}]}, "action": {"verb": {"text": "submit", "tense": "past"}, "text": "submitted", "normalized": "submit"}}, {"subject": {"text": "292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC", "keywords": [{"text": "severely active UC"}, {"text": "severely UC"}, {"text": "pivotal Phase"}, {"text": "alongside data"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "ulcerative colitis", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "University of Canterbury", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Canterbury"}}]}, "sentence": " Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "object": {"text": "a Phase 3 clinical study", "keywords": [{"text": "Phase"}, {"text": "clinical study"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "895 patients", "keywords": [{"text": "patients"}]}, "sentence": " Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "object": {"text": "vedolizumab induction and maintenance treatment", "keywords": [{"text": "vedolizumab induction"}, {"text": "maintenance treatment"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involving", "normalized": "involve"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "\u3000Takeda obtained the New Drug Application Approval in July 2018.", "object": {"text": "the New Drug Application Approval", "keywords": [{"text": "Drug Application Approval"}]}, "action": {"verb": {"text": "obtain", "tense": "past"}, "text": "obtained", "normalized": "obtain"}}, {"subject": {"text": "'Entyvio", "keywords": [{"text": "Entyvio"}]}, "sentence": " 'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "object": {"text": "approved in more than 60 countries worldwide", "keywords": [{"text": "countries"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "'Entyvio", "keywords": [{"text": "Entyvio"}]}, "sentence": " 'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "object": {"text": "a robust clinical and real-world evidence base", "keywords": [{"text": "real-world evidence base"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda", "keywords": [{"text": "Japan Pharma Business"}, {"text": "Masato Iwasaki"}, {"text": "Takeda"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Masato Iwasaki"}, {"type": "JobTitle", "text": "President"}, {"type": "Company", "text": "Japan Pharma Business Unit"}, {"type": "JobTitle", "text": "Director of Takeda"}]}, "sentence": " 'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "object": {"text": "'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base", "keywords": [{"text": "real-world evidence base"}, {"text": "countries"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "'Takeda", "keywords": [{"text": "Takeda"}]}, "sentence": " 'Takeda is pleased to provide healthcare providers and patients with an important new treatment option for ulcerative colitis and continue our mission of delivering innovative medicines for patients living with gastrointestinal diseases.'", "object": {"text": "pleased to provide healthcare providers", "keywords": [{"text": "healthcare providers"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "innovative medicines", "keywords": [{"text": "innovative medicines"}]}, "sentence": " 'Takeda is pleased to provide healthcare providers and patients with an important new treatment option for ulcerative colitis and continue our mission of delivering innovative medicines for patients living with gastrointestinal diseases.'", "object": {"text": "for patients living with gastrointestinal diseases", "keywords": [{"text": "gastrointestinal diseases"}, {"text": "patients"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "The adult dose of vedolizumab (genetical recombination) for intravenous infusion", "keywords": [{"text": "genetical recombination"}, {"text": "intravenous infusion"}, {"text": "adult dose"}, {"text": "vedolizumab"}]}, "sentence": " The adult dose of vedolizumab (genetical recombination) for intravenous infusion is 300 mg/dose.", "object": {"text": "300 mg/dose", "keywords": [{"text": "mg/dose"}], "entities": [{"type": "Quantity", "text": "300 mg"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The drug", "keywords": [{"text": "drug"}]}, "sentence": " The drug should be administered at Week 0, 2 and 6 after the initial administration at 8-week intervals thereafter.", "action": {"verb": {"text": "administer", "tense": "future"}, "text": "should be administered", "normalized": "should be administer"}}, {"subject": {"text": "Ulcerative Colitis", "keywords": [{"text": "Ulcerative Colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "object": {"text": "one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "common forms"}, {"text": "IBD"}, {"text": "people"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}, {"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the most common forms of inflammatory bowel disease (IBD)", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "IBD"}, {"text": "common forms"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}, {"type": "HealthCondition", "text": "IBD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Inflammatory bowel disease", "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}}]}, "sentence": " Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "object": {"text": "over 220,000 people 1 in Japan", "keywords": [{"text": "people"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "UC", "keywords": [{"text": "UC"}], "entities": [{"type": "Organization", "text": "ulcerative colitis"}]}, "sentence": " UC is a chronic, relapsing, remitting, inflammatory condition of the gastrointestinal", "object": {"text": "a chronic", "keywords": [{"text": "chronic"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "UC", "keywords": [{"text": "UC"}], "entities": [{"type": "Organization", "text": "ulcerative colitis"}]}, "sentence": " UC is a chronic, relapsing, remitting, inflammatory condition of the gastrointestinal", "object": {"text": "a chronic", "keywords": [{"text": "chronic"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "relapse", "tense": "present"}, "text": "relapsing", "normalized": "relapse"}}, {"subject": {"text": "GI) tract that", "keywords": [{"text": "GI"}, {"text": "tract"}]}, "sentence": " (GI) tract that is often progressive in nature.", "object": {"text": "often progressive in nature", "keywords": [{"text": "nature"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the innermost lining of the large intestine and often presents with symptoms of abdominal discomfort and loose bowel movements, including blood or pus", "keywords": [{"text": "loose bowel movements"}, {"text": "innermost lining"}, {"text": "abdominal discomfort"}, {"text": "symptoms"}], "entities": []}, "sentence": " UC involves the innermost lining of the large intestine and often presents with symptoms of abdominal discomfort and loose bowel movements, including blood or pus.", "object": {"text": "UC", "keywords": [{"text": "UC"}], "entities": [{"type": "Organization", "text": "ulcerative colitis"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involves", "normalized": "involve"}}, {"subject": {"text": "blood or pus", "keywords": [{"text": "blood"}, {"text": "pus"}]}, "sentence": " UC involves the innermost lining of the large intestine and often presents with symptoms of abdominal discomfort and loose bowel movements, including blood or pus.", "object": {"text": "bowel movements", "keywords": [{"text": "bowel movements"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "recent research", "keywords": [{"text": "recent research"}]}, "sentence": " The cause of UC is not fully understood, but recent research suggests hereditary, genetic, and environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC.", "object": {"text": "hereditary, genetic, and environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC", "keywords": [{"text": "genetically predisposed individuals"}, {"text": "abnormal immune response"}, {"text": "microbial antigens"}, {"text": "environmental factors"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "suggest", "tense": "present"}, "text": "suggests", "normalized": "suggest"}}, {"subject": {"text": "hereditary, genetic, and environmental factors, and/or an abnormal immune response to microbial antigens", "keywords": [{"text": "abnormal immune response"}, {"text": "microbial antigens"}, {"text": "environmental factors"}]}, "sentence": " The cause of UC is not fully understood, but recent research suggests hereditary, genetic, and environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC.", "object": {"text": "individuals can lead to UC", "keywords": [{"text": "UC"}, {"text": "individuals"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "action": {"verb": {"text": "predispose", "tense": "past"}, "text": "predisposed", "normalized": "predispose"}}, {"subject": {"text": "individuals", "keywords": [{"text": "individuals"}]}, "sentence": " The cause of UC is not fully understood, but recent research suggests hereditary, genetic, and environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC.", "object": {"text": "microbial antigens", "keywords": [{"text": "microbial antigens"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "can lead", "normalized": "can lead"}}, {"subject": {"text": "Entyvio (vedolizumab)", "keywords": [{"text": "Entyvio"}, {"text": "vedolizumab"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio (vedolizumab) is a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.", "object": {"text": "a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide", "keywords": [{"text": "severe ulcerative colitis"}, {"text": "prescription medicine"}, {"text": "Crohn"}, {"text": "UC"}], "entities": [{"type": "Company", "text": "Entyvio"}, {"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "UC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a prescription medicine", "keywords": [{"text": "prescription medicine"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio (vedolizumab) is a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.", "object": {"text": "approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide", "keywords": [{"text": "severe ulcerative colitis"}, {"text": "Crohn"}, {"text": "UC"}, {"text": "adults"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "UC"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "a prescription medicine", "keywords": [{"text": "prescription medicine"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio (vedolizumab) is a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.", "object": {"text": "with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide", "keywords": [{"text": "severe ulcerative colitis"}, {"text": "Crohn"}, {"text": "UC"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Organization", "text": "UC"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "has been approved", "normalized": "have be approve"}}, {"subject": {"text": "an increased number of inflammatory white blood cells entering the mucosal lining of the bowel", "keywords": [{"text": "inflammatory white blood"}, {"text": "mucosal lining"}, {"text": "bowel"}, {"text": "cells"}]}, "sentence": " In people with UC, there are an increased number of inflammatory white blood cells entering the mucosal lining of the bowel.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "inflammatory white blood cells", "keywords": [{"text": "inflammatory white blood"}, {"text": "cells"}]}, "sentence": " In people with UC, there are an increased number of inflammatory white blood cells entering the mucosal lining of the bowel.", "object": {"text": "the mucosal lining of the bowel", "keywords": [{"text": "mucosal lining"}, {"text": "bowel"}]}, "action": {"verb": {"text": "enter", "tense": "present"}, "text": "entering", "normalized": "enter"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " The presence of these inflammatory cells can lead to the symptoms most commonly seen in people who have UC.", "object": {"text": "UC", "keywords": [{"text": "UC"}], "entities": [{"type": "Organization", "text": "ulcerative colitis"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio is designed to reduce this inflammation by blocking the movement of the white blood cells into the inflamed gut tissue.", "object": {"text": "this inflammation", "keywords": [{"text": "inflammation"}]}, "action": {"verb": {"text": "reduce", "tense": "future"}, "text": "is designed to reduce", "normalized": "be design to reduce"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio is designed to reduce this inflammation by blocking the movement of the white blood cells into the inflamed gut tissue.", "object": {"text": "the movement of the white blood cells", "keywords": [{"text": "white blood cells"}, {"text": "movement"}]}, "action": {"verb": {"text": "block", "tense": "present"}, "text": "blocking", "normalized": "block"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio specifically binds to the alpha 4 beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation.", "object": {"text": "to the alpha 4 beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation", "keywords": [{"text": "white blood cells"}, {"text": "beta7 integrin"}, {"text": "gut tissue"}, {"text": "inflammation"}]}, "action": {"verb": {"text": "bind", "tense": "present"}, "text": "binds", "normalized": "bind"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio specifically binds to the alpha 4 beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation.", "object": {"text": "its interaction", "keywords": [{"text": "interaction"}]}, "action": {"verb": {"text": "block", "tense": "present"}, "text": "blocks", "normalized": "block"}}, {"subject": {"text": "Entyvio", "keywords": [{"text": "Entyvio"}], "entities": [{"type": "Company", "text": "Entyvio"}]}, "sentence": " Entyvio specifically binds to the alpha 4 beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation.", "object": {"text": "the white blood cells", "keywords": [{"text": "white blood cells"}]}, "action": {"verb": {"text": "inhibit", "tense": "present"}, "text": "inhibiting", "normalized": "inhibit"}}, {"subject": {"text": "the white blood cells", "keywords": [{"text": "white blood cells"}]}, "sentence": " Entyvio specifically binds to the alpha 4 beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation.", "object": {"text": "the inflamed gut tissue", "keywords": [{"text": "gut tissue"}]}, "action": {"verb": {"text": "enter", "tense": "present"}, "text": "entering", "normalized": "enter"}}, {"subject": {"text": "Gastrointestinal (GI) diseases", "keywords": [{"text": "(GI) diseases"}, {"text": "diseases"}]}, "sentence": " Gastrointestinal (GI) diseases can be complex, debilitating and life-changing.", "object": {"text": "complex"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "can be", "normalized": "can be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda aspires to advance how patients manage their disease.", "object": {"text": "to advance"}, "action": {"verb": {"text": "aspire", "tense": "present"}, "text": "aspires", "normalized": "aspire"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Takeda aspires to advance how patients manage their disease.", "object": {"text": "their disease", "keywords": [{"text": "disease"}]}, "action": {"verb": {"text": "manage", "tense": "present"}, "text": "manage", "normalized": "manage"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders.", "object": {"text": "leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "high unmet need"}, {"text": "acid-related diseases"}, {"text": "motility disorders"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Our GI Research & Development team", "keywords": [{"text": "GI Research"}, {"text": "Development team"}], "entities": [{"type": "JobTitle", "text": "Development team"}]}, "sentence": " Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "object": {"text": "in celiac disease and liver diseases", "keywords": [{"text": "celiac disease"}, {"text": "liver diseases"}], "entities": [{"type": "HealthCondition", "text": "celiac disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is also exploring", "normalized": "be also explore"}}, {"subject": {"text": "Our GI Research & Development team", "keywords": [{"text": "GI Research"}, {"text": "Development team"}], "entities": [{"type": "JobTitle", "text": "Development team"}]}, "sentence": " Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "object": {"text": "solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies", "keywords": [{"text": "celiac disease"}, {"text": "scientific advancements"}, {"text": "liver diseases"}, {"text": "microbiome therapies"}], "entities": [{"type": "HealthCondition", "text": "celiac disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}]}, "action": {"verb": {"text": "explore", "tense": "present"}, "text": "is also exploring", "normalized": "be also explore"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited ( TSE: 4502 )", "keywords": [{"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pha r maceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "a global"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "research and development-driven pha r maceutical company", "keywords": [{"text": "development-driven pha"}, {"text": "maceutical company"}, {"text": "research"}]}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pha r maceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "better health", "keywords": [{"text": "health"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "bringing", "normalized": "bring"}}, {"subject": {"text": "a global, research and development-driven pha r maceutical company", "keywords": [{"text": "development-driven pha"}, {"text": "maceutical company"}, {"text": "research"}]}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pha r maceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "science", "keywords": [{"text": "science"}]}, "action": {"verb": {"text": "translate", "tense": "present"}, "text": "translating", "normalized": "translate"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation.", "object": {"text": "R&D both", "keywords": [{"text": "R&D"}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducts", "normalized": "conduct"}}, {"subject": {"text": "Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets,", "keywords": [{"text": "Innovative products"}, {"text": "Takeda"}, {"text": "gastroenterology"}, {"text": "oncology"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda.", "object": {"text": "currently fueling the growth of Takeda", "keywords": [{"text": "Takeda"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the growth of Takeda", "keywords": [{"text": "Takeda"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda.", "object": {"text": "Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets,", "keywords": [{"text": "Innovative products"}, {"text": "Takeda"}, {"text": "gastroenterology"}, {"text": "oncology"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "fueling", "normalized": "fuel"}}, {"subject": {"text": "Around 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "committed to improving quality of life", "keywords": [{"text": "quality"}, {"text": "life"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The drug information", "keywords": [{"text": "drug information"}]}, "sentence": " The drug information contained herein is intended to disclose Takeda's corporate information.", "object": {"text": "herein is intended to disclose Takeda's corporate information", "keywords": [{"text": "corporate information"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "contain", "tense": "past"}, "text": "contained", "normalized": "contain"}}, {"subject": {"text": "The drug information contained herein", "keywords": [{"text": "drug information"}]}, "sentence": " The drug information contained herein is intended to disclose Takeda's corporate information.", "object": {"text": "intended to disclose Takeda's corporate information", "keywords": [{"text": "corporate information"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "to disclose Takeda's corporate information", "keywords": [{"text": "Takeda"}, {"text": "corporate information"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " The drug information contained herein is intended to disclose Takeda's corporate information.", "object": {"text": "The drug information contained herein", "keywords": [{"text": "drug information"}]}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "intended", "normalized": "intend"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.983641, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Inflammation", "relevance": 0.710668, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Pharmacology", "relevance": 0.600906, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Crohn's disease", "relevance": 0.58119, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Inflammatory bowel disease", "relevance": 0.525634, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Gastroenterology", "relevance": 0.517055, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Immune system", "relevance": 0.485373, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Food and Drug Administration", "relevance": 0.394806, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Colon", "relevance": 0.393289, "dbpedia_resource": "http://dbpedia.org/resource/Colon_(anatomy)"}, {"text": "Medicine", "relevance": 0.365149, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.339679, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Blood", "relevance": 0.332464, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Colonoscopy", "relevance": 0.328885, "dbpedia_resource": "http://dbpedia.org/resource/Colonoscopy"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.30705, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Intestine", "relevance": 0.302713, "dbpedia_resource": "http://dbpedia.org/resource/Intestine"}, {"text": "Biopsy", "relevance": 0.300658, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}, {"text": "Helminthic therapy", "relevance": 0.30005, "dbpedia_resource": "http://dbpedia.org/resource/Helminthic_therapy"}, {"text": "New Drug Application", "relevance": 0.294906, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Clinical trial", "relevance": 0.290286, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "White blood cell", "relevance": 0.284373, "dbpedia_resource": "http://dbpedia.org/resource/White_blood_cell"}, {"text": "Endothelium", "relevance": 0.280489, "dbpedia_resource": "http://dbpedia.org/resource/Endothelium"}, {"text": "Diarrhea", "relevance": 0.275118, "dbpedia_resource": "http://dbpedia.org/resource/Diarrhea"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.26916, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Abdominal pain", "relevance": 0.267474, "dbpedia_resource": "http://dbpedia.org/resource/Abdominal_pain"}], "categories": [{"score": 0.864075, "label": "/health and fitness/disease"}, {"score": 0.356605, "label": "/health and fitness/therapy"}, {"score": 0.221073, "label": "/health and fitness/disorders"}], "relations": [{"type": "locatedAt", "sentence": "Osaka, Japan, November 7, 2018 --- Takeda Pharmaceutical Company Limited ( TSE: 4502 ) ('Takeda') today announced the launch of Entyvio \u00ae (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.", "score": 0.739348, "arguments": [{"text": "Osaka", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}, {"text": "Japan", "location": [7, 12], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "score": 0.929413, "arguments": [{"text": "Masato Iwasaki", "location": [911, 925], "entities": [{"type": "Person", "text": "Masato Iwasaki"}]}, {"text": "said", "location": [906, 910], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "residesIn", "sentence": "'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "score": 0.880306, "arguments": [{"text": "Masato Iwasaki", "location": [911, 925], "entities": [{"type": "Person", "text": "Masato Iwasaki"}]}, {"text": "Ph.D.", "location": [927, 932], "entities": [{"type": "GeopoliticalEntity", "text": "Ph.D."}]}]}, {"type": "employedBy", "sentence": "'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "score": 0.374701, "arguments": [{"text": "President", "location": [934, 943], "entities": [{"type": "Person", "text": "President"}]}, {"text": "Japan Pharma Business Unit and", "location": [951, 981], "entities": [{"type": "Organization", "text": "Japan Pharma Business Unit and", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "employedBy", "sentence": "'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "score": 0.587858, "arguments": [{"text": "Director", "location": [982, 990], "entities": [{"type": "Person", "text": "Director"}]}, {"text": "Japan Pharma Business Unit and", "location": [951, 981], "entities": [{"type": "Organization", "text": "Japan Pharma Business Unit and", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "managerOf", "sentence": "'Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,' said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda.", "score": 0.548641, "arguments": [{"text": "Director", "location": [982, 990], "entities": [{"type": "Person", "text": "Director"}]}, {"text": "Takeda", "location": [994, 1000], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "'Takeda is pleased to provide healthcare providers and patients with an important new treatment option for ulcerative colitis and continue our mission of delivering innovative medicines for patients living with gastrointestinal diseases.", "score": 0.867823, "arguments": [{"text": "patients", "location": [1057, 1065], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ulcerative colitis", "location": [1109, 1127], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "'Takeda is pleased to provide healthcare providers and patients with an important new treatment option for ulcerative colitis and continue our mission of delivering innovative medicines for patients living with gastrointestinal diseases.", "score": 0.849361, "arguments": [{"text": "patients", "location": [1192, 1200], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diseases", "location": [1230, 1238], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "employedBy", "sentence": "' Overview of Entyvio Brand name Entyvio \u00ae for I.V. Infusion 300mg Generic name Vedolizumab [Genetical Recombination] Effects / Indications Induction and maintenance therapy for moderately to severely active ulcerative colitis (The drug should be used only in patients with inadequate response to conventional treatment.", "score": 0.860349, "arguments": [{"text": "300mg\nGeneric", "location": [1300, 1313], "entities": [{"type": "Person", "text": "300mg\nGeneric"}]}, {"text": "Entyvio \u00ae for I.V. Infusion", "location": [1272, 1299], "entities": [{"type": "Organization", "text": "Entyvio \u00ae for I.V. Infusion", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Drug Price Entyvio \u00ae for I.V. Infusion 300mg 274,490 yen About Ulcerative Colitis Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "score": 0.453647, "arguments": [{"text": "300mg", "location": [1837, 1842], "entities": [{"type": "Person", "text": "300mg\nGeneric"}]}, {"text": "I.V. Infusion", "location": [1823, 1836], "entities": [{"type": "Organization", "text": "Entyvio \u00ae for I.V. Infusion", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Drug Price Entyvio \u00ae for I.V. Infusion 300mg 274,490 yen About Ulcerative Colitis Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "score": 0.631695, "arguments": [{"text": "Price\nEntyvio \u00ae", "location": [1803, 1818], "entities": [{"type": "Person", "text": "Price\nEntyvio \u00ae"}]}, {"text": "I.V. Infusion", "location": [1823, 1836], "entities": [{"type": "Organization", "text": "Entyvio \u00ae for I.V. Infusion", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Drug Price Entyvio \u00ae for I.V. Infusion 300mg 274,490 yen About Ulcerative Colitis Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "score": 0.503195, "arguments": [{"text": "300mg", "location": [1837, 1842], "entities": [{"type": "Person", "text": "300mg\nGeneric"}]}, {"text": "Ulcerative Colitis\nUlcerative Colitis", "location": [1861, 1898], "entities": [{"type": "Organization", "text": "Ulcerative Colitis\nUlcerative Colitis"}]}]}, {"type": "agentOf", "sentence": "Osaka, Japan, November 7, 2018 --- Takeda Pharmaceutical Company Limited ( TSE: 4502 ) ('Takeda') today announced the launch of Entyvio \u00ae (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.", "score": 0.564257, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [35, 72], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [104, 113], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "Drug Price Entyvio \u00ae for I.V. Infusion 300mg 274,490 yen About Ulcerative Colitis Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "score": 0.788786, "arguments": [{"text": "300mg", "location": [1837, 1842], "entities": [{"type": "Person", "text": "300mg\nGeneric"}]}, {"text": "inflammatory bowel disease", "location": [1934, 1960], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Drug Price Entyvio \u00ae for I.V. Infusion 300mg 274,490 yen About Ulcerative Colitis Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "score": 0.661762, "arguments": [{"text": "people", "location": [1991, 1997], "entities": [{"type": "Person", "text": "people"}]}, {"text": "inflammatory bowel disease", "location": [1934, 1960], "entities": [{"type": "HealthCondition", "text": "inflammatory bowel disease"}]}]}, {"type": "locatedAt", "sentence": "Drug Price Entyvio \u00ae for I.V. Infusion 300mg 274,490 yen About Ulcerative Colitis Ulcerative Colitis is one of the most common forms of inflammatory bowel disease (IBD), affecting over 220,000 people 1 in Japan.", "score": 0.802281, "arguments": [{"text": "people", "location": [1991, 1997], "entities": [{"type": "Person", "text": "people"}]}, {"text": "Japan", "location": [2003, 2008], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "UC is a chronic, relapsing, remitting, inflammatory condition of the gastrointestinal 1 The total of people granted medical claimant and/or registration certificates (for the treatment of UC) in 2013 (Japan Intractable Diseases Information Center website) (GI) tract that is often progressive in nature.", "score": 0.858408, "arguments": [{"text": "website", "location": [2257, 2264], "entities": [{"type": "Organization", "text": "website"}]}, {"text": "Japan Intractable Diseases Information Center", "location": [2211, 2256], "entities": [{"type": "Organization", "text": "Japan Intractable Diseases Information Center", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "partOfMany", "sentence": "About Entyvio Entyvio (vedolizumab) is a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.", "score": 0.576145, "arguments": [{"text": "Entyvio\nEntyvio", "location": [2714, 2729], "entities": [{"type": "Person", "text": "Entyvio\nEntyvio"}]}, {"text": "adults", "location": [2798, 2804], "entities": [{"type": "Person", "text": "adults"}]}]}, {"type": "hasAttribute", "sentence": "About Entyvio Entyvio (vedolizumab) is a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.", "score": 0.877347, "arguments": [{"text": "adults", "location": [2798, 2804], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "ulcerative colitis", "location": [2829, 2847], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "About Entyvio Entyvio (vedolizumab) is a prescription medicine that has been approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.", "score": 0.650401, "arguments": [{"text": "Crohn", "location": [2856, 2861], "entities": [{"type": "Person", "text": "Crohn"}]}, {"text": "ulcerative colitis", "location": [2829, 2847], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "employedBy", "sentence": "In people with UC, there are an increased number of inflammatory white blood cells entering the mucosal lining of the bowel.", "score": 0.470696, "arguments": [{"text": "people", "location": [2917, 2923], "entities": [{"type": "Person", "text": "people"}]}, {"text": "UC", "location": [2929, 2931], "entities": [{"type": "Organization", "text": "UC"}]}]}, {"type": "timeOf", "sentence": "Mucosal addressing cell adhesion molecule 1 (MAdCAM-1) is preferentially expressed on the endothelial lining of blood vessels in the lymphoid tissue of the bowel.", "score": 0.733586, "arguments": [{"text": "MAdCAM-1", "location": [3320, 3328], "entities": [{"type": "Date", "text": "MAdCAM-1"}]}, {"text": "expressed", "location": [3348, 3357], "entities": [{"type": "EventCommunication", "text": "expressed"}]}]}, {"type": "locatedAt", "sentence": "Mucosal addressing cell adhesion molecule 1 (MAdCAM-1) is preferentially expressed on the endothelial lining of blood vessels in the lymphoid tissue of the bowel.", "score": 0.110097, "arguments": [{"text": "blood", "location": [3387, 3392], "entities": [{"type": "Substance", "text": "blood"}]}, {"text": "vessels", "location": [3393, 3400], "entities": [{"type": "Vehicle", "text": "vessels"}]}]}, {"type": "timeOf", "sentence": "Osaka, Japan, November 7, 2018 --- Takeda Pharmaceutical Company Limited ( TSE: 4502 ) ('Takeda') today announced the launch of Entyvio \u00ae (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.", "score": 0.692851, "arguments": [{"text": "today", "location": [98, 103], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [104, 113], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Entyvio specifically binds to the alpha 4 beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation.", "score": 0.845753, "arguments": [{"text": "Entyvio", "location": [3525, 3532], "entities": [{"type": "Person", "text": "Entyvio\nEntyvio"}]}, {"text": "binds", "location": [3546, 3551], "entities": [{"type": "EventCommunication", "text": "binds"}]}]}, {"type": "agentOf", "sentence": "Takeda aspires to advance how patients manage their disease.", "score": 0.977357, "arguments": [{"text": "Takeda", "location": [4081, 4087], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "aspires", "location": [4088, 4095], "entities": [{"type": "EventCommunication", "text": "aspires"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.931421, "arguments": [{"text": "team", "location": [4348, 4352], "entities": [{"type": "Person", "text": "team"}]}, {"text": "celiac disease", "location": [4384, 4398], "entities": [{"type": "HealthCondition", "text": "celiac disease"}]}]}, {"type": "hasAttribute", "sentence": "Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.", "score": 0.761418, "arguments": [{"text": "team", "location": [4348, 4352], "entities": [{"type": "Person", "text": "team"}]}, {"text": "liver diseases", "location": [4403, 4417], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "employedBy", "sentence": "Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation.", "score": 0.418637, "arguments": [{"text": "partners", "location": [4929, 4937], "entities": [{"type": "Person", "text": "partners"}]}, {"text": "Takeda conducts R&D", "location": [4884, 4903], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.642779, "arguments": [{"text": "partners", "location": [5251, 5259], "entities": [{"type": "Person", "text": "partners"}]}, {"text": "Takeda", "location": [5242, 5248], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.908452, "arguments": [{"text": "employees", "location": [5162, 5171], "entities": [{"type": "Person", "text": "employees"}]}, {"text": "Takeda", "location": [5155, 5161], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Media Contacts: JPBU Communications Ryoko Omichi ryoko.omichi@takeda.com +81 (0) 3-3278-2065 Media outside Japan Luke Willats TEL: +41-44-555-1145 Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.560985, "arguments": [{"text": "Ryoko Omichi\nryoko.omichi@takeda.com +81", "location": [5654, 5694], "entities": [{"type": "Person", "text": "Ryoko Omichi\nryoko.omichi@takeda.com +81"}]}, {"text": "JPBU Communications", "location": [5634, 5653], "entities": [{"type": "Organization", "text": "JPBU Communications", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Media Contacts: JPBU Communications Ryoko Omichi ryoko.omichi@takeda.com +81 (0) 3-3278-2065 Media outside Japan Luke Willats TEL: +41-44-555-1145 Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.387594, "arguments": [{"text": "Media", "location": [5711, 5716], "entities": [{"type": "Organization", "text": "Media"}]}, {"text": "Japan", "location": [5725, 5730], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Media Contacts: JPBU Communications Ryoko Omichi ryoko.omichi@takeda.com +81 (0) 3-3278-2065 Media outside Japan Luke Willats TEL: +41-44-555-1145 Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.908574, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [5816, 5846], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Disclaimer", "location": [5805, 5815], "entities": [{"type": "GeopoliticalEntity", "text": "Disclaimer"}]}]}, {"type": "agentOf", "sentence": "Media Contacts: JPBU Communications Ryoko Omichi ryoko.omichi@takeda.com +81 (0) 3-3278-2065 Media outside Japan Luke Willats TEL: +41-44-555-1145 Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.815908, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [5816, 5846], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [5847, 5856], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "clientOf", "sentence": "Osaka, Japan, November 7, 2018 --- Takeda Pharmaceutical Company Limited ( TSE: 4502 ) ('Takeda') today announced the launch of Entyvio \u00ae (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.", "score": 0.453259, "arguments": [{"text": "patients", "location": [214, 222], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "Entyvio \u00ae", "location": [128, 137], "entities": [{"type": "Organization", "text": "Entyvio \u00ae for I.V. Infusion", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Media Contacts: JPBU Communications Ryoko Omichi ryoko.omichi@takeda.com +81 (0) 3-3278-2065 Media outside Japan Luke Willats TEL: +41-44-555-1145 Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.759746, "arguments": [{"text": "07 November 2018", "location": [5873, 5889], "entities": [{"type": "Date", "text": "07 November 2018"}]}, {"text": "published", "location": [5847, 5856], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "productOf", "sentence": "Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "score": 0.944848, "arguments": [{"text": "Drug Application", "location": [315, 331], "entities": [{"type": "Product", "text": "Drug Application Approval"}]}, {"text": "Takeda", "location": [292, 298], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "productOf", "sentence": "Takeda obtained the New Drug Application Approval in July 2018.", "score": 0.851349, "arguments": [{"text": "Drug Application Approval", "location": [746, 771], "entities": [{"type": "Product", "text": "Drug Application Approval"}]}, {"text": "Takeda", "location": [722, 728], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "score": 0.559591, "arguments": [{"text": "Ministry of Health, Labour and Welfare", "location": [348, 386], "entities": [{"type": "Organization", "text": "Ministry of Health, Labour and Welfare", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Japanese", "location": [339, 347], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "score": 0.693064, "arguments": [{"text": "Ministry of Health, Labour and Welfare", "location": [348, 386], "entities": [{"type": "Organization", "text": "Ministry of Health, Labour and Welfare", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "MHLW", "location": [388, 392], "entities": [{"type": "Ticker", "text": "MHLW"}]}]}, {"type": "timeOf", "sentence": "Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "score": 0.938206, "arguments": [{"text": "CCT-101", "location": [441, 448], "entities": [{"type": "Date", "text": "CCT-101"}]}, {"text": "Study", "location": [435, 440], "entities": [{"type": "EventCommunication", "text": "Study"}]}]}, {"type": "partOfMany", "sentence": "Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.", "score": 0.877312, "arguments": [{"text": "patients", "location": [498, 506], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "Japanese", "location": [489, 497], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "ulcerative colitis", "sentiment": {"score": -0.120755, "label": "negative"}, "relevance": 0.980586}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.958891}, {"text": "white blood cells", "sentiment": {"score": -0.678689, "label": "negative"}, "relevance": 0.880689}, {"text": "active ulcerative colitis", "sentiment": {"score": -0.611958, "label": "negative"}, "relevance": 0.750193}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.734581}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.718287, "label": "negative"}, "relevance": 0.67201}, {"text": "New Drug Application", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.651747}, {"text": "Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.651612}, {"text": "Takeda employees", "sentiment": {"score": 0.753152, "label": "positive"}, "relevance": 0.651488}, {"text": "severely active UC", "sentiment": {"score": -0.492254, "label": "negative"}, "relevance": 0.60553}, {"text": "severe ulcerative colitis", "sentiment": {"score": -0.22448, "label": "negative"}, "relevance": 0.55372}, {"text": "genetical recombination", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515147}, {"text": "inflammatory white blood", "sentiment": {"score": -0.679687, "label": "negative"}, "relevance": 0.513196}, {"text": "severely UC", "sentiment": {"score": -0.492254, "label": "negative"}, "relevance": 0.512392}, {"text": "Drug Application Approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509975}, {"text": "[Genetical Recombination]", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508257}, {"text": "Japan Pharma Business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507699}, {"text": "important new treatment", "sentiment": {"score": 0.452044, "label": "positive"}, "relevance": 0.506013}, {"text": "I.V. Infusion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503065}, {"text": "Japan Intractable Diseases", "sentiment": {"score": -0.640742, "label": "negative"}, "relevance": 0.497928}, {"text": "innovative medicines", "sentiment": {"score": 0.451932, "label": "positive"}, "relevance": 0.493588}, {"text": "loose bowel movements", "sentiment": {"score": -0.798122, "label": "negative"}, "relevance": 0.491407}, {"text": "unmet need", "sentiment": {"score": -0.426049, "label": "negative"}, "relevance": 0.489877}, {"text": "real-world evidence base", "sentiment": {"score": 0.675847, "label": "positive"}, "relevance": 0.487884}, {"text": "Information Center website", "sentiment": {"score": -0.640742, "label": "negative"}, "relevance": 0.484542}, {"text": "clinical study", "sentiment": {"score": -0.492254, "label": "negative"}, "relevance": 0.482984}, {"text": "gut tissue", "sentiment": {"score": -0.678189, "label": "negative"}, "relevance": 0.481345}, {"text": "patient disease support", "sentiment": {"score": 0.45182, "label": "positive"}, "relevance": 0.476763}, {"text": "genetically predisposed individuals", "sentiment": {"score": -0.554681, "label": "negative"}, "relevance": 0.476663}, {"text": "Mucosal addressing cell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474115}, {"text": "high unmet need", "sentiment": {"score": -0.405876, "label": "negative"}, "relevance": 0.47385}, {"text": "patients", "sentiment": {"score": -0.0653966, "label": "negative"}, "relevance": 0.473439}, {"text": "abnormal immune response", "sentiment": {"score": -0.554681, "label": "negative"}, "relevance": 0.469718}, {"text": "document Permalink Disclaimer", "sentiment": {"score": -0.677643, "label": "negative"}, "relevance": 0.468948}, {"text": "neuroscience therapeutic areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453376}, {"text": "Entyvio", "sentiment": {"score": -0.76911, "label": "negative"}, "relevance": 0.446957}, {"text": "Japanese patients", "sentiment": {"score": -0.492254, "label": "negative"}, "relevance": 0.434685}, {"text": "inflammatory cells", "sentiment": {"score": -0.795866, "label": "negative"}, "relevance": 0.426276}, {"text": "inflammatory condition", "sentiment": {"score": -0.778704, "label": "negative"}, "relevance": 0.424439}, {"text": "gastrointestinal diseases", "sentiment": {"score": 0.452044, "label": "positive"}, "relevance": 0.422021}, {"text": "maintenance treatment", "sentiment": {"score": -0.492254, "label": "negative"}, "relevance": 0.416136}, {"text": "Drug Price", "sentiment": {"score": -0.373181, "label": "negative"}, "relevance": 0.416047}, {"text": "vedolizumab induction", "sentiment": {"score": -0.492254, "label": "negative"}, "relevance": 0.413931}, {"text": "development code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410985}, {"text": "Masato Iwasaki", "sentiment": {"score": 0.213238, "label": "positive"}, "relevance": 0.410462}, {"text": "Study CCT-101", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410185}, {"text": "intravenous infusion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408186}, {"text": "Japanese Ministry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408077}]}, "extracted_metadata": {"sha1": "72b0f3870ea86e0a785c5675627fdbe457d9ac6e", "filename": "1541556038397.zip-768994a260081e5b43ecc413728fa80a.xml", "file_type": "json"}, "external_links": ["https://www.takeda.com/newsroom/newsreleases/2018/takeda-announces-launch-of-entyvio-vedolizumab-for-the-treatment-of-adult-patients--with-moderately-to-severely-active-ulcerative-colitis-in-japan/", "https://www.takeda.com/investors/", "http://www.publicnow.com/view/A12E04983712764A787DE452C036F6C929EC58CA", "https://www.takeda.com/newsroom/"], "title": "Takeda Pharmaceutical : Announces Launch of Entyvio\u00ae (vedolizumab) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis in Japan | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "ITMyjf7lo02dK1sDYtsyaMyow3AYuYzJ_JCPF4o3ze_HXBj40PHoxXoAnPqgAddo", "result_metadata": {"score": 35.223633}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.463714, "label": "negative"}, "text": "Insomnia", "relevance": 0.33, "type": "HealthCondition"}], "sentiment": {"document": {"score": -0.538398, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Capitalism", "relevance": 0.881203, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}, {"text": "Stock market", "relevance": 0.822259, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Insomnia", "relevance": 0.76208, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Supply and demand", "relevance": 0.721158, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}], "categories": [{"score": 0.802192, "label": "/health and fitness"}, {"score": 0.374828, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.291421, "label": "/health and fitness/disorders/sleep disorders"}], "relations": [], "keywords": [{"text": "Insomnia Treatment Drugs", "sentiment": {"score": -0.463714, "label": "negative"}, "relevance": 0.935761}, {"text": "Global Industry size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.665059}, {"text": "demand", "sentiment": {"score": 0.395553, "label": "positive"}, "relevance": 0.329999}, {"text": "trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.311344}, {"text": "market", "sentiment": {"score": -0.463714, "label": "negative"}, "relevance": 0.227418}, {"text": "share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226217}, {"text": "growth", "sentiment": {"score": 0.41172, "label": "positive"}, "relevance": 0.225817}]}, "crawl_date": "2018-11-06T16:33:52Z", "url": "https://industrytoday.co.uk/market-research-industry-today/insomnia-treatment-drugs-market--global-industry-size--share--growth--demand--trends-and-forecast-2026/164563/164563", "host": "industrytoday.co.uk", "text": "Inc., F.Hoffman La-Roche AG, Mylan N.V., Pernix Therapeutics, Pfizer, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T10:48:00Z", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": -0.519616, "label": "negative"}, "text": "insomnia", "relevance": 0.828075, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": -0.147079, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.200548, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0.518045, "label": "positive"}, "text": "US", "relevance": 0.188139, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": -0.371716, "label": "negative"}, "text": "Mn", "relevance": 0.186232, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": -0.828535, "label": "negative"}, "text": "North America", "relevance": 0.166221, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.816621, "label": "negative"}, "text": "Asia Pacific", "relevance": 0.156699, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.152422, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "strategic initiatives", "relevance": 0.141531, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.137123, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sumitomo Dainippon Pharma Co. Ltd.", "relevance": 0.128363, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Phamaceutical Industries Ltd", "relevance": 0.127798, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan N.V.", "relevance": 0.126666, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.413555, "label": "negative"}, "text": "Vanda Pharmaceuticals", "relevance": 0.125855, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.121484, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pernix Therapeutics", "relevance": 0.118217, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@IndustryToday", "relevance": 0.118217, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.118217, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10 years", "relevance": 0.118217, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5 years", "relevance": 0.118217, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7 years", "relevance": 0.118217, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.5%", "relevance": 0.118217, "type": "Quantity"}], "sentiment": {"document": {"score": 0.15315, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The global insomnia treatment drugs market", "keywords": [{"text": "insomnia treatment drugs"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "sentence": " The global insomnia treatment drugs market was valued at US$ 2,689.6 Mn in 2017, and is expected to reach US$ 4,332.4 Mn by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.", "object": {"text": "valued at US$ 2,689.6 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The global insomnia treatment drugs market", "keywords": [{"text": "insomnia treatment drugs"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "sentence": " The global insomnia treatment drugs market was valued at US$ 2,689.6 Mn in 2017, and is expected to reach US$ 4,332.4 Mn by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.", "object": {"text": "at US$ 2,689.6 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "was valued", "normalized": "be value"}}, {"subject": {"text": "$ 4,332.4 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 4,332.4"}]}, "sentence": " The global insomnia treatment drugs market was valued at US$ 2,689.6 Mn in 2017, and is expected to reach US$ 4,332.4 Mn by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.", "object": {"text": "US", "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "us"}, "sentence": " Follow us on Twitter @IndustryToday Simply by reading Credence Research Data new Insomnia Treatment Drugs; Data, Size, Analysis, and Forecasts to 2026 report, you can stay ahead of your competition.", "object": {"text": "on Twitter @IndustryToday Simply", "keywords": [{"text": "Twitter"}], "entities": [{"type": "TwitterHandle", "text": "@IndustryToday"}]}, "action": {"verb": {"text": "Follow", "tense": "present"}, "text": "Follow", "normalized": "Follow"}}, {"subject": {"text": "Follow us on Twitter @IndustryToday", "keywords": [{"text": "Twitter"}], "entities": [{"type": "TwitterHandle", "text": "@IndustryToday"}]}, "sentence": " Follow us on Twitter @IndustryToday Simply by reading Credence Research Data new Insomnia Treatment Drugs; Data, Size, Analysis, and Forecasts to 2026 report, you can stay ahead of your competition.", "object": {"text": "Credence Research Data new Insomnia Treatment Drugs", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "Credence Research Data"}]}, "action": {"verb": {"text": "read", "tense": "present"}, "text": "reading", "normalized": "read"}}, {"subject": {"text": "Credence Research Data", "keywords": [{"text": "Credence Research Data"}]}, "sentence": " Credence Research Data projects that the global Insomnia Treatment Drugs market Expected to Exhibit Rapid Growth during The Forecast Period.Market Competition Assessment:", "object": {"text": "that the global Insomnia Treatment Drugs market Expected to Exhibit Rapid Growth during The Forecast Period.Market Competition Assessment", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "Exhibit Rapid Growth"}, {"text": "Forecast Period.Market Competition"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "projects", "normalized": "project"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Currently North America is leading the regional segment for insomnia treatment drugs market.", "object": {"text": "leading the regional segment for insomnia treatment drugs market", "keywords": [{"text": "insomnia treatment drugs"}, {"text": "regional segment"}, {"text": "market"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Currently North America is leading the regional segment for insomnia treatment drugs market.", "object": {"text": "the regional segment", "keywords": [{"text": "regional segment"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "is leading", "normalized": "be lead"}}, {"subject": {"text": "Increasing number of geriatric population", "keywords": [{"text": "geriatric population"}, {"text": "number"}]}, "sentence": " Increasing number of geriatric population suffering with sleep disorders and rising prevalence of addiction and stress in the youth drive the insomnia treatment drugs market in North America.", "object": {"text": "with sleep disorders and rising prevalence of addiction and stress", "keywords": [{"text": "sleep disorders"}, {"text": "prevalence"}, {"text": "addiction"}, {"text": "stress"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "Asia Pacific", "keywords": [{"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc.", "object": {"text": "anticipated to exhibit steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Asia Pacific", "keywords": [{"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc.", "object": {"text": "steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is anticipated to exhibit", "normalized": "be anticipate to exhibit"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc.", "object": {"text": "with chronic pain, hypertension, anxiety etc", "keywords": [{"text": "chronic pain"}, {"text": "hypertension"}, {"text": "anxiety"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "the pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " Accurate diagnosis of insomnia has spurred the pharmaceutical companies to manufacture generic drugs in abundant quantity to cater the medicinal requirements of the huge patient base in the Asia Pacific region.", "object": {"text": "generic drugs", "keywords": [{"text": "generic drugs"}]}, "action": {"verb": {"text": "manufacture", "tense": "future"}, "text": "to manufacture", "normalized": "to manufacture"}}, {"subject": {"text": "the pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": " Accurate diagnosis of insomnia has spurred the pharmaceutical companies to manufacture generic drugs in abundant quantity to cater the medicinal requirements of the huge patient base in the Asia Pacific region.", "object": {"text": "the medicinal requirements", "keywords": [{"text": "medicinal requirements"}]}, "action": {"verb": {"text": "cater", "tense": "future"}, "text": "to cater", "normalized": "to cater"}}, {"subject": {"text": "The key players", "keywords": [{"text": "key players"}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " The key players actively engaged in the insomnia treatment drugs market are Merck & Co. Inc., F.Hoffman La-Roche AG, Mylan N.V., Pernix Therapeutics, Pfizer, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co. Ltd., Teva Phamaceutical Industries Ltd, and Vanda Pharmaceuticals, Inc.", "object": {"text": "in the insomnia treatment drugs market", "keywords": [{"text": "insomnia treatment drugs"}, {"text": "market"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "action": {"verb": {"text": "engage", "tense": "past"}, "text": "engaged", "normalized": "engage"}}, {"subject": {"text": "The key players actively engaged in the insomnia treatment drugs market", "keywords": [{"text": "insomnia treatment drugs"}, {"text": "key players"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "HealthCondition", "text": "insomnia"}]}, "sentence": " The key players actively engaged in the insomnia treatment drugs market are Merck & Co. Inc., F.Hoffman La-Roche AG, Mylan N.V., Pernix Therapeutics, Pfizer, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co. Ltd., Teva Phamaceutical Industries Ltd, and Vanda Pharmaceuticals, Inc.", "object": {"text": "Merck & Co. Inc., F.Hoffman La-Roche AG, Mylan N.V., Pernix Therapeutics, Pfizer, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Sumitomo Dainippon Pharma Co. Ltd., Teva Phamaceutical Industries Ltd, and Vanda Pharmaceuticals, Inc", "keywords": [{"text": "Sumitomo Dainippon Pharma"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Teva Phamaceutical Industries"}, {"text": "F.Hoffman La-Roche AG"}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Mylan N.V."}, {"type": "Company", "text": "Pernix Therapeutics"}, {"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Sumitomo Dainippon Pharma Co. Ltd."}, {"type": "Company", "text": "Teva Phamaceutical Industries Ltd"}, {"type": "Company", "text": "Vanda Pharmaceuticals"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Credence Research Data examine which region", "keywords": [{"text": "Credence Research Data"}, {"text": "region"}]}, "sentence": " With an assessment of the leading markets, such as the US, and EU, Credence Research Data examine which region is equipped the largest markets and what % of the global Insomnia Treatment Drugs market they make up.", "object": {"text": "equipped the largest markets", "keywords": [{"text": "largest markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "region", "keywords": [{"text": "region"}]}, "sentence": " With an assessment of the leading markets, such as the US, and EU, Credence Research Data examine which region is equipped the largest markets and what % of the global Insomnia Treatment Drugs market they make up.", "object": {"text": "the largest markets", "keywords": [{"text": "largest markets"}]}, "action": {"verb": {"text": "equip", "tense": "past"}, "text": "is equipped", "normalized": "be equip"}}, {"subject": {"text": "they", "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " With an assessment of the leading markets, such as the US, and EU, Credence Research Data examine which region is equipped the largest markets and what % of the global Insomnia Treatment Drugs market they make up.", "object": {"text": "the global Insomnia Treatment Drugs market", "keywords": [{"text": "Insomnia Treatment Drugs"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "make", "normalized": "make"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report tells you in a tight, focused and easily accessible format.Get here the sample here: https://www.credenceresearch.com/sample-request/59249 This Credence Research Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand growth of Insomnia Treatment Drugs.", "action": {"verb": {"text": "tell", "tense": "present"}, "text": "tells", "normalized": "tell"}}, {"subject": {"text": "https://www.credenceresearch.com/sample-request/59249 This Credence Research Data report", "keywords": [{"text": "Credence Research Data"}]}, "sentence": " This report tells you in a tight, focused and easily accessible format.Get here the sample here: https://www.credenceresearch.com/sample-request/59249 This Credence Research Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand growth of Insomnia Treatment Drugs.", "object": {"text": "the single tool", "keywords": [{"text": "single tool"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "you"}, "sentence": " This report tells you in a tight, focused and easily accessible format.Get here the sample here: https://www.credenceresearch.com/sample-request/59249 This Credence Research Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand growth of Insomnia Treatment Drugs.", "object": {"text": "with the latest trends in all regional markets and why all stakeholders demand growth of Insomnia Treatment Drugs", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "latest trends"}, {"text": "regional markets"}, {"text": "stakeholders"}]}, "action": {"verb": {"text": "equip", "tense": "future"}, "text": "to equip", "normalized": "to equip"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report will arm you with all you and your company require to develop, price, launch, and market an Insomnia Treatment Drugs.With more than 200 pages, and over 140 charts, tables, and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.\u2022 Insomnia Treatment Drugs market size and drivers: detailed analysis of the Insomnia Treatment Drugs during 2018\u20132026, including highlights of the demand drivers and growth stimulators for the industry.", "object": {"text": "you"}, "action": {"verb": {"text": "arm", "tense": "future"}, "text": "will arm", "normalized": "will arm"}}, {"subject": {"text": "your company", "keywords": [{"text": "company"}]}, "sentence": " This report will arm you with all you and your company require to develop, price, launch, and market an Insomnia Treatment Drugs.With more than 200 pages, and over 140 charts, tables, and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.\u2022 Insomnia Treatment Drugs market size and drivers: detailed analysis of the Insomnia Treatment Drugs during 2018\u20132026, including highlights of the demand drivers and growth stimulators for the industry.", "object": {"text": "to develop, price, launch", "keywords": [{"text": "launch"}, {"text": "price"}]}, "action": {"verb": {"text": "require", "tense": "present"}, "text": "require", "normalized": "require"}}, {"subject": {"text": "this dedicated specialist report", "keywords": [{"text": "dedicated specialist report"}]}, "sentence": " This report will arm you with all you and your company require to develop, price, launch, and market an Insomnia Treatment Drugs.With more than 200 pages, and over 140 charts, tables, and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.\u2022 Insomnia Treatment Drugs market size and drivers: detailed analysis of the Insomnia Treatment Drugs during 2018\u20132026, including highlights of the demand drivers and growth stimulators for the industry.", "object": {"text": "you remain equipped and fully informed, to succeed in this competitive market.\u2022 Insomnia Treatment Drugs market size and drivers: detailed analysis of the Insomnia Treatment Drugs during 2018\u20132026, including highlights of the demand drivers and growth stimulators for the industry", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "competitive market.\u2022 Insomnia"}, {"text": "Drugs market size"}, {"text": "growth stimulators"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "will ensure", "normalized": "will ensure"}}, {"subject": {"text": "It"}, "sentence": " It also provides a snapshot of the country\u2019s expenditure and modernization patterns\u2022 Porter\u2019s Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u2022 Import and Export Dynamics: analysis of prevalent trends in the country\u2019s imports and exports over the last five years\u2022 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs.", "object": {"text": "a snapshot of the country\u2019s expenditure and modernization patterns\u2022 Porter\u2019s Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u2022 Import and Export Dynamics: analysis of prevalent trends in the country\u2019s imports and exports over the last five years\u2022 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "modernization patterns\u2022 Porter"}, {"text": "years\u2022 Competitive landscape"}, {"text": "prevalent trends"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}, {"type": "HealthCondition", "text": "insomnia"}, {"type": "Quantity", "text": "five years"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "modernization patterns\u2022 Porter", "keywords": [{"text": "modernization patterns\u2022 Porter"}]}, "sentence": " It also provides a snapshot of the country\u2019s expenditure and modernization patterns\u2022 Porter\u2019s Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u2022 Import and Export Dynamics: analysis of prevalent trends in the country\u2019s imports and exports over the last five years\u2022 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs.", "object": {"text": "Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u2022 Import and Export Dynamics: analysis of prevalent trends in the country\u2019s imports and exports over the last five years\u2022 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "years\u2022 Competitive landscape"}, {"text": "prevalent trends"}, {"text": "bargaining power"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}, {"type": "HealthCondition", "text": "insomnia"}, {"type": "Quantity", "text": "five years"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "imports and exports", "keywords": [{"text": "imports"}, {"text": "exports"}]}, "sentence": " It also provides a snapshot of the country\u2019s expenditure and modernization patterns\u2022 Porter\u2019s Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u2022 Import and Export Dynamics: analysis of prevalent trends in the country\u2019s imports and exports over the last five years\u2022 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs.", "object": {"text": "the country", "keywords": [{"text": "country"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "investors\u2022", "keywords": [{"text": "investors\u2022"}]}, "sentence": " It provides an overview of key players, together with insights such as key alliances, strategic initiatives, and a brief financial analysis\u2022 Attitudes of wealth managers and private banks to targeting impact investors\u2022 A global market snapshot of impact investments\u2022 Strategies for targeting impact investments and key market regulations\u2022 High-profile HNWI and UHNWI impact investorsGet here the sample here: https://www.credenceresearch.com/sample-request/59249 Key Answers How will these country\u2019s markets develop?", "object": {"text": "impact", "keywords": [{"text": "impact"}]}, "action": {"verb": {"text": "target", "tense": "future"}, "text": "targeting", "normalized": "target"}}, {"subject": {"text": "these country", "keywords": [{"text": "country"}]}, "sentence": " It provides an overview of key players, together with insights such as key alliances, strategic initiatives, and a brief financial analysis\u2022 Attitudes of wealth managers and private banks to targeting impact investors\u2022 A global market snapshot of impact investments\u2022 Strategies for targeting impact investments and key market regulations\u2022 High-profile HNWI and UHNWI impact investorsGet here the sample here: https://www.credenceresearch.com/sample-request/59249 Key Answers How will these country\u2019s markets develop?", "object": {"text": "markets develop", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "has", "tense": "future"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report will tell you - TODAY Which Insomnia Treatment Drugs lead the market in 2019?", "object": {"text": "TODAY Which Insomnia Treatment Drugs lead the market in 2019", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "market"}]}, "action": {"verb": {"text": "tell", "tense": "future"}, "text": "will tell", "normalized": "will tell"}}, {"subject": {"text": "the same industry", "keywords": [{"text": "industry"}]}, "sentence": " Will the same industry be as successful in 2026?", "object": {"text": "as successful in 2026"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "other countries and region", "keywords": [{"text": "countries"}, {"text": "region"}]}, "sentence": " Which other countries and region contribute most?", "object": {"text": "most"}, "action": {"verb": {"text": "contribute", "tense": "present"}, "text": "contribute", "normalized": "contribute"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report tells you.", "object": {"text": "you"}, "action": {"verb": {"text": "tell", "tense": "present"}, "text": "tells", "normalized": "tell"}}, {"subject": {"text": "PLUS In-depth country analysis Discover which countries and regions", "keywords": [{"text": "In-depth country analysis"}, {"text": "Discover"}, {"text": "regions"}, {"text": "countries"}]}, "sentence": " PLUS In-depth country analysis Discover which countries and regions will drive the Insomnia Treatment Drugs market to 2026?", "object": {"text": "the Insomnia Treatment Drugs market", "keywords": [{"text": "Insomnia Treatment Drugs"}, {"text": "market"}], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "will drive", "normalized": "will drive"}}, {"subject": {"text": "Exclusive Industry", "keywords": [{"text": "Exclusive Industry"}]}, "sentence": " Exclusive Industry sourced information, not available anywhere else For more Inquiry: https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "source", "tense": "past"}, "text": "sourced", "normalized": "source"}}, {"subject": {"text": "https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research", "keywords": [{"text": "UsCredence Research"}, {"text": "https://www.credenceresearch.com/inquiry-before-buying/59249"}]}, "sentence": " Exclusive Industry sourced information, not available anywhere else For more Inquiry: https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits.", "object": {"text": "a worldwide market research", "keywords": [{"text": "worldwide market research"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research", "keywords": [{"text": "UsCredence Research"}, {"text": "https://www.credenceresearch.com/inquiry-before-buying/59249"}]}, "sentence": " Exclusive Industry sourced information, not available anywhere else For more Inquiry: https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits.", "object": {"text": "firm", "keywords": [{"text": "firm"}]}, "action": {"verb": {"text": "counsel", "tense": "present"}, "text": "counseling", "normalized": "counsel"}}, {"subject": {"text": "a worldwide market research and counseling firm", "keywords": [{"text": "worldwide market research"}, {"text": "firm"}]}, "sentence": " Exclusive Industry sourced information, not available anywhere else For more Inquiry: https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits.", "object": {"text": "organizations, governments, non-legislative associations, and not-for-benefits", "keywords": [{"text": "non-legislative associations"}, {"text": "governments"}, {"text": "organizations"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "serves driving", "normalized": "serve drive"}}, {"subject": {"text": "We"}, "sentence": " We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.", "object": {"text": "some assistance", "keywords": [{"text": "assistance"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "enduring enhancements", "keywords": [{"text": "enhancements"}]}, "sentence": " We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.", "object": {"text": "to their execution and understand their most imperative objectives", "keywords": [{"text": "imperative objectives"}, {"text": "execution"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "We"}, "sentence": " We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.", "object": {"text": "their most imperative objectives", "keywords": [{"text": "imperative objectives"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "we"}, "sentence": " Over almost a century, we've manufactured a firm extraordinarily prepared for this task.Contact Us:105 N 1st ST #429SAN JOSE", "object": {"text": "manufactured a firm extraordinarily prepared for this task.Contact Us", "keywords": [{"text": "firm"}, {"text": "task.Contact"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " Over almost a century, we've manufactured a firm extraordinarily prepared for this task.Contact Us:105 N 1st ST #429SAN JOSE", "object": {"text": "a firm extraordinarily prepared for this task.Contact Us", "keywords": [{"text": "firm"}, {"text": "task.Contact"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "manufacture", "tense": "past"}, "text": "manufactured", "normalized": "manufacture"}}, {"subject": {"text": "a firm", "keywords": [{"text": "firm"}]}, "sentence": " Over almost a century, we've manufactured a firm extraordinarily prepared for this task.Contact Us:105 N 1st ST #429SAN JOSE", "object": {"text": "for this task.Contact Us", "keywords": [{"text": "task.Contact"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "prepare", "tense": "past"}, "text": "prepared", "normalized": "prepare"}}], "concepts": [{"text": "Pharmaceutical industry", "relevance": 0.927399, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.880944, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Ramelteon", "relevance": 0.800423, "dbpedia_resource": "http://dbpedia.org/resource/Ramelteon"}, {"text": "Pharmacology", "relevance": 0.771023, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Insomnia", "relevance": 0.744905, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Generic drug", "relevance": 0.739584, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "International trade", "relevance": 0.730474, "dbpedia_resource": "http://dbpedia.org/resource/International_trade"}, {"text": "The Key", "relevance": 0.689983, "dbpedia_resource": "http://dbpedia.org/resource/The_Key_(novel)"}, {"text": "Supply and demand", "relevance": 0.682268, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}, {"text": "Asia-Pacific", "relevance": 0.671191, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Market", "relevance": 0.66854, "dbpedia_resource": "http://dbpedia.org/resource/Market"}], "categories": [{"score": 0.786218, "label": "/health and fitness/disorders/sleep disorders"}, {"score": 0.348143, "label": "/finance/financial news"}, {"score": 0.337363, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Insomnia Treatment Drugs market: Global Industry size, share, growth, demand, trends and forecast 2026 The global insomnia treatment drugs market was valued at US$ 2,689.6 Mn in 2017, and is expected to reach US$ 4,332.4 Mn by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.", "score": 0.579244, "arguments": [{"text": "drugs", "location": [133, 138], "entities": [{"type": "Substance", "text": "Drugs"}]}, {"text": "US$", "location": [160, 163], "entities": [{"type": "Facility", "text": "US$"}]}]}, {"type": "partOf", "sentence": "It also provides a snapshot of the country's expenditure and modernization patterns\u00b7 Porter's Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u00b7 Import and Export Dynamics: analysis of prevalent trends in the country's imports and exports over the last five years\u00b7 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs.", "score": 0.387364, "arguments": [{"text": "Force", "location": [2876, 2881], "entities": [{"type": "Organization", "text": "Force"}]}, {"text": "Insomnia Treatment Drugs", "location": [2898, 2922], "entities": [{"type": "Organization", "text": "Insomnia Treatment Drugs.With", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "It also provides a snapshot of the country's expenditure and modernization patterns\u00b7 Porter's Five Force analysis of the Insomnia Treatment Drugs: analysis of the market points by determining the business power of suppliers, bargaining power of buyers, threats of substitution, the intensity of competitiveness, and barriers to entry\u00b7 Import and Export Dynamics: analysis of prevalent trends in the country's imports and exports over the last five years\u00b7 Competitive landscape and strategic insights: analysis of the competitive landscape of the Insomnia Treatment Drugs.", "score": 0.249796, "arguments": [{"text": "imports", "location": [3186, 3193], "entities": [{"type": "Vehicle", "text": "imports"}]}, {"text": "country", "location": [3176, 3183], "entities": [{"type": "GeopoliticalEntity", "text": "country", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Exclusive Industry sourced information, not available anywhere else For more Inquiry: https://www.credenceresearch.com/inquiry-before-buying/59249 About UsCredence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits.", "score": 0.529, "arguments": [{"text": "firm", "location": [4561, 4565], "entities": [{"type": "Organization", "text": "Insomnia Treatment Drugs.With", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "counseling", "location": [4550, 4560], "entities": [{"type": "EventCommunication", "text": "counseling"}]}]}, {"type": "employedBy", "sentence": "We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.", "score": 0.595431, "arguments": [{"text": "customers", "location": [4679, 4688], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "our", "location": [4675, 4678], "entities": [{"type": "Organization", "text": "organizations"}]}]}, {"type": "agentOf", "sentence": "We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.", "score": 0.846028, "arguments": [{"text": "their", "location": [4742, 4747], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "execution", "location": [4748, 4757], "entities": [{"type": "EventLegal", "text": "execution"}]}]}, {"type": "locatedAt", "sentence": "Contact Us:105 N 1st ST #429SAN JOSE", "score": 0.478982, "arguments": [{"text": "#429SAN JOSE", "location": [4919, 4931], "entities": [{"type": "Person", "text": "#429SAN JOSE"}]}, {"text": "N 1st ST", "location": [4910, 4918], "entities": [{"type": "Facility", "text": "N 1st ST"}]}]}, {"type": "partOf", "sentence": "Follow us on Twitter @IndustryToday Simply by reading Credence Research Data new Insomnia Treatment Drugs; Data, Size, Analysis, and Forecasts to 2026 report, you can stay ahead of your competition.", "score": 0.437228, "arguments": [{"text": "Insomnia Treatment Drugs", "location": [389, 413], "entities": [{"type": "Organization", "text": "Insomnia Treatment Drugs.With", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Credence Research Data", "location": [362, 384], "entities": [{"type": "Organization", "text": "Credence Research Data", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Increasing number of geriatric population suffering with sleep disorders and rising prevalence of addiction and stress in the youth drive the insomnia treatment drugs market in North America.", "score": 0.527545, "arguments": [{"text": "drugs", "location": [958, 963], "entities": [{"type": "Substance", "text": "Drugs"}]}, {"text": "North America", "location": [974, 987], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc. Accurate diagnosis of insomnia has spurred the pharmaceutical companies to manufacture generic drugs in abundant quantity to cater the medicinal requirements of the huge patient base in the Asia Pacific region.", "score": 0.224977, "arguments": [{"text": "Asia", "location": [989, 993], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [994, 1001], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "hasAttribute", "sentence": "Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc. Accurate diagnosis of insomnia has spurred the pharmaceutical companies to manufacture generic drugs in abundant quantity to cater the medicinal requirements of the huge patient base in the Asia Pacific region.", "score": 0.910776, "arguments": [{"text": "patients", "location": [1115, 1123], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "insomnia", "location": [1103, 1111], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "hasAttribute", "sentence": "Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc. Accurate diagnosis of insomnia has spurred the pharmaceutical companies to manufacture generic drugs in abundant quantity to cater the medicinal requirements of the huge patient base in the Asia Pacific region.", "score": 0.526068, "arguments": [{"text": "patients", "location": [1115, 1123], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic pain", "location": [1139, 1151], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific is anticipated to exhibit steady growth during the forecast period owing to the rising prevalence of insomnia in patients suffering with chronic pain, hypertension, anxiety etc. Accurate diagnosis of insomnia has spurred the pharmaceutical companies to manufacture generic drugs in abundant quantity to cater the medicinal requirements of the huge patient base in the Asia Pacific region.", "score": 0.645533, "arguments": [{"text": "Pacific", "location": [1375, 1382], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "region", "location": [1383, 1389], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}]}, {"type": "agentOf", "sentence": "Get here the sample here: https://www.credenceresearch.com/sample-request/59249 This Credence Research Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand growth of Insomnia Treatment Drugs.", "score": 0.950103, "arguments": [{"text": "Credence Research Data", "location": [2077, 2099], "entities": [{"type": "Organization", "text": "Credence Research Data", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "report", "location": [2100, 2106], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "managerOf", "sentence": "This report will arm you with all you and your company require to develop, price, launch, and market an Insomnia Treatment Drugs.With more than 200 pages, and over 140 charts, tables, and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.", "score": 0.44254, "arguments": [{"text": "your", "location": [2296, 2300], "entities": [{"type": "Person", "text": "your"}]}, {"text": "company", "location": [2301, 2308], "entities": [{"type": "Organization", "text": "Insomnia Treatment Drugs.With", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "This report will arm you with all you and your company require to develop, price, launch, and market an Insomnia Treatment Drugs.With more than 200 pages, and over 140 charts, tables, and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.", "score": 0.982774, "arguments": [{"text": "specialist", "location": [2465, 2475], "entities": [{"type": "Person", "text": "Porter"}]}, {"text": "report", "location": [2476, 2482], "entities": [{"type": "EventCommunication", "text": "report"}]}]}], "keywords": [{"text": "insomnia treatment drugs", "sentiment": {"score": -0.459294, "label": "negative"}, "relevance": 0.941967}, {"text": "treatment drugs market", "sentiment": {"score": -0.477554, "label": "negative"}, "relevance": 0.686273}, {"text": "global insomnia treatment", "sentiment": {"score": -0.37147, "label": "negative"}, "relevance": 0.512984}, {"text": "Credence Research Data", "sentiment": {"score": -0.371347, "label": "negative"}, "relevance": 0.503602}, {"text": "new Insomnia Treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.428726}, {"text": "Insomnia Treatment Drugs.With", "sentiment": {"score": -0.326349, "label": "negative"}, "relevance": 0.418361}, {"text": "market.\u2022 Insomnia Treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417755}, {"text": "Drugs market size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39335}, {"text": "generic drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362206}, {"text": "Global Industry size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.359821}, {"text": "global market snapshot", "sentiment": {"score": 0.308139, "label": "positive"}, "relevance": 0.358561}, {"text": "worldwide market research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357757}, {"text": "key market regulations\u2022", "sentiment": {"score": 0.308139, "label": "positive"}, "relevance": 0.357071}, {"text": "Research Data report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35663}, {"text": "Research Data examine", "sentiment": {"score": -0.431065, "label": "negative"}, "relevance": 0.35161}, {"text": "Forecast Period.Market Competition", "sentiment": {"score": -0.311628, "label": "negative"}, "relevance": 0.350728}, {"text": "dedicated specialist report", "sentiment": {"score": 0.514242, "label": "positive"}, "relevance": 0.349235}, {"text": "Sumitomo Dainippon Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348324}, {"text": "Currently North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348002}, {"text": "key players", "sentiment": {"score": 0.196368, "label": "positive"}, "relevance": 0.347906}, {"text": "Asia Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347776}, {"text": "Exhibit Rapid Growth", "sentiment": {"score": -0.311628, "label": "negative"}, "relevance": 0.347705}, {"text": "Teva Phamaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347331}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347218}, {"text": "https://www.credenceresearch.com/sample-request/59249 Key Answers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345733}, {"text": "In-depth country analysis", "sentiment": {"score": -0.476764, "label": "negative"}, "relevance": 0.345633}, {"text": "years\u2022 Competitive landscape", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345347}, {"text": "huge patient base", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345343}, {"text": "impact investments\u2022 Strategies", "sentiment": {"score": 0.308139, "label": "positive"}, "relevance": 0.34476}, {"text": "UHNWI impact investorsGet", "sentiment": {"score": 0.308139, "label": "positive"}, "relevance": 0.344669}, {"text": "F.Hoffman La-Roche AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344604}, {"text": "brief financial analysis\u2022", "sentiment": {"score": 0.308139, "label": "positive"}, "relevance": 0.34309}, {"text": "modernization patterns\u2022 Porter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343047}, {"text": "easily accessible format.Get", "sentiment": {"score": 0.598417, "label": "positive"}, "relevance": 0.342409}, {"text": "market points", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335465}, {"text": "detailed analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328819}, {"text": "steady growth", "sentiment": {"score": -0.816621, "label": "negative"}, "relevance": 0.328587}, {"text": "Force analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328546}, {"text": "growth stimulators", "sentiment": {"score": 0.401963, "label": "positive"}, "relevance": 0.32752}, {"text": "UsCredence Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326877}, {"text": "largest markets", "sentiment": {"score": -0.431065, "label": "negative"}, "relevance": 0.326608}, {"text": "regional markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326503}, {"text": "Sanofi S.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326418}, {"text": "youth drive", "sentiment": {"score": -0.828535, "label": "negative"}, "relevance": 0.325846}, {"text": "key alliances", "sentiment": {"score": 0.546955, "label": "positive"}, "relevance": 0.325795}, {"text": "regional segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325612}, {"text": "pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325477}, {"text": "Co. Inc.", "sentiment": {"score": -0.353616, "label": "negative"}, "relevance": 0.325442}, {"text": "High-profile HNWI", "sentiment": {"score": 0.308139, "label": "positive"}, "relevance": 0.325384}]}, "extracted_metadata": {"sha1": "e611434ebd85d65886c5aec964e76e1bc6787225", "filename": "1541522032595.zip-4565b00f61bbf09886b7362e482e1e98.xml", "file_type": "json"}, "external_links": ["https://www.credenceresearch.com/inquiry-before-buying/59249", "http://twitter.com/IndustryToday", "https://www.credenceresearch.com/sample-request/59249"], "title": "Insomnia Treatment Drugs market: Global Industry size, share, growth, demand, trends and forecast 2026", "forum_title": "Industry Today"}, {"id": "zEo3-FN5Zwbwu9MU5wDjJWdW6fF0E4JqDjeOTCiI-JLRKb6dTE8txIyWGoBk-l_8", "result_metadata": {"score": 34.526886}, "author": "www.4-traders.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Corporate governance", "relevance": 0.84297, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Management", "relevance": 0.801, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Board of directors", "relevance": 0.788543, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}], "categories": [{"score": 0.546388, "label": "/science"}, {"score": 0.522631, "label": "/art and entertainment/movies"}, {"score": 0.431269, "label": "/business and industrial/company"}], "relations": [], "keywords": [{"text": "Strengthens Management Team", "sentiment": {"score": 0.447494, "label": "positive"}, "relevance": 0.942892}, {"text": "Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594878}, {"text": "New Directors", "sentiment": {"score": 0.447494, "label": "positive"}, "relevance": 0.575219}, {"text": "Board", "sentiment": {"score": 0.447494, "label": "positive"}, "relevance": 0.3226}]}, "crawl_date": "2018-11-07T14:31:39Z", "url": "https://www.marketscreener.com/news/Myovant-Sciences-Strengthens-Management-Team-and-Adds-New-Directors-to-the-Board--27563424/", "host": "marketscreener.com", "text": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-07T00:00:00Z", "enriched_text": {"entities": [{"count": 12, "sentiment": {"score": -0.540317, "label": "negative"}, "text": "Myovant", "relevance": 0.786684, "type": "Person"}, {"count": 4, "sentiment": {"score": -0.398488, "label": "negative"}, "text": "Vice President", "relevance": 0.776047, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences", "relevance": 0.762959, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.350266, "label": "negative"}, "text": "Senior Vice President of Technical Operations", "relevance": 0.641729, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": 0.346895, "label": "positive"}, "text": "Myovant", "relevance": 0.624391, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President of Pharmaceutical Operations & Development", "relevance": 0.570893, "type": "JobTitle"}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Board", "relevance": 0.559154, "type": "Organization", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President of Commercial Operations and Executive Vice President", "relevance": 0.55204, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": -0.540317, "label": "negative"}, "text": "endocrine diseases", "relevance": 0.545386, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}, {"count": 6, "sentiment": {"score": 0.384414, "label": "positive"}, "text": "Frank Torti", "relevance": 0.543079, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Executive Vice President and Chief Financial Officer", "relevance": 0.53501, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of Primary Care Marketing", "relevance": 0.51305, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myrtle Potter", "relevance": 0.507991, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Global Quality Affairs", "relevance": 0.503763, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President, Global Medicines Commercialization", "relevance": 0.50181, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President, U.S. Quality Operations", "relevance": 0.494683, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer of Myovant", "relevance": 0.492333, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.374377, "label": "negative"}, "text": "Jeff Nornhold", "relevance": 0.459114, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.453963, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences, Ltd.", "relevance": 0.445901, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.441472, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Financial Officer", "relevance": 0.439563, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant Sciences Ltd.", "relevance": 0.435776, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President", "relevance": 0.435553, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mark Guinan", "relevance": 0.435362, "type": "Person"}, {"count": 4, "sentiment": {"score": 0.355856, "label": "positive"}, "text": "Kim Sablich", "relevance": 0.421765, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and CEO", "relevance": 0.412479, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.350266, "label": "negative"}, "text": "Impax Laboratories", "relevance": 0.406926, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Urovant Sciences", "relevance": 0.400182, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.399468, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Commercial Officer", "relevance": 0.391785, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.386497, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant", "relevance": 0.377117, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lynn Seely", "relevance": 0.3678, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.363272, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.839652, "label": "positive"}, "text": "Ms. Potter", "relevance": 0.3593, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.432699, "label": "negative"}, "text": "Amneal Pharmaceuticals, Inc.", "relevance": 0.358761, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Pharma", "relevance": 0.347163, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.34337, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEA", "relevance": 0.342826, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "New Enterprise Associates", "dbpedia_resource": "http://dbpedia.org/resource/New_Enterprise_Associates"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BASEL", "relevance": 0.342064, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Basel", "dbpedia_resource": "http://dbpedia.org/resource/Basel"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant Sciences", "relevance": 0.336645, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Impax", "relevance": 0.327582, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0.482677, "label": "positive"}, "text": "Management Team", "relevance": 0.327405, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denison University", "relevance": 0.326997, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Denison University", "dbpedia_resource": "http://dbpedia.org/resource/Denison_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.325978, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Chicago", "relevance": 0.3252, "type": "Organization", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Operating Officer of Genentech", "relevance": 0.318417, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.317962, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.317133, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}], "sentiment": {"document": {"score": 0.162215, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D.,", "keywords": [{"text": "veterans Myrtle Potter"}, {"text": "Mark Guinan"}, {"text": "Frank Torti"}, {"text": "M.D"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}, {"type": "Person", "text": "Mark Guinan"}, {"type": "Person", "text": "Frank Torti"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Myovant", "keywords": [{"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D.,", "keywords": [{"text": "veterans Myrtle Potter"}, {"text": "Mark Guinan"}, {"text": "Frank Torti"}, {"text": "M.D"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}, {"type": "Person", "text": "Mark Guinan"}, {"type": "Person", "text": "Frank Torti"}]}, "action": {"verb": {"text": "appoint", "tense": "past"}, "text": "has appointed", "normalized": "have appoint"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "been appointed Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "appointed Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "object": {"text": "Chairman of the Board", "keywords": [{"text": "Chairman"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Chairman"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}]}, "action": {"verb": {"text": "appoint", "tense": "past"}, "text": "has been appointed", "normalized": "have be appoint"}}, {"subject": {"text": "we"}, "sentence": " 'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are pleased to announce", "normalized": "be please to announce"}}, {"subject": {"text": "we"}, "sentence": " 'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "object": {"text": "to announce the strengthening of our management team and Board", "keywords": [{"text": "strengthening"}, {"text": "management team"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Management Team"}]}, "action": {"verb": {"text": "please", "tense": "past"}, "text": "pleased", "normalized": "please"}}, {"subject": {"text": "we"}, "sentence": " 'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "object": {"text": "the strengthening of our management team and Board", "keywords": [{"text": "strengthening"}, {"text": "management team"}, {"text": "Board"}], "entities": [{"type": "JobTitle", "text": "Management Team"}]}, "action": {"verb": {"text": "announce", "tense": "future"}, "text": "are pleased to announce", "normalized": "be please to announce"}}, {"subject": {"text": "Lynn Seely, M.D., President and CEO of Myovant", "keywords": [{"text": "Lynn Seely"}, {"text": "CEO"}, {"text": "President"}, {"text": "M.D."}], "entities": [{"type": "Person", "text": "Lynn Seely"}, {"type": "JobTitle", "text": "President and CEO"}, {"type": "Company", "text": "Myovant"}]}, "sentence": " 'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "object": {"text": "'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth", "keywords": [{"text": "ongoing global Phase"}, {"text": "top-line data"}, {"text": "clinical trials"}, {"text": "management team"}], "entities": [{"type": "JobTitle", "text": "Management Team"}, {"type": "Location", "text": "Myovant", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "'Ms. Potter's decades of commercial experience", "keywords": [{"text": "commercial experience"}, {"text": "decades"}, {"text": "Potter"}], "entities": [{"type": "Person", "text": "Ms. Potter"}]}, "sentence": " 'Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "object": {"text": "her"}, "action": {"verb": {"text": "position", "tense": "present"}, "text": "position", "normalized": "position"}}, {"subject": {"text": "'Ms. Potter", "keywords": [{"text": "Potter"}], "entities": [{"type": "Person", "text": "Ms. Potter"}]}, "sentence": " 'Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "object": {"text": "Myovant's Board of diverse industry and healthcare leaders", "keywords": [{"text": "diverse industry"}, {"text": "healthcare leaders"}, {"text": "Myovant"}], "entities": [{"type": "Person", "text": "Myovant"}]}, "action": {"verb": {"text": "chair", "tense": "future"}, "text": "to chair", "normalized": "to chair"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.'", "object": {"text": "committed to achieving our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.'", "object": {"text": "to achieving our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "commit", "tense": "past"}, "text": "are committed", "normalized": "be commit"}}, {"subject": {"text": "we"}, "sentence": " Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.'", "object": {"text": "our mission of becoming the leading company in women's health and endocrine diseases", "keywords": [{"text": "endocrine diseases"}, {"text": "mission"}, {"text": "company"}, {"text": "women"}], "entities": [{"type": "HealthCondition", "text": "endocrine diseases", "disambiguation": {"subtype": ["Disease"], "name": "Endocrine disease", "dbpedia_resource": "http://dbpedia.org/resource/Endocrine_disease"}}]}, "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy.", "object": {"text": "as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy", "keywords": [{"text": "Primary Care Marketing"}, {"text": "Vice President"}, {"text": "revenue forecasts"}, {"text": "execution plans"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Primary Care Marketing"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Organization", "text": "GSK"}, {"type": "Person", "text": "Kim Sablich"}, {"type": "Location", "text": "Trelegy", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy", "keywords": [{"text": "Advair\u00ae"}, {"text": "Breo"}, {"text": "Anoro\u00ae"}, {"text": "Incruse\u00ae"}], "entities": [{"type": "Location", "text": "Trelegy", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, Tanzeum\u2122, Levitra\u00ae, and Trelegy.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "she"}, "sentence": " Prior to that, she was Vice President, Global Medicines Commercialization in the United Kingdom, and before that, Vice President, Vaccines Commercial Strategies.", "object": {"text": "Vice President, Global Medicines Commercialization in the United Kingdom, and before that, Vice President, Vaccines Commercial Strategies", "keywords": [{"text": "Vice President"}, {"text": "Global Medicines Commercialization"}, {"text": "Vaccines Commercial Strategies"}, {"text": "United Kingdom"}], "entities": [{"type": "JobTitle", "text": "Vice President, Global Medicines Commercialization"}, {"type": "Location", "text": "United Kingdom", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "JobTitle", "text": "Vice President"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "GSK", "keywords": [{"text": "GSK"}], "entities": [{"type": "Organization", "text": "GSK"}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "15 years", "entities": [{"type": "Quantity", "text": "15 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas", "keywords": [{"text": "vaccines business areas"}, {"text": "customer insights"}, {"text": "commercial organization"}, {"text": "product management"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "object": {"text": "responsibility", "keywords": [{"text": "responsibility"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "direct-to-consumer marketing"}, {"text": "extensive experience"}, {"text": "consumer strategies"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "led the development of consumer strategies and national multi-channel campaigns for multiple products", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "consumer strategies"}, {"text": "multiple products"}, {"text": "development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "Ms. Sablich", "keywords": [{"text": "Ms. Sablich"}], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " Ms. Sablich has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products.", "object": {"text": "the development of consumer strategies and national multi-channel campaigns", "keywords": [{"text": "national multi-channel campaigns"}, {"text": "consumer strategies"}, {"text": "development"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "having led", "normalized": "have lead"}}, {"subject": {"text": "She", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " She is currently a member of the Board of Directors of AllerGenis LLC.", "object": {"text": "a member of the Board of Directors of AllerGenis LLC", "keywords": [{"text": "AllerGenis LLC"}, {"text": "member"}, {"text": "Board"}, {"text": "Directors"}], "entities": [{"type": "Person", "text": "Kim Sablich"}, {"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Company", "text": "AllerGenis LLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "She", "entities": [{"type": "Person", "text": "Kim Sablich"}]}, "sentence": " She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.", "object": {"text": "a B.A.", "keywords": [{"text": "B.A"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), where he was responsible for Impax's manufacturing, supply chain, quality and technical operations.", "object": {"text": "responsible for Impax's manufacturing, supply chain, quality and technical operations", "keywords": [{"text": "Impax"}, {"text": "supply chain"}, {"text": "technical operations"}, {"text": "manufacturing"}], "entities": [{"type": "Company", "text": "Impax"}, {"type": "Person", "text": "Jeff Nornhold"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "object": {"text": "as Impax's Senior Vice President", "keywords": [{"text": "Senior Vice President"}, {"text": "Impax"}], "entities": [{"type": "Person", "text": "Impax"}, {"type": "JobTitle", "text": "Senior Vice President, Global Quality Affairs"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "object": {"text": "a sustainable quality and compliance program", "keywords": [{"text": "sustainable quality"}, {"text": "compliance program"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "establishing", "normalized": "establish"}}, {"subject": {"text": "Mr. Nornhold", "keywords": [{"text": "Mr. Nornhold"}], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Prior to Impax, Mr. Nornhold served as Vice President, Quality Operations - International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients.", "object": {"text": "as Vice President, Quality Operations - International for Watson Pharmaceuticals, Inc. (now Allergan PLC), and was responsible for ex-U.S. manufacturing sites for both dosage and active pharmaceutical ingredients", "keywords": [{"text": "active pharmaceutical ingredients"}, {"text": "Allergan PLC"}, {"text": "ex-U.S. manufacturing sites"}, {"text": "Watson Pharmaceuticals"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Watson Pharmaceuticals, Inc."}, {"type": "Company", "text": "Allergan PLC"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Watson"}]}, "sentence": " While at Watson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "object": {"text": "as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites", "keywords": [{"text": "Vice President"}, {"text": "U.S. Quality Operations"}, {"text": "quality initiatives"}, {"text": "U.S. sites"}], "entities": [{"type": "JobTitle", "text": "Vice President, U.S. Quality Operations"}, {"type": "Person", "text": "Watson"}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Watson"}]}, "sentence": " Earlier in his career, he held numerous leadership positions in the pharmaceutical industry.", "object": {"text": "numerous leadership positions", "keywords": [{"text": "numerous leadership positions"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "Mr. Nornhold", "keywords": [{"text": "Mr. Nornhold"}], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, "sentence": " Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "object": {"text": "a B.S. in chemistry", "keywords": [{"text": "B.S."}, {"text": "chemistry"}]}, "action": {"verb": {"text": "earn", "tense": "past"}, "text": "earned", "normalized": "earn"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "object": {"text": "for Roivant Pharma, a division of Roivant Sciences", "keywords": [{"text": "Roivant Pharma"}, {"text": "Roivant Sciences"}, {"text": "division"}], "entities": [{"type": "Company", "text": "Roivant Pharma"}, {"type": "Organization", "text": "Roivant Sciences"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "She"}, "sentence": " She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "object": {"text": "of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech", "keywords": [{"text": "Executive Vice President"}, {"text": "Chief Operating Officer"}, {"text": "Myrtle Potter"}, {"text": "Commercial Operations"}], "entities": [{"type": "Company", "text": "Myrtle Potter & Company"}, {"type": "Company", "text": "AllerGenis LLC"}, {"type": "JobTitle", "text": "President of Commercial Operations and Executive Vice President"}, {"type": "JobTitle", "text": "Chief Operating Officer of Genentech"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "she"}, "sentence": " Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb.", "object": {"text": "various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "various positions"}, {"text": "President"}, {"text": "Cardiovascular/Metabolics"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "President of Cardiovascular/Metabolics at Bristol-Myers Squibb", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "President"}, {"text": "Cardiovascular/Metabolics"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb.", "object": {"text": "Genentech, she held various positions", "keywords": [{"text": "various positions"}, {"text": "Genentech"}], "entities": [{"type": "Company", "text": "Genentech", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "She"}, "sentence": " She is a graduate of the University of Chicago.", "object": {"text": "a graduate of the University of Chicago", "keywords": [{"text": "graduate"}, {"text": "University"}, {"text": "Chicago"}], "entities": [{"type": "Organization", "text": "University of Chicago", "disambiguation": {"subtype": ["Location", "Company", "PeriodicalPublisher", "CollegeUniversity"], "name": "University of Chicago", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Chicago"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "object": {"text": "on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Roivant family"}, {"text": "Urovant Sciences"}, {"text": "Axovant Sciences"}], "entities": [{"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Location", "text": "Roivant", "disambiguation": {"subtype": ["City"]}}, {"type": "Company", "text": "Urovant Sciences"}, {"type": "Company", "text": "Axovant Sciences"}, {"type": "Company", "text": "Arbutus Biopharma"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "Urovant Sciences, Axovant Sciences and Arbutus Biopharma", "keywords": [{"text": "Arbutus Biopharma"}, {"text": "Urovant Sciences"}, {"text": "Axovant Sciences"}], "entities": [{"type": "Company", "text": "Urovant Sciences"}, {"type": "Company", "text": "Axovant Sciences"}, {"type": "Company", "text": "Arbutus Biopharma"}]}, "sentence": " In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "object": {"text": "companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.", "object": {"text": "previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc", "keywords": [{"text": "Medco Health Solutions"}, {"text": "Express Scripts Holding"}, {"text": "Amazon"}, {"text": "boards"}], "entities": [{"type": "Organization", "text": "Board", "disambiguation": {"subtype": ["Industry"], "name": "Board game", "dbpedia_resource": "http://dbpedia.org/resource/Board_game"}}, {"type": "Company", "text": "Amazon", "disambiguation": {"subtype": [], "name": "Amazon.com", "dbpedia_resource": "http://dbpedia.org/resource/Amazon.com"}}, {"type": "Company", "text": "Express Scripts Holding Co."}, {"type": "Company", "text": "Medco Health Solutions Inc"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ms. Potter", "keywords": [{"text": "Ms. Potter"}], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, "sentence": " Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc.", "object": {"text": "Medco Health Solutions Inc", "keywords": [{"text": "Medco Health Solutions"}], "entities": [{"type": "Company", "text": "Medco Health Solutions Inc"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc.", "object": {"text": "for Quest Diagnostics Inc", "keywords": [{"text": "Quest Diagnostics"}], "entities": [{"type": "Company", "text": "Quest Diagnostics Inc"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "object": {"text": "for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry", "keywords": [{"text": "Hill-Rom Holdings Inc."}, {"text": "medical technologies"}, {"text": "related services"}, {"text": "healthcare industry"}], "entities": [{"type": "Company", "text": "Hill-Rom Holdings Inc.", "disambiguation": {"subtype": ["Company"], "name": "Hill-Rom Holdings", "dbpedia_resource": "http://dbpedia.org/resource/Hill-Rom_Holdings"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "object": {"text": "in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business", "keywords": [{"text": "Chief Procurement Officer"}, {"text": "Vice President"}, {"text": "operations roles"}, {"text": "long career"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Chief Procurement Officer"}, {"type": "JobTitle", "text": "Chief Financial Officer"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business", "keywords": [{"text": "Chief Procurement Officer"}, {"text": "Vice President"}, {"text": "CFO"}, {"text": "pharmaceutical business"}], "entities": [{"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Chief Procurement Officer"}, {"type": "JobTitle", "text": "Chief Financial Officer"}]}, "sentence": " Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "object": {"text": "Johnson & Johnson", "keywords": [{"text": "Johnson"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "object": {"text": "Johnson & Johnson", "keywords": [{"text": "Johnson"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}, {"subject": {"text": "Mr. Guinan", "keywords": [{"text": "Mr. Guinan"}], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "object": {"text": "a number of financial roles", "keywords": [{"text": "financial roles"}, {"text": "number"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Mark Guinan"}]}, "sentence": " He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.", "object": {"text": "a B.A. in economics", "keywords": [{"text": "B.A."}, {"text": "economics"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Dr. Torti", "keywords": [{"text": "Dr. Torti"}], "entities": [{"type": "Person", "text": "Frank Torti"}]}, "sentence": " Dr. Torti serves as Vant Investment Chair for Roivant Pharma, a division of Roivant Sciences.", "object": {"text": "as Vant Investment Chair", "keywords": [{"text": "Vant Investment Chair"}], "entities": [{"type": "JobTitle", "text": "partner"}]}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}], "concepts": [{"text": "Management occupations", "relevance": 0.953873, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Vice president", "relevance": 0.6832, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Corporate governance", "relevance": 0.649409, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Vice President of the United States", "relevance": 0.641712, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Clinical trial", "relevance": 0.593127, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Chief executive officer", "relevance": 0.582733, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Vice presidents", "relevance": 0.486808, "dbpedia_resource": "http://dbpedia.org/resource/Vice_presidents"}, {"text": "George W. Bush", "relevance": 0.485794, "dbpedia_resource": "http://dbpedia.org/resource/George_W._Bush"}, {"text": "Richard Nixon", "relevance": 0.480149, "dbpedia_resource": "http://dbpedia.org/resource/Richard_Nixon"}, {"text": "Gerald Ford", "relevance": 0.47803, "dbpedia_resource": "http://dbpedia.org/resource/Gerald_Ford"}, {"text": "Chief executives", "relevance": 0.475675, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Executive officer", "relevance": 0.47427, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "De facto", "relevance": 0.469373, "dbpedia_resource": "http://dbpedia.org/resource/De_facto"}, {"text": "President pro tempore of the United States Senate", "relevance": 0.453581, "dbpedia_resource": "http://dbpedia.org/resource/President_pro_tempore_of_the_United_States_Senate"}, {"text": "Electoral College", "relevance": 0.452617, "dbpedia_resource": "http://dbpedia.org/resource/Electoral_College_(United_States)"}], "categories": [{"score": 0.594488, "label": "/health and fitness"}, {"score": 0.472831, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.431983, "label": "/finance/financial news"}], "relations": [{"type": "locatedAt", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.956957, "arguments": [{"text": "BASEL", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "BASEL"}]}, {"text": "Switzerland", "location": [7, 18], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.919569, "arguments": [{"text": "Board of Directors", "location": [761, 779], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "Myovant", "location": [751, 758], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "partOf", "sentence": "'Ms. Potter's decades of commercial experience perfectly position her to chair Myovant's Board of diverse industry and healthcare leaders.", "score": 0.824904, "arguments": [{"text": "Board of", "location": [1216, 1224], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "Myovant", "location": [1206, 1213], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "affectedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.423376, "arguments": [{"text": "Potter", "location": [789, 795], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "appointed", "location": [805, 814], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "affectedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.499875, "arguments": [{"text": "Chairman", "location": [815, 823], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "appointed", "location": [805, 814], "entities": [{"type": "EventPersonnel", "text": "appointed"}]}]}, {"type": "employedBy", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.599421, "arguments": [{"text": "Chairman", "location": [815, 823], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "Board", "location": [831, 836], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "agentOf", "sentence": "'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "score": 0.569544, "arguments": [{"text": "we", "location": [937, 939], "entities": [{"type": "Person", "text": "we"}]}, {"text": "announce", "location": [955, 963], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "score": 0.891942, "arguments": [{"text": "management team", "location": [989, 1004], "entities": [{"type": "Person", "text": "management team"}]}, {"text": "our", "location": [985, 988], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "agentOf", "sentence": "'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "score": 0.760998, "arguments": [{"text": "Lynn Seely", "location": [1079, 1089], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "said", "location": [1074, 1078], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "'With top-line data from each of our five ongoing global Phase 3 clinical trials expected in 2019, we are pleased to announce the strengthening of our management team and Board as we look forward to the next stage of Myovant's growth,' said Lynn Seely, M.D., President and CEO of Myovant.", "score": 0.79961, "arguments": [{"text": "CEO", "location": [1111, 1114], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "Myovant", "location": [1118, 1125], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.", "score": 0.708248, "arguments": [{"text": "Chief Executive Officer", "location": [6424, 6447], "entities": [{"type": "Person", "text": "Lynn Seely"}]}, {"text": "Myovant", "location": [6451, 6458], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "employedBy", "sentence": "Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.", "score": 0.357695, "arguments": [{"text": "women", "location": [1353, 1358], "entities": [{"type": "Person", "text": "women"}]}, {"text": "company", "location": [1342, 1349], "entities": [{"type": "Organization", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "hasAttribute", "sentence": "Together, we are committed to achieving our mission of becoming the leading company in women's health and endocrine diseases.", "score": 0.683725, "arguments": [{"text": "women", "location": [1353, 1358], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [1382, 1390], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "' Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.413073, "arguments": [{"text": "Ms.", "location": [1432, 1435], "entities": [{"type": "Person", "text": "Kim Sablich"}]}, {"text": "Myovant's Management Team", "location": [1406, 1431], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.923866, "arguments": [{"text": "Ltd.", "location": [67, 71], "entities": [{"type": "Organization", "text": "Ltd.\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "MYOV", "location": [79, 83], "entities": [{"type": "Ticker", "text": "MYOV"}]}]}, {"type": "locatedAt", "sentence": "' Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.335323, "arguments": [{"text": "she", "location": [1540, 1543], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "where", "location": [1534, 1539], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "locatedAt", "sentence": "Before joining GSK, Ms. Sablich spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organization across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas.", "score": 0.244545, "arguments": [{"text": "she", "location": [1957, 1960], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "where", "location": [1951, 1956], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "memberOf", "sentence": "She is currently a member of the Board of Directors of AllerGenis LLC.", "score": 0.805736, "arguments": [{"text": "member", "location": [2385, 2391], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Board of Directors of AllerGenis LLC", "location": [2399, 2435], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "affectedBy", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.", "score": 0.515151, "arguments": [{"text": "She", "location": [2437, 2440], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "earned", "location": [2441, 2447], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "educatedAt", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.", "score": 0.770997, "arguments": [{"text": "She", "location": [2437, 2440], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Denison University", "location": [2460, 2478], "entities": [{"type": "Organization", "text": "Denison University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "agentOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.", "score": 0.803177, "arguments": [{"text": "M.B.A.", "location": [2486, 2492], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "earned", "location": [2441, 2447], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.", "score": 0.782197, "arguments": [{"text": "The Wharton School of the University of Pennsylvania", "location": [2498, 2550], "entities": [{"type": "Organization", "text": "The Wharton School of the University of Pennsylvania"}]}, {"text": "earned", "location": [2441, 2447], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "partOf", "sentence": "She earned a B.A. from Denison University and an M.B.A. from The Wharton School of the University of Pennsylvania.", "score": 0.656094, "arguments": [{"text": "M.B.A.", "location": [2486, 2492], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "The Wharton School of the University of Pennsylvania", "location": [2498, 2550], "entities": [{"type": "Organization", "text": "The Wharton School of the University of Pennsylvania"}]}]}, {"type": "employedBy", "sentence": "Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "score": 0.464161, "arguments": [{"text": "Senior Vice President", "location": [2827, 2848], "entities": [{"type": "Person", "text": "Senior Vice President"}]}, {"text": "Impax", "location": [2819, 2824], "entities": [{"type": "Organization", "text": "Technical Operations for Impax Laboratories"}]}]}, {"type": "partOf", "sentence": "Prior to that, he served as Impax's Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program.", "score": 0.286576, "arguments": [{"text": "Impax", "location": [2819, 2824], "entities": [{"type": "Organization", "text": "Technical Operations for Impax Laboratories"}]}, {"text": "Global Quality Affairs", "location": [2850, 2872], "entities": [{"type": "Organization", "text": "Global Quality Affairs", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.77953, "arguments": [{"text": "women", "location": [196, 201], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [225, 233], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "partOf", "sentence": "While at Watson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.986659, "arguments": [{"text": "Quality Operations", "location": [3263, 3281], "entities": [{"type": "Organization", "text": "Quality Operations"}]}, {"text": "U.S.", "location": [3258, 3262], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "While at Watson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.472767, "arguments": [{"text": "he", "location": [3289, 3291], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "execution", "location": [3316, 3325], "entities": [{"type": "EventLegal", "text": "execution"}]}]}, {"type": "locatedAt", "sentence": "While at Watson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites.", "score": 0.153194, "arguments": [{"text": "sites", "location": [3362, 3367], "entities": [{"type": "Location", "text": "sites"}]}, {"text": "U.S.", "location": [3357, 3361], "entities": [{"type": "GeopoliticalEntity", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "affectedBy", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.916672, "arguments": [{"text": "Nornhold", "location": [3466, 3474], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "earned", "location": [3475, 3481], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "awardedTo", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.677837, "arguments": [{"text": "B.S.", "location": [3484, 3488], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "Nornhold", "location": [3466, 3474], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}]}, {"type": "educatedAt", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.522032, "arguments": [{"text": "Nornhold", "location": [3466, 3474], "entities": [{"type": "Person", "text": "Jeff Nornhold"}]}, {"text": "University of Southern California Marshall School of Business", "location": [3561, 3622], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.967546, "arguments": [{"text": "Bowling Green State University", "location": [3507, 3537], "entities": [{"type": "Organization", "text": "Bowling Green State University"}]}, {"text": "earned", "location": [3475, 3481], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.931533, "arguments": [{"text": "M.B.A.", "location": [3545, 3551], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "earned", "location": [3475, 3481], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "agentOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.815323, "arguments": [{"text": "University of Southern California Marshall School of Business", "location": [3561, 3622], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}, {"text": "earned", "location": [3475, 3481], "entities": [{"type": "EventEducation", "text": "earned"}]}]}, {"type": "awardedBy", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.562099, "arguments": [{"text": "B.S.", "location": [3484, 3488], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "Bowling Green State University", "location": [3507, 3537], "entities": [{"type": "Organization", "text": "Bowling Green State University"}]}]}, {"type": "timeOf", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.956741, "arguments": [{"text": "today", "location": [235, 240], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [241, 250], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Mr. Nornhold earned a B.S. in chemistry from Bowling Green State University and an M.B.A. from the University of Southern California Marshall School of Business.", "score": 0.516218, "arguments": [{"text": "M.B.A.", "location": [3545, 3551], "entities": [{"type": "Organization", "text": "M.B.A."}]}, {"text": "University of Southern California Marshall School of Business", "location": [3561, 3622], "entities": [{"type": "Organization", "text": "University of Southern California Marshall School of Business"}]}]}, {"type": "employedBy", "sentence": "New Myovant Directors Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.60273, "arguments": [{"text": "Directors", "location": [3636, 3645], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Myovant", "location": [3628, 3635], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "partOf", "sentence": "New Myovant Directors Ms. Potter currently serves as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.880253, "arguments": [{"text": "division", "location": [3720, 3728], "entities": [{"type": "Organization", "text": "Chair for Roivant Pharma"}]}, {"text": "Roivant Sciences", "location": [3732, 3748], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "partOf", "sentence": "Dr. Torti serves as Vant Investment Chair for Roivant Pharma, a division of Roivant Sciences.", "score": 0.882512, "arguments": [{"text": "division", "location": [5227, 5235], "entities": [{"type": "Organization", "text": "Chair for Roivant Pharma"}]}, {"text": "Roivant Sciences", "location": [5239, 5255], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.361243, "arguments": [{"text": "Myrtle Potter", "location": [3802, 3815], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "Company", "location": [3818, 3825], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.543684, "arguments": [{"text": "President", "location": [3836, 3845], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "Commercial Operations", "location": [3849, 3870], "entities": [{"type": "Organization", "text": "Commercial Operations", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.417585, "arguments": [{"text": "Executive Vice President", "location": [3875, 3899], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "Genentech", "location": [3932, 3941], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "She previously served as Chief Executive Officer of Myrtle Potter & Company, LLC, and President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech.", "score": 0.582966, "arguments": [{"text": "Chief Operating Officer", "location": [3905, 3928], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "Genentech", "location": [3932, 3941], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb.", "score": 0.495487, "arguments": [{"text": "President", "location": [4001, 4010], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "Cardiovascular", "location": [4014, 4028], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}]}, {"type": "partOf", "sentence": "Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb.", "score": 0.472406, "arguments": [{"text": "Cardiovascular", "location": [4014, 4028], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}, {"text": "Bristol-Myers Squibb", "location": [4043, 4063], "entities": [{"type": "Organization", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "educatedAt", "sentence": "She is a graduate of the University of Chicago.", "score": 0.588971, "arguments": [{"text": "graduate", "location": [4074, 4082], "entities": [{"type": "Person", "text": "Executive Vice President"}]}, {"text": "University of Chicago", "location": [4090, 4111], "entities": [{"type": "Organization", "text": "University of Chicago"}]}]}, {"type": "partOf", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.876053, "arguments": [{"text": "Board", "location": [4143, 4148], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "our", "location": [4139, 4142], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "managerOf", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.634813, "arguments": [{"text": "Vice President", "location": [278, 292], "entities": [{"type": "Person", "text": "Chief Procurement Officer"}]}, {"text": "Primary Care Marketing", "location": [296, 318], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.630567, "arguments": [{"text": "family", "location": [4221, 4227], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Roivant", "location": [4213, 4220], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.630567, "arguments": [{"text": "family", "location": [5843, 5849], "entities": [{"type": "Person", "text": "family"}]}, {"text": "Roivant", "location": [5835, 5842], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Ms. Potter also serves on the boards of other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences and Arbutus Biopharma.", "score": 0.26758, "arguments": [{"text": "family", "location": [4221, 4227], "entities": [{"type": "Person", "text": "family"}]}, {"text": "companies", "location": [4231, 4240], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "partOf", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.371016, "arguments": [{"text": "Amazon", "location": [4360, 4366], "entities": [{"type": "Organization", "text": "Amazon"}]}, {"text": "Express Scripts Holding Co.", "location": [4368, 4395], "entities": [{"type": "Organization", "text": "Express Scripts Holding Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.563959, "arguments": [{"text": "Mr.", "location": [4429, 4432], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "Medco Health Solutions Inc.", "location": [4401, 4428], "entities": [{"type": "Organization", "text": "Medco Health Solutions Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Ms. Potter has previously served on the boards of Amazon, Express Scripts Holding Co., and Medco Health Solutions Inc. Mr. Guinan serves as the Executive Vice President and Chief Financial Officer for Quest Diagnostics Inc. He previously served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the healthcare industry.", "score": 0.732579, "arguments": [{"text": "Chief Financial Officer", "location": [4483, 4506], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "Quest Diagnostics Inc.", "location": [4511, 4533], "entities": [{"type": "Organization", "text": "Quest Diagnostics Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Prior to that, he served in a number of finance and operations roles in a long career at Johnson & Johnson, including as Vice President, Chief Procurement Officer, and as CFO of the pharmaceutical business.", "score": 0.654973, "arguments": [{"text": "CFO", "location": [4883, 4886], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "pharmaceutical business", "location": [4894, 4917], "entities": [{"type": "Organization", "text": "pharmaceutical business", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Before joining Johnson & Johnson, Mr. Guinan held a number of financial roles at Procter & Gamble.", "score": 0.691061, "arguments": [{"text": "Guinan", "location": [4957, 4963], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "Procter & Gamble", "location": [5000, 5016], "entities": [{"type": "Organization", "text": "Procter & Gamble", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.", "score": 0.759648, "arguments": [{"text": "B.A.", "location": [5032, 5036], "entities": [{"type": "Degree", "text": "B.A."}]}, {"text": "He", "location": [5018, 5020], "entities": [{"type": "Person", "text": "Mark Guinan"}]}]}, {"type": "managerOf", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.", "score": 0.490685, "arguments": [{"text": "Olin", "location": [5103, 5107], "entities": [{"type": "Person", "text": "Olin"}]}, {"text": "Business School", "location": [5108, 5123], "entities": [{"type": "Organization", "text": "Business School"}]}]}, {"type": "employedBy", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.", "score": 0.589514, "arguments": [{"text": "Olin", "location": [5103, 5107], "entities": [{"type": "Person", "text": "Olin"}]}, {"text": "Washington University", "location": [5127, 5148], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "locatedAt", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.502038, "arguments": [{"text": "Primary Care Marketing", "location": [296, 318], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}, {"text": "United States", "location": [326, 339], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "' Additions to Myovant's Management Team Ms. Sablich previously served as Vice President, Primary Care Marketing in the United States for GSK, where she was responsible for revenue forecasts, product strategies and execution plans for a broad portfolio of products including Advair\u00ae, Breo, Anoro\u00ae, Incruse\u00ae, TanzeumM, Levitra\u00ae, and Trelegy.", "score": 0.589281, "arguments": [{"text": "Primary Care Marketing", "location": [1481, 1503], "entities": [{"type": "Organization", "text": "Primary Care Marketing"}]}, {"text": "United States", "location": [1511, 1524], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.", "score": 0.722472, "arguments": [{"text": "Business School", "location": [5108, 5123], "entities": [{"type": "Organization", "text": "Business School"}]}, {"text": "Washington University", "location": [5127, 5148], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "basedIn", "sentence": "He received a B.A. in economics from the University of Notre Dame and an M.B.A. from Olin Business School at Washington University in St. Louis.", "score": 0.75597, "arguments": [{"text": "Washington University", "location": [5127, 5148], "entities": [{"type": "Organization", "text": "Washington University", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "St. Louis", "location": [5152, 5161], "entities": [{"type": "GeopoliticalEntity", "text": "St. Louis"}]}]}, {"type": "employedBy", "sentence": "Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm.", "score": 0.747172, "arguments": [{"text": "partner", "location": [5284, 5291], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "New Enterprise Associates", "location": [5295, 5320], "entities": [{"type": "Organization", "text": "New Enterprise Associates", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to Roivant, he was a partner at New Enterprise Associates (NEA), a leading venture capital firm.", "score": 0.500302, "arguments": [{"text": "partner", "location": [5284, 5291], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "venture capital firm", "location": [5338, 5358], "entities": [{"type": "Organization", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "employedBy", "sentence": "Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials.", "score": 0.623622, "arguments": [{"text": "researcher", "location": [5546, 5556], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "Duke University Center for Clinical & Genetic Economics where", "location": [5564, 5625], "entities": [{"type": "Organization", "text": "Duke University Center for Clinical & Genetic Economics where"}]}]}, {"type": "employedBy", "sentence": "Prior to NEA, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trial research and economic evaluations of multinational clinical trials.", "score": 0.25709, "arguments": [{"text": "he", "location": [5626, 5628], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "Duke University Center for Clinical & Genetic Economics where", "location": [5564, 5625], "entities": [{"type": "Organization", "text": "Duke University Center for Clinical & Genetic Economics where"}]}]}, {"type": "partOf", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.876053, "arguments": [{"text": "Board", "location": [5758, 5763], "entities": [{"type": "Organization", "text": "Board of Directors of AllerGenis LLC"}]}, {"text": "our", "location": [5754, 5757], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "In addition to serving on our Board, Dr. Torti also serves on the boards of several other companies in the Roivant family of companies, including Urovant Sciences, Axovant Sciences, Dermavant Sciences and Respivant Sciences.", "score": 0.26758, "arguments": [{"text": "family", "location": [5843, 5849], "entities": [{"type": "Person", "text": "family"}]}, {"text": "companies", "location": [5853, 5862], "entities": [{"type": "Organization", "text": "companies"}]}]}, {"type": "employedBy", "sentence": "Dr. Torti received an M.D. from the University of North Carolina School of Medicine and an M.B.A. with distinction from Harvard Business School.", "score": 0.420243, "arguments": [{"text": "M.D.", "location": [5975, 5979], "entities": [{"type": "Person", "text": "Frank Torti"}]}, {"text": "University of North Carolina School of Medicine", "location": [5989, 6036], "entities": [{"type": "Organization", "text": "University of North Carolina School of Medicine"}]}]}, {"type": "partOfMany", "sentence": "Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.", "score": 0.775883, "arguments": [{"text": "Kathleen Sebelius", "location": [6132, 6149], "entities": [{"type": "Person", "text": "Kathleen Sebelius"}]}, {"text": "directors", "location": [6114, 6123], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.", "score": 0.661912, "arguments": [{"text": "Secretary of Health and Human Services", "location": [6163, 6201], "entities": [{"type": "Person", "text": "Secretary of Health and Human Services"}]}, {"text": "directors", "location": [6114, 6123], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ -- Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the United States for GlaxoSmithKline (GSK), will join Myovant Sciences as Chief Commercial Officer, and Jeff Nornhold, formerly Senior Vice President of Technical Operations for Impax Laboratories (now Amneal Pharmaceuticals, Inc.), has joined Myovant as Senior Vice President of Pharmaceutical Operations & Development.", "score": 0.526746, "arguments": [{"text": "Senior Vice President of", "location": [578, 602], "entities": [{"type": "Person", "text": "Senior Vice President of"}]}, {"text": "Pharmaceutical Operations & Development", "location": [603, 642], "entities": [{"type": "Organization", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "employedBy", "sentence": "Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.", "score": 0.898976, "arguments": [{"text": "Secretary of Health and Human Services", "location": [6163, 6201], "entities": [{"type": "Person", "text": "Secretary of Health and Human Services"}]}, {"text": "U.S.", "location": [6158, 6162], "entities": [{"type": "GeopoliticalEntity", "text": "Pharmaceutical Operations & Development"}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.", "score": 0.964757, "arguments": [{"text": "Obama", "location": [6213, 6218], "entities": [{"type": "Person", "text": "Obama"}]}, {"text": "administration", "location": [6219, 6233], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "Myovant's other directors include Kathleen Sebelius, former U.S. Secretary of Health and Human Services during the Obama administration; Vivek Ramaswamy, the founder and CEO of Roivant Sciences; Terrie Curran, President, Global Inflammation and Immunology Franchise of Celgene Corporation; and Lynn Seely, M.D., President and Chief Executive Officer of Myovant.", "score": 0.787492, "arguments": [{"text": "CEO", "location": [6268, 6271], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "Roivant Sciences", "location": [6275, 6291], "entities": [{"type": "Organization", "text": "Roivant Sciences"}]}]}, {"type": "hasAttribute", "sentence": "About Myovant Sciences Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.", "score": 0.748964, "arguments": [{"text": "women", "location": [6630, 6635], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [6659, 6667], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "employedBy", "sentence": "Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.", "score": 0.317786, "arguments": [{"text": "candidate", "location": [6692, 6701], "entities": [{"type": "Person", "text": "Kathleen Sebelius"}]}, {"text": "Myovant", "location": [6669, 6676], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.926071, "arguments": [{"text": "men", "location": [7087, 7090], "entities": [{"type": "Person", "text": "women"}]}, {"text": "prostate cancer", "location": [7105, 7120], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO).", "score": 0.833615, "arguments": [{"text": "HERO", "location": [7122, 7126], "entities": [{"type": "Person", "text": "HERO"}]}, {"text": "prostate cancer", "location": [7105, 7120], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "managerOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.679646, "arguments": [{"text": "Takeda", "location": [7318, 7324], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Pharmaceuticals International AG", "location": [7325, 7357], "entities": [{"type": "Organization", "text": "Pharmaceuticals International AG"}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.469702, "arguments": [{"text": "Takeda", "location": [7318, 7324], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "granted", "location": [7358, 7365], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.923796, "arguments": [{"text": "Pharmaceuticals International AG", "location": [7325, 7357], "entities": [{"type": "Organization", "text": "Pharmaceuticals International AG"}]}, {"text": "granted", "location": [7358, 7365], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.842806, "arguments": [{"text": "Myrtle Potter", "location": [697, 710], "entities": [{"type": "Person", "text": "Myrtle Potter"}]}, {"text": "veterans", "location": [688, 696], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.499432, "arguments": [{"text": "Myovant", "location": [7366, 7373], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "granted", "location": [7358, 7365], "entities": [{"type": "EntertainmentAward", "text": "granted"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.793107, "arguments": [{"text": "countries", "location": [7486, 7495], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Asian", "location": [7480, 7485], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.252388, "arguments": [{"text": "countries", "location": [7486, 7495], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "where", "location": [7496, 7501], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "locatedAt", "sentence": "Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.", "score": 0.322552, "arguments": [{"text": "Takeda", "location": [7502, 7508], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "where", "location": [7496, 7501], "entities": [{"type": "Facility", "text": "where"}]}]}, {"type": "employedBy", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.307066, "arguments": [{"text": "women", "location": [7729, 7734], "entities": [{"type": "Person", "text": "women"}]}, {"text": "its", "location": [7662, 7665], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}, {"type": "hasAttribute", "sentence": "Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases.", "score": 0.66745, "arguments": [{"text": "women", "location": [7729, 7734], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [7758, 7766], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "For more information, please visit Myovant's website at www.myovant.com .", "score": 0.698574, "arguments": [{"text": "Myovant", "location": [7803, 7810], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "www.myovant.com", "location": [7824, 7839], "entities": [{"type": "Web", "text": "www.myovant.com"}]}]}, {"type": "hasAttribute", "sentence": "Forward-Looking Statements This press release contains forward-looking statements, including without limitation: Myovant's focus on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases; and the statements and quote related to the timing of reporting clinical trial results.", "score": 0.748964, "arguments": [{"text": "women", "location": [8047, 8052], "entities": [{"type": "Person", "text": "women"}]}, {"text": "diseases", "location": [8076, 8084], "entities": [{"type": "HealthCondition", "text": "prostate cancer"}]}]}, {"type": "agentOf", "sentence": "Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled 'Risk Factors' set forth in Myovant's Quarterly Report on Form 10-Q which was filed with the Securities and Exchange Commission on August 7, 2018, and other filings that Myovant makes with the SEC from time to time.", "score": 0.890088, "arguments": [{"text": "Myovant", "location": [9323, 9330], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}, {"text": "Report", "location": [9343, 9349], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.", "score": 0.811261, "arguments": [{"text": "investors", "location": [9931, 9940], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "cautioned", "location": [9945, 9954], "entities": [{"type": "EventCommunication", "text": "cautioned"}]}]}, {"type": "partOfMany", "sentence": "In addition, Myovant has appointed industry veterans Myrtle Potter, Mark Guinan, and Frank Torti, M.D., to Myovant's Board of Directors, and Ms. Potter has been appointed Chairman of the Board.", "score": 0.977454, "arguments": [{"text": "Mark Guinan", "location": [712, 723], "entities": [{"type": "Person", "text": "Mark Guinan"}]}, {"text": "veterans", "location": [688, 696], "entities": [{"type": "Person", "text": "veterans"}]}]}, {"type": "employedBy", "sentence": "Investor Contact : Frank Karbe Chief Financial Officer Myovant Sciences, Inc. investors@myovant.com Media Contact : Julie Normart W2O pure jnormart@w2ogroup.com 415.946.1087 View original content to download multimedia: http://www.prnewswire.com/news-releases/myovant-strengthens-management-team-and-adds-new-directors-to-the-board-300745444.html SOURCE Myovant Sciences, Ltd. Attachments Original document Permalink Disclaimer Myovant Sciences Ltd. published this content on 07 November 2018 and is solely responsible for the information contained herein.", "score": 0.545099, "arguments": [{"text": "Julie Normart\nW2O", "location": [10284, 10301], "entities": [{"type": "Person", "text": "Julie Normart\nW2O"}]}, {"text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact", "location": [10223, 10281], "entities": [{"type": "Organization", "text": "Myovant Sciences, Inc.\ninvestors@myovant.com\nMedia Contact"}]}]}], "keywords": [{"text": "Vice President", "sentiment": {"score": -0.374377, "label": "negative"}, "relevance": 0.93303}, {"text": "Senior Vice President", "sentiment": {"score": -0.350266, "label": "negative"}, "relevance": 0.771976}, {"text": "forward-looking statements", "sentiment": {"score": -0.340174, "label": "negative"}, "relevance": 0.746383}, {"text": "Myovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672074}, {"text": "Executive Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.60972}, {"text": "Chief Financial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587037}, {"text": "endocrine diseases", "sentiment": {"score": -0.540317, "label": "negative"}, "relevance": 0.58634}, {"text": "Dr. Torti", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572563}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534156}, {"text": "Ms. Potter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527544}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518701}, {"text": "Primary Care Marketing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518184}, {"text": "Roivant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.489484}, {"text": "clinical trials", "sentiment": {"score": -0.320971, "label": "negative"}, "relevance": 0.483249}, {"text": "New Myovant Directors", "sentiment": {"score": 0.724216, "label": "positive"}, "relevance": 0.483037}, {"text": "Myovant Sciences Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48201}, {"text": "innovative therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476587}, {"text": "Ms. Sablich", "sentiment": {"score": 0.355856, "label": "positive"}, "relevance": 0.474587}, {"text": "technical operations", "sentiment": {"score": 0.021767, "label": "positive"}, "relevance": 0.47332}, {"text": "Mr. Nornhold", "sentiment": {"score": -0.374377, "label": "negative"}, "relevance": 0.466331}, {"text": "Chief Commercial Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457686}, {"text": "Impax Laboratories", "sentiment": {"score": -0.350266, "label": "negative"}, "relevance": 0.452604}, {"text": "actual results", "sentiment": {"score": -0.340174, "label": "negative"}, "relevance": 0.444808}, {"text": "U.S. Quality Operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436878}, {"text": "Urovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436508}, {"text": "Axovant Sciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436481}, {"text": "Chief Operating Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433784}, {"text": "Vaccines Commercial Strategies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427458}, {"text": "Chief Procurement Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427116}, {"text": "Green State University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426881}, {"text": "Global Quality Affairs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425602}, {"text": "Amneal Pharmaceuticals", "sentiment": {"score": -0.464058, "label": "negative"}, "relevance": 0.425468}, {"text": "Mr. Guinan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425434}, {"text": "veterans Myrtle Potter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424554}, {"text": "Lynn Seely", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423026}, {"text": "Roivant Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422562}, {"text": "Roivant family", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421301}, {"text": "Olin Business School", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421125}, {"text": "vaccines business areas", "sentiment": {"score": -0.323443, "label": "negative"}, "relevance": 0.420728}, {"text": "Medco Health Solutions", "sentiment": {"score": 0.480265, "label": "positive"}, "relevance": 0.420155}, {"text": "Global Medicines Commercialization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41901}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418304}, {"text": "management team", "sentiment": {"score": 0.482677, "label": "positive"}, "relevance": 0.418267}, {"text": "ongoing global Phase", "sentiment": {"score": -0.320971, "label": "negative"}, "relevance": 0.417938}, {"text": "clinical trial results", "sentiment": {"score": -0.252545, "label": "negative"}, "relevance": 0.417843}, {"text": "Duke University Center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417327}, {"text": "clinical trial research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416778}, {"text": "multinational clinical trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415957}, {"text": "Harvard Business School", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41566}, {"text": "numerous healthcare companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414683}]}, "extracted_metadata": {"sha1": "9b8f85f02d822109f40042d1c6475dd352fdcf63", "filename": "1541601099368.zip-315dc405df1dd29f32ed04ffb99e89b4.xml", "file_type": "json"}, "external_links": ["http://investors.myovant.com/news-releases/2018/11-07-2018-133112398", "http://www.myovant.com/", "http://www.publicnow.com/view/B447B3797DF0927E48627DD7F5AC9E0E192738BE", "http://www.prnewswire.com/news-releases/myovant-strengthens-management-team-and-adds-new-directors-to-the-board-300745444.html"], "title": "Myovant Sciences : Strengthens Management Team and Adds New Directors to the Board", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "dorq-Yr4INhJ9kupJwz_aLb7Ja-WMnpddS9OG7MeGFjhKaWuzXnaiR8w7adZ3zTx", "result_metadata": {"score": 33.235275}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.325017, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.725716, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910547}, {"text": "Barclays", "sentiment": {"score": 0.325017, "label": "positive"}, "relevance": 0.775237}, {"text": "Amendment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.639858}]}, "crawl_date": "2018-11-06T17:50:37Z", "url": "http://www.4-traders.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-Amendment-27556787/", "host": "4-traders.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T00:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.768629, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.670315, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.622507, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.539728, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.523084, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470354, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.429685, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.413243, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,661,364 1.49%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,775,786 1.48%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,185,679 1.53%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,382,579 4.20%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,958,750 4.30%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.413243, "type": "Quantity"}], "sentiment": {"document": {"score": 0.108646, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,958,750 4.30% 33,382,579 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,382,579 4.20"}, {"type": "Quantity", "text": "33,958,750 4.30"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,661,364 1.49% 12,185,679 1.53% (2) Cash-settled derivatives: 11,775,786 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,958,750 4.30% 33,382,579 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 06 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 06 November 2018 15:45:04 UTC", "object": {"text": "04 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.976642, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.738485, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.694815, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.618623, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.504929, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.410101, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.403195, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378276, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.347171, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.324863, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.323927, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Barclays", "relevance": 0.311982, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Unit type", "relevance": 0.301912, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.298787, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}], "categories": [{"score": 0.579378, "label": "/real estate/buying and selling homes"}, {"score": 0.479027, "label": "/finance/financial news"}, {"score": 0.441203, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 3,200 4,593.4218 JPY Ordinary NPV Sale 5,000 4,618.5000 JPY Ordinary NPV Sale 5,800 4,591.7931 JPY Ordinary NPV Sale 7,300 4,620.4246 JPY Ordinary NPV Sale 7,800 4,617.1794 JPY Ordinary NPV Sale 9,100 4,623.8131 JPY Ordinary NPV Sale 19,500 4,627.0000 JPY Ordinary NPV Sale 35,000 TRANSFER Ordinary NPV Sale 87,500 4,612.3805 JPY Ordinary NPV Sale 112,200 4,600.9073 JPY Ordinary NPV Sale 405,900 4,599.9152 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 27,900 4,595.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5290, 5291], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5293, 5300], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6264, 6270], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6281, 6288], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7189, 7195], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7203, 7207], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7645, 7651], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7659, 7672], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7270, 7294], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7262, 7267], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9791, 9815], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9783, 9788], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7429, 7434], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7448, 7475], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9950, 9955], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9969, 9996], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7721, 7727], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7753, 7765], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9285, 9286], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9276, 9284], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005644/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 06 November 2018 and is solely responsible for the information contained herein.", "score": 0.990154, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10162, 10195], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10196, 10205], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005644/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 06 November 2018 and is solely responsible for the information contained herein.", "score": 0.648658, "arguments": [{"text": "November 2018", "location": [10225, 10238], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10196, 10205], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975925}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.83233}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.795155}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507263}, {"text": "TRANSFER Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506266}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501822}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500621}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.482082}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459972}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446833}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418884}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403557}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.367609}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362186}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355904}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354998}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354531}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354004}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352646}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352397}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351798}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351434}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.350688}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.348719}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339301}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.335605}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.335333}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.3353}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335069}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.334789}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334738}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333995}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33392}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33384}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333739}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333362}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333045}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332529}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332222}, {"text": "agreements", "sentiment": {"score": 0.0334629, "label": "positive"}, "relevance": 0.332206}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33193}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331392}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331386}, {"text": "disclosure requirements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331349}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.331152}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331085}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330985}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329955}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329785}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329631}]}, "extracted_metadata": {"sha1": "f84db090ebdd218236f357e28d3b68ed5e36e813", "filename": "1541526637569.zip-8841ac984cb72d8c62a40bdc870c0e77.xml", "file_type": "json"}, "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51894276&newsitemid=20181106005644&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=5d2ce51607ac7d116a5f90f817e7137d", "https://www.businesswire.com/news/home/20181106005644/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51894276&newsitemid=20181106005644&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=738fefea6ae35c9b9fdbbc7e5b5e1365", "http://www.publicnow.com/view/9DCE7F700476336D5125B95D5B3D4C9F35BDA173", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1205586"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - Amendment", "forum_title": "F100 Stock Quote | FTSE 100 Index Stock Price () | Autre: F100 | MarketScreener"}, {"id": "s0pxmlYKYX9i_QGeT8df72oThXyIAq5jdLd725NVA6Mko2MlEVHrylYT6llPoSFN", "result_metadata": {"score": 32.842712}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.325017, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.725716, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.967508}, {"text": "Amendment | MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.828342}, {"text": "Barclays", "sentiment": {"score": 0.325017, "label": "positive"}, "relevance": 0.697545}]}, "crawl_date": "2018-11-06T16:11:37Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-Amendment-27556787/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.768629, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.670315, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.622507, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.539728, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.523084, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470354, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.429685, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.413243, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,661,364 1.49%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,775,786 1.48%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,185,679 1.53%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,382,579 4.20%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,958,750 4.30%", "relevance": 0.413243, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.413243, "type": "Quantity"}], "sentiment": {"document": {"score": 0.108646, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,958,750 4.30% 33,382,579 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,382,579 4.20"}, {"type": "Quantity", "text": "33,958,750 4.30"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,661,364 1.49% 12,185,679 1.53% (2) Cash-settled derivatives: 11,775,786 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,958,750 4.30% 33,382,579 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 06 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 06 November 2018 15:45:04 UTC", "object": {"text": "04 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.976642, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.738485, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.694815, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.618623, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.504929, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.410101, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.403195, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378276, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.347171, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.324863, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.323927, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Barclays", "relevance": 0.311982, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Unit type", "relevance": 0.301912, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.298787, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}], "categories": [{"score": 0.579378, "label": "/real estate/buying and selling homes"}, {"score": 0.479027, "label": "/finance/financial news"}, {"score": 0.441203, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 3,200 4,593.4218 JPY Ordinary NPV Sale 5,000 4,618.5000 JPY Ordinary NPV Sale 5,800 4,591.7931 JPY Ordinary NPV Sale 7,300 4,620.4246 JPY Ordinary NPV Sale 7,800 4,617.1794 JPY Ordinary NPV Sale 9,100 4,623.8131 JPY Ordinary NPV Sale 19,500 4,627.0000 JPY Ordinary NPV Sale 35,000 TRANSFER Ordinary NPV Sale 87,500 4,612.3805 JPY Ordinary NPV Sale 112,200 4,600.9073 JPY Ordinary NPV Sale 405,900 4,599.9152 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 27,900 4,595.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5290, 5291], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5293, 5300], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6264, 6270], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6281, 6288], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7189, 7195], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7203, 7207], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7645, 7651], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7659, 7672], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7270, 7294], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7262, 7267], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9791, 9815], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9783, 9788], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7429, 7434], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7448, 7475], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9950, 9955], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9969, 9996], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7721, 7727], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7753, 7765], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9285, 9286], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9276, 9284], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005644/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 06 November 2018 and is solely responsible for the information contained herein.", "score": 0.990154, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10162, 10195], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10196, 10205], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005644/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 06 November 2018 and is solely responsible for the information contained herein.", "score": 0.648658, "arguments": [{"text": "November 2018", "location": [10225, 10238], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10196, 10205], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975925}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.83233}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.795155}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507263}, {"text": "TRANSFER Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506266}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501822}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500621}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.482082}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459972}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446833}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418884}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403557}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.367609}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362186}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355904}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354998}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354531}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354004}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352646}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352397}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351798}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351434}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.350688}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.348719}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339301}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.335605}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.335333}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.3353}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335069}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.334789}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334738}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333995}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33392}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33384}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333739}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333362}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333045}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332529}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332222}, {"text": "agreements", "sentiment": {"score": 0.0334629, "label": "positive"}, "relevance": 0.332206}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33193}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331392}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331386}, {"text": "disclosure requirements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331349}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.331152}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331085}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330985}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329955}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329785}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329631}]}, "extracted_metadata": {"sha1": "40c0fc7be8f4fe0fde59173ed51a5d732b843d4f", "filename": "1541520697589.zip-5c43a19d7ee37cc09d0ddb163f0beffe.xml", "file_type": "json"}, "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51894276&newsitemid=20181106005644&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=5d2ce51607ac7d116a5f90f817e7137d", "https://www.businesswire.com/news/home/20181106005644/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51894276&newsitemid=20181106005644&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=738fefea6ae35c9b9fdbbc7e5b5e1365", "http://www.publicnow.com/view/9DCE7F700476336D5125B95D5B3D4C9F35BDA173", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1205586"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - Amendment | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "LNzHZbkE_QEqbVAFzAp3OQuiJyggjwjzi5n2iLLNIJtTKMVCfFqR374CaGW888eu", "result_metadata": {"score": 32.82607}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-06T23:57:36Z", "url": "https://www.businesswire.com/news/home/20181106005521/en/BARCLAYS-PLC-UK-Regulatory-Announcement-FORM-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T12:45:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADR Purchase", "relevance": 0.834819, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.744192, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.711044, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.57695, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.571928, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.551568, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542892, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.526724, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512814, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.469862, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453047, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,670,800 1.47%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,795,186 1.48%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,195,715 1.53%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,392,415 4.20%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,987,586 4.28%", "relevance": 0.453047, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453047, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,987,586 4.28% 33,392,415 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,392,415 4.20"}, {"type": "Quantity", "text": "33,987,586 4.28"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,670,800 1.47% 12,195,715 1.53% (2) Cash-settled derivatives: 11,795,186 1.48% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,987,586 4.28% 33,392,415 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658859 Time of Receipt (offset from UTC): 20181106T122047+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.977361, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.738909, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.695982, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.62005, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.50558, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.410458, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.404421, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378539, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.347738, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.33126, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.3292, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.32448, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.302358, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.295232, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.575465, "label": "/real estate/buying and selling homes"}, {"score": 0.465943, "label": "/finance/financial news"}, {"score": 0.458162, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "agentOf", "sentence": "Sale 2,800 4,576.7500 JPY Ordinary NPV Sale 2,800 4,572.1428 JPY Ordinary NPV Sale 2,900 4,570.3103 JPY Ordinary NPV Sale 5,400 4,560.9166 JPY Ordinary NPV Sale 7,700 4,558.8831 JPY Ordinary NPV Sale 10,000 4,540.0000 JPY Ordinary NPV Sale 11,300 4,552.2477 JPY Ordinary NPV Sale 12,800 4,570.9921 JPY Ordinary NPV Sale 44,900 4,555.1358 JPY Ordinary NPV Sale 82,500 4,561.5369 JPY Ordinary NPV Sale 181,500 4,566.0743 JPY Ordinary NPV Sale 223,000 4,557.8067 JPY Ordinary NPV Sale 227,700 4,557.4848 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 200 4,583.1150 JPY Ordinary NPV CFD Long 19,400 4,589.5410 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing,", "score": 0.682599, "arguments": [{"text": "i", "location": [5335, 5336], "entities": [{"type": "Person", "text": "JPY Ordinary NPV CFD"}]}, {"text": "Writing", "location": [5338, 5345], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6309, 6315], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6326, 6333], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7234, 7240], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7248, 7252], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7680, 7686], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7694, 7707], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7315, 7339], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7307, 7312], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9826, 9850], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9818, 9823], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7474, 7479], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7493, 7520], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9985, 9990], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10004, 10031], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7756, 7762], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7788, 7800], "entities": [{"type": "Organization", "text": "Barclays PLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9320, 9321], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9311, 9319], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658859 Time of Receipt (offset from UTC): 20181106T122047+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [10131, 10134], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10110, 10117], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.988856}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.804919}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.791308}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505846}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502481}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498715}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.495009}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.494495}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457871}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.444806}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417897}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412139}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388945}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371832}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.362448}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358828}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357454}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355775}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354882}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.354532}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354409}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353565}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351465}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35139}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341295}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340291}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.33553}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335027}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.334813}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334504}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334445}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334269}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333961}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.333759}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333589}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333109}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.333052}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33289}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332523}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331918}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331788}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331337}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331304}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.331259}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331046}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330602}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329724}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329576}, {"text": "derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.329022}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329022}]}, "extracted_metadata": {"sha1": "685941d216bf77f53f629749f4ccec7ff08d7006", "filename": "1541548656829.zip-9d805681861172ce542a2574047caaa2.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: FORM 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "IFAtXR2AdbnQ6oYEb5PQ2i7nTrcGfVtHLYkXo5SxOEPqpoVnkaGNCY0J_dF6Npq6", "result_metadata": {"score": 32.310246}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.6964, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.412502, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.901143}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587635}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506342}, {"text": "Amendment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302334}]}, "crawl_date": "2018-11-06T23:33:37Z", "url": "https://www.businesswire.com/news/home/20181106005644/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T15:31:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.744987, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.711742, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.577501, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.573505, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.552168, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542922, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.527647, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512909, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.470653, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453727, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,661,364 1.49%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,775,786 1.48%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,185,679 1.53%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,382,579 4.20%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,958,750 4.30%", "relevance": 0.453727, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453727, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,958,750 4.30% 33,382,579 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,382,579 4.20"}, {"type": "Quantity", "text": "33,958,750 4.30"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,661,364 1.49% 12,185,679 1.53% (2) Cash-settled derivatives: 11,775,786 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,958,750 4.30% 33,382,579 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658874 Time of Receipt (offset from UTC): 20181106T145802+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.98098, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.74085, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.701862, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.626964, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.508906, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.412258, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.410503, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.379862, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.35058, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.330487, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.327275, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.304616, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.301409, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Barclays", "relevance": 0.297231, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.58576, "label": "/real estate/buying and selling homes"}, {"score": 0.465078, "label": "/finance/financial news"}, {"score": 0.448545, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 3,200 4,593.4218 JPY Ordinary NPV Sale 5,000 4,618.5000 JPY Ordinary NPV Sale 5,800 4,591.7931 JPY Ordinary NPV Sale 7,300 4,620.4246 JPY Ordinary NPV Sale 7,800 4,617.1794 JPY Ordinary NPV Sale 9,100 4,623.8131 JPY Ordinary NPV Sale 19,500 4,627.0000 JPY Ordinary NPV Sale 35,000 TRANSFER Ordinary NPV Sale 87,500 4,612.3805 JPY Ordinary NPV Sale 112,200 4,600.9073 JPY Ordinary NPV Sale 405,900 4,599.9152 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 27,900 4,595.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5272, 5273], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5275, 5282], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6246, 6252], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6263, 6270], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 6 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7171, 7177], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7185, 7189], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7627, 7633], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7641, 7654], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7252, 7276], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7244, 7249], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9773, 9797], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9765, 9770], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7411, 7416], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7430, 7457], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9932, 9937], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9951, 9978], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7703, 7709], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7735, 7747], "entities": [{"type": "Organization", "text": "Contacts BARCLAYS PLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9267, 9268], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9258, 9266], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658874 Time of Receipt (offset from UTC): 20181106T145802+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10078, 10081], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10057, 10064], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.978727}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.834724}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.797513}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511214}, {"text": "TRANSFER Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509475}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505299}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503997}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.495317}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460313}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447296}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417929}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41231}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.362558}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35896}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357597}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355951}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355105}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354596}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.354499}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353712}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352618}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351713}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351465}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340278}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339665}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.335548}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335533}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335091}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.335007}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33453}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334487}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334325}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334031}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.333842}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333731}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333187}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.333041}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332946}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332597}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332055}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331959}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331483}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.331437}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331406}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331284}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33067}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329797}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329693}, {"text": "derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.329117}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329094}]}, "extracted_metadata": {"sha1": "32db89ef40bf07eb151034e5ebc4a6a5d8450fee", "filename": "1541547217550.zip-9c0707f8b81ccd52f4b2e40c078e1070.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - Amendment", "forum_title": "All News | Business Wire"}, {"id": "QIEQIgszx4jMSSZIvaLXci940NiOe6My0yAIrXnqaUkqsaz21fF83CocgXA1uhT2", "result_metadata": {"score": 32.22299}, "author": "TBD", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4 months", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": -0.364216, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Clinical response within 4 months", "keywords": [{"text": "Clinical response"}], "entities": [{"type": "Quantity", "text": "4 months"}]}, "sentence": "Clinical response within 4 months may predict sustained UC remission with Entyvio", "object": {"text": "sustained UC remission with Entyvio", "keywords": [{"text": "UC remission"}, {"text": "Entyvio"}]}, "action": {"verb": {"text": "predict", "tense": "future"}, "text": "predict", "normalized": "predict"}}], "concepts": [], "categories": [{"score": 0.553607, "label": "/health and fitness"}, {"score": 0.490823, "label": "/health and fitness/therapy"}, {"score": 0.455483, "label": "/health and fitness/disorders"}], "relations": [], "keywords": [{"text": "UC remission", "sentiment": {"score": -0.364216, "label": "negative"}, "relevance": 0.984195}, {"text": "Clinical response", "sentiment": {"score": -0.364217, "label": "negative"}, "relevance": 0.824888}, {"text": "Entyvio", "sentiment": {"score": -0.364217, "label": "negative"}, "relevance": 0.466837}]}, "crawl_date": "2018-11-06T20:26:08Z", "url": "https://www.healio.com/gastroenterology/inflammatory-bowel-disease/news/online/%7b91039d4d-ccce-41cd-af63-aca51d6d6794%7d/clinical-response-within-4-months-may-predict-sustained-uc-remission-with-entyvio", "host": "healio.com", "text": "Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, VHsquared Ltd, Warner Chilcott, Wyeth, Zealand, and Zyngenia.", "main_image_url": "https://www.healio.com/~/media/images/fscss/i3wyanokecdncom/healio_safe_image.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-06T20:05:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "UCB Pharma", "relevance": 0.796068, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Salix Pharma", "relevance": 0.730304, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Albireo Pharma", "relevance": 0.718604, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ferring Pharma", "relevance": 0.710072, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sigmoid Pharma", "relevance": 0.699155, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mesoblast Pharma", "relevance": 0.673091, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Avir Pharma", "relevance": 0.66246, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharma", "relevance": 0.655251, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.253478, "label": "positive"}, "text": "UC", "relevance": 0.653901, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Utica College", "dbpedia_resource": "http://dbpedia.org/resource/Utica_College"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ironwood Pharma", "relevance": 0.652287, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "gICare Pharma", "relevance": 0.647216, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vertex Pharma", "relevance": 0.64655, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.317531, "label": "positive"}, "text": "Synergy Pharma Inc.", "relevance": 0.644984, "type": "Company"}, {"count": 8, "sentiment": {"score": 0, "label": "neutral"}, "text": "Janssen Biotech", "relevance": 0.643883, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Robarts Clinical Trials Inc", "relevance": 0.594113, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brian G. Feagan", "relevance": 0.584137, "type": "Person"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.491261, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Robarts Research Institute", "relevance": 0.45927, "type": "Organization", "disambiguation": {"subtype": [], "name": "Robarts Research Institute", "dbpedia_resource": "http://dbpedia.org/resource/Robarts_Research_Institute"}}, {"count": 4, "sentiment": {"score": 0.300943, "label": "positive"}, "text": "Amgen", "relevance": 0.455247, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.451192, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 2, "sentiment": {"score": -0.595678, "label": "negative"}, "text": "ulcerative colitis", "relevance": 0.449191, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"count": 4, "sentiment": {"score": -0.595678, "label": "negative"}, "text": "Entyvio", "relevance": 0.438875, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kyowa Hakko Kirin Co Ltd", "relevance": 0.437249, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.427217, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lycera BioTech", "relevance": 0.415145, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.410896, "type": "Person"}, {"count": 2, "sentiment": {"score": 0.266659, "label": "positive"}, "text": "Calypso Biotech", "relevance": 0.402925, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prometheus Therapeutics and Diagnostics", "relevance": 0.402056, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": -0.710112, "label": "negative"}, "text": "Bowel Diseases", "relevance": 0.390392, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Feagan", "relevance": 0.389636, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alex Young", "relevance": 0.387508, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.387124, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tillotts", "relevance": 0.384925, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim", "relevance": 0.382794, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Western Ontario", "relevance": 0.379726, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Western Ontario", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Western_Ontario"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen Idec", "relevance": 0.378765, "type": "Company", "disambiguation": {"subtype": [], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.377563, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.400748, "label": "positive"}, "text": "Nestle", "relevance": 0.371778, "type": "Company", "disambiguation": {"subtype": ["CandyBarManufacturer"], "name": "Nestl\u00e9", "dbpedia_resource": "http://dbpedia.org/resource/Nestl\u00e9"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk", "relevance": 0.368628, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Warner Chilcott", "relevance": 0.359736, "type": "Company", "disambiguation": {"subtype": [], "name": "Warner Chilcott", "dbpedia_resource": "http://dbpedia.org/resource/Warner_Chilcott"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "consultant", "relevance": 0.358248, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wyeth", "relevance": 0.354467, "type": "Company", "disambiguation": {"subtype": [], "name": "Wyeth", "dbpedia_resource": "http://dbpedia.org/resource/Wyeth"}}, {"count": 2, "sentiment": {"score": 0.321242, "label": "positive"}, "text": "Lilly", "relevance": 0.35412, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zealand", "relevance": 0.352178, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zyngenia", "relevance": 0.349135, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Baxter Healthcare Corp.", "relevance": 0.347817, "type": "Company", "disambiguation": {"subtype": [], "name": "Baxter International", "dbpedia_resource": "http://dbpedia.org/resource/Baxter_International"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.344839, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.342958, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.338868, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TiGenix", "relevance": 0.336387, "type": "Company", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}], "sentiment": {"document": {"score": 0.0231151, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "ulcerative colitis", "keywords": [{"text": "ulcerative colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "object": {"text": "a full induction course of Entyvio", "keywords": [{"text": "induction course"}, {"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "clinical remission", "keywords": [{"text": "clinical remission"}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "action": {"verb": {"text": "achieve", "tense": "past"}, "text": "achieved", "normalized": "achieve"}}, {"subject": {"text": "clinical remission by week 14 of therapy", "keywords": [{"text": "clinical remission"}, {"text": "therapy"}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "object": {"text": "a better chance of experiencing sustained remission", "keywords": [{"text": "better chance"}, {"text": "remission"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy", "keywords": [{"text": "ulcerative colitis"}, {"text": "clinical remission"}, {"text": "induction course"}, {"text": "Patients"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "object": {"text": "sustained remission", "keywords": [{"text": "remission"}]}, "action": {"verb": {"text": "experience", "tense": "future"}, "text": "experiencing", "normalized": "experience"}}, {"subject": {"text": "research", "keywords": [{"text": "research"}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues", "keywords": [{"text": "Robarts Research Institute"}, {"text": "Brian G. Feagan"}, {"text": "Western Ontario"}, {"text": "colleagues"}], "entities": [{"type": "Person", "text": "Brian G. Feagan"}, {"type": "Organization", "text": "Robarts Research Institute", "disambiguation": {"subtype": [], "name": "Robarts Research Institute", "dbpedia_resource": "http://dbpedia.org/resource/Robarts_Research_Institute"}}, {"type": "Organization", "text": "University of Western Ontario", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Western Ontario", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Western_Ontario"}}]}, "sentence": " Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "object": {"text": "while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission", "keywords": [{"text": "anti-TNF agents"}, {"text": "Takeda"}, {"text": "remission"}, {"text": "UC"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}, {"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "UC", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Utica College", "dbpedia_resource": "http://dbpedia.org/resource/Utica_College"}}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "anti-TNF agents", "keywords": [{"text": "anti-TNF agents"}]}, "sentence": " Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "object": {"text": "remission", "keywords": [{"text": "remission"}]}, "action": {"verb": {"text": "sustain", "tense": "future"}, "text": "to sustain", "normalized": "to sustain"}}, {"subject": {"text": "UC", "keywords": [{"text": "UC"}]}, "sentence": " \u201cAn unmet need in managing moderate-to-severe UC is sustaining clinical remission,\u201d they wrote.", "object": {"text": "moderate-to-severe"}, "action": {"verb": {"text": "manage", "tense": "present"}, "text": "managing", "normalized": "manage"}}, {"subject": {"text": "An unmet need in managing moderate-to-severe UC", "keywords": [{"text": "moderate-to-severe UC"}, {"text": "unmet need"}]}, "sentence": " \u201cAn unmet need in managing moderate-to-severe UC is sustaining clinical remission,\u201d they wrote.", "object": {"text": "sustaining clinical remission", "keywords": [{"text": "clinical remission"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "An unmet need in managing moderate-to-severe UC", "keywords": [{"text": "moderate-to-severe UC"}, {"text": "unmet need"}]}, "sentence": " \u201cAn unmet need in managing moderate-to-severe UC is sustaining clinical remission,\u201d they wrote.", "object": {"text": "clinical remission", "keywords": [{"text": "clinical remission"}]}, "action": {"verb": {"text": "sustain", "tense": "present"}, "text": "is sustaining", "normalized": "be sustain"}}, {"subject": {"text": "they"}, "sentence": " \u201cAn unmet need in managing moderate-to-severe UC is sustaining clinical remission,\u201d they wrote.", "object": {"text": "An unmet need in managing moderate-to-severe UC is sustaining clinical remission", "keywords": [{"text": "moderate-to-severe UC"}, {"text": "unmet need"}, {"text": "clinical remission"}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "Patients", "keywords": [{"text": "Patients"}]}, "sentence": " \u201cPatients who achieve this outcome should benefit from improved [quality of life], reduced exposure to corticosteroids , and decreased risk of disease-related complications.\u201d", "object": {"text": "this outcome", "keywords": [{"text": "outcome"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieve", "normalized": "achieve"}}, {"subject": {"text": "Patients who achieve this outcome should benefit", "keywords": [{"text": "outcome"}, {"text": "Patients"}]}, "sentence": " \u201cPatients who achieve this outcome should benefit from improved [quality of life], reduced exposure to corticosteroids , and decreased risk of disease-related complications.\u201d", "object": {"text": "exposure", "keywords": [{"text": "exposure"}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " In a post hoc exploratory analysis of patients with UC in the GEMINI 1 study, researchers assessed the long-term efficacy of vedolizumab in a set of patients who were in clinical remission by week 14 after three induction doses at weeks 0, 2 and 6.", "object": {"text": "the long-term efficacy of vedolizumab", "keywords": [{"text": "long-term efficacy"}, {"text": "vedolizumab"}]}, "action": {"verb": {"text": "assess", "tense": "past"}, "text": "assessed", "normalized": "assess"}}, {"subject": {"text": "They"}, "sentence": " They evaluated clinical remission using two measures; a partial Mayo Score (pMS) of at least 2 with no subscore greater than 1, and a rectal bleeding subscore (RBS) of 0 throughout weeks 14, 26, 38 and 52.", "object": {"text": "clinical remission", "keywords": [{"text": "clinical remission"}]}, "action": {"verb": {"text": "evaluate", "tense": "past"}, "text": "evaluated", "normalized": "evaluate"}}, {"subject": {"text": "They"}, "sentence": " They evaluated clinical remission using two measures; a partial Mayo Score (pMS) of at least 2 with no subscore greater than 1, and a rectal bleeding subscore (RBS) of 0 throughout weeks 14, 26, 38 and 52.", "object": {"text": "two measures", "keywords": [{"text": "measures"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "620 patients prescribed vedolizumab and 149 patients prescribed placebo", "keywords": [{"text": "patients"}, {"text": "placebo"}, {"text": "vedolizumab"}]}, "sentence": " The analysis included 620 patients prescribed vedolizumab and 149 patients prescribed placebo.", "object": {"text": "The analysis", "keywords": [{"text": "analysis"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "included", "normalized": "include"}}, {"subject": {"text": "620 patients", "keywords": [{"text": "patients"}]}, "sentence": " The analysis included 620 patients prescribed vedolizumab and 149 patients prescribed placebo.", "object": {"text": "vedolizumab", "keywords": [{"text": "vedolizumab"}]}, "action": {"verb": {"text": "prescribe", "tense": "past"}, "text": "prescribed", "normalized": "prescribe"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " A higher percentage of patients who received vedolizumab achieved remission at week 14 compared with patients who received placebo in terms of both pMS (32.7% vs.", "object": {"text": "vedolizumab achieved remission", "keywords": [{"text": "remission"}, {"text": "vedolizumab"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "A higher percentage of patients who received vedolizumab", "keywords": [{"text": "higher percentage"}, {"text": "patients"}, {"text": "vedolizumab"}]}, "sentence": " A higher percentage of patients who received vedolizumab achieved remission at week 14 compared with patients who received placebo in terms of both pMS (32.7% vs.", "object": {"text": "remission", "keywords": [{"text": "remission"}]}, "action": {"verb": {"text": "achieve", "tense": "past"}, "text": "achieved", "normalized": "achieve"}}, {"subject": {"text": "A higher percentage of patients who received vedolizumab achieved remission at week 14", "keywords": [{"text": "higher percentage"}, {"text": "remission"}, {"text": "patients"}, {"text": "vedolizumab"}]}, "sentence": " A higher percentage of patients who received vedolizumab achieved remission at week 14 compared with patients who received placebo in terms of both pMS (32.7% vs.", "object": {"text": "with patients who received placebo in terms of both pMS (32.7% vs", "keywords": [{"text": "placebo"}, {"text": "pMS"}, {"text": "vs"}, {"text": "patients"}], "entities": [{"type": "Quantity", "text": "32.7"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " A higher percentage of patients who received vedolizumab achieved remission at week 14 compared with patients who received placebo in terms of both pMS (32.7% vs.", "object": {"text": "placebo", "keywords": [{"text": "placebo"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "a higher percentage of vedolizumab patients", "keywords": [{"text": "higher percentage"}, {"text": "vedolizumab patients"}]}, "sentence": " Of the patients in remission at week 14, a higher percentage of vedolizumab patients sustained remission compared with placebo (pMS, 66.5% vs.", "object": {"text": "remission", "keywords": [{"text": "remission"}]}, "action": {"verb": {"text": "sustain", "tense": "past"}, "text": "sustained", "normalized": "sustain"}}, {"subject": {"text": "a higher percentage of vedolizumab patients sustained remission", "keywords": [{"text": "higher percentage"}, {"text": "remission"}, {"text": "vedolizumab patients"}]}, "sentence": " Of the patients in remission at week 14, a higher percentage of vedolizumab patients sustained remission compared with placebo (pMS, 66.5% vs.", "object": {"text": "with placebo (pMS, 66.5% vs", "keywords": [{"text": "vs"}], "entities": [{"type": "Quantity", "text": "66.5"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "the findings", "keywords": [{"text": "findings"}]}, "sentence": " Additionally, the findings were consistent whether the patients were anti-TNF naive or if they previously failed anti-TNF therapy.", "object": {"text": "consistent whether the patients were anti-TNF naive or if they previously failed anti-TNF therapy", "keywords": [{"text": "anti-TNF therapy"}, {"text": "patients"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Feagan and colleagues", "keywords": [{"text": "colleagues"}, {"text": "Feagan"}], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, "sentence": " Feagan and colleagues wrote that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab.", "object": {"text": "that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab", "keywords": [{"text": "sustained remission"}, {"text": "clinical remission"}, {"text": "predictor"}, {"text": "findings"}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "their findings show", "keywords": [{"text": "findings"}]}, "sentence": " Feagan and colleagues wrote that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab.", "object": {"text": "a predictor", "keywords": [{"text": "predictor"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "could be", "normalized": "could be"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " \u201cThese findings support the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label,\u201d they wrote.", "object": {"text": "the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label", "keywords": [{"text": "standard 3-dose induction"}, {"text": "final decision"}, {"text": "clinical benefit"}, {"text": "U.S. label"}], "entities": [{"type": "Organization", "text": "EU"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "the full standard 3-dose induction course of vedolizumab", "keywords": [{"text": "standard 3-dose induction"}]}, "sentence": " \u201cThese findings support the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label,\u201d they wrote.", "action": {"verb": {"text": "complete", "tense": "future"}, "text": "must be completed", "normalized": "must be complete"}}, {"subject": {"text": "a final decision on clinical benefit", "keywords": [{"text": "final decision"}, {"text": "clinical benefit"}]}, "sentence": " \u201cThese findings support the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label,\u201d they wrote.", "object": {"text": "10 or 14, dependent on EU or U.S. label", "keywords": [{"text": "U.S. label"}, {"text": "EU"}], "entities": [{"type": "Organization", "text": "EU"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "assess", "tense": "past"}, "text": "is assessed", "normalized": "be assess"}}, {"subject": {"text": "they"}, "sentence": " \u201cThese findings support the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label,\u201d they wrote.", "object": {"text": "the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label", "keywords": [{"text": "standard 3-dose induction"}, {"text": "final decision"}, {"text": "clinical benefit"}, {"text": "U.S. label"}], "entities": [{"type": "Organization", "text": "EU"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "These data", "keywords": [{"text": "data"}]}, "sentence": " \u201cThese data also provide strong evidence for the long-term benefit conferred by vedolizumab on sustained clinical remission in patients with moderate-to-severe UC, independent of prior TNF antagonist treatment history.\u201d\u2013 by Alex Young", "object": {"text": "strong evidence for the long-term benefit conferred by vedolizumab on sustained clinical remission in patients with moderate-to-severe UC", "keywords": [{"text": "sustained clinical remission"}, {"text": "moderate-to-severe UC"}, {"text": "long-term benefit"}, {"text": "strong evidence"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "by vedolizumab on sustained clinical remission in patients with moderate-to-severe UC", "keywords": [{"text": "sustained clinical remission"}, {"text": "moderate-to-severe UC"}, {"text": "vedolizumab"}, {"text": "patients"}]}, "sentence": " \u201cThese data also provide strong evidence for the long-term benefit conferred by vedolizumab on sustained clinical remission in patients with moderate-to-severe UC, independent of prior TNF antagonist treatment history.\u201d\u2013 by Alex Young", "object": {"text": "the long-term benefit", "keywords": [{"text": "long-term benefit"}]}, "action": {"verb": {"text": "confer", "tense": "past"}, "text": "conferred", "normalized": "confer"}}, {"subject": {"text": "He"}, "sentence": " He has received grant and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, and UCB Pharma.", "object": {"text": "received grant and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "Janssen Biotech"}, {"text": "research support"}, {"text": "Centocor"}], "entities": [{"type": "Company", "text": "Amgen", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Janssen Biotech", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"type": "Company", "text": "Janssen Biotech", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He"}, "sentence": " He has received grant and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, and UCB Pharma.", "object": {"text": "grant and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, and UCB Pharma", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "UCB Pharma"}, {"text": "Janssen Biotech"}, {"text": "research support"}], "entities": [{"type": "Company", "text": "Amgen", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Janssen Biotech", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"type": "Company", "text": "Janssen Biotech", "disambiguation": {"subtype": [], "name": "Janssen Biotech", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Biotech"}}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Tillotts"}, {"type": "Company", "text": "UCB Pharma"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "has received", "normalized": "have receive"}}, {"subject": {"text": "ulcerative colitis", "keywords": [{"text": "ulcerative colitis"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "object": {"text": "a full induction course of Entyvio", "keywords": [{"text": "induction course"}, {"text": "Entyvio"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "clinical remission", "keywords": [{"text": "clinical remission"}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "action": {"verb": {"text": "achieve", "tense": "past"}, "text": "achieved", "normalized": "achieve"}}, {"subject": {"text": "clinical remission by week 14 of therapy", "keywords": [{"text": "clinical remission"}, {"text": "therapy"}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "object": {"text": "a better chance of experiencing sustained remission", "keywords": [{"text": "better chance"}, {"text": "remission"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy", "keywords": [{"text": "ulcerative colitis"}, {"text": "clinical remission"}, {"text": "induction course"}, {"text": "Patients"}], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Ulcerative colitis", "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}}, {"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "object": {"text": "sustained remission", "keywords": [{"text": "remission"}]}, "action": {"verb": {"text": "experience", "tense": "future"}, "text": "experiencing", "normalized": "experience"}}, {"subject": {"text": "research", "keywords": [{"text": "research"}]}, "sentence": " Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues", "keywords": [{"text": "Robarts Research Institute"}, {"text": "Brian G. Feagan"}, {"text": "Western Ontario"}, {"text": "colleagues"}], "entities": [{"type": "Person", "text": "Brian G. Feagan"}, {"type": "Organization", "text": "Robarts Research Institute", "disambiguation": {"subtype": [], "name": "Robarts Research Institute", "dbpedia_resource": "http://dbpedia.org/resource/Robarts_Research_Institute"}}, {"type": "Organization", "text": "University of Western Ontario", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Western Ontario", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Western_Ontario"}}]}, "sentence": " Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "object": {"text": "while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission", "keywords": [{"text": "anti-TNF agents"}, {"text": "Takeda"}, {"text": "remission"}, {"text": "UC"}], "entities": [{"type": "Location", "text": "Entyvio", "disambiguation": {"subtype": ["City"]}}, {"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "UC", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Utica College", "dbpedia_resource": "http://dbpedia.org/resource/Utica_College"}}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "anti-TNF agents", "keywords": [{"text": "anti-TNF agents"}]}, "sentence": " Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "object": {"text": "remission", "keywords": [{"text": "remission"}]}, "action": {"verb": {"text": "sustain", "tense": "future"}, "text": "to sustain", "normalized": "to sustain"}}, {"subject": {"text": "UC", "keywords": [{"text": "UC"}]}, "sentence": " \u201cAn unmet need in managing moderate-to-severe UC is sustaining clinical remission,\u201d they wrote.", "object": {"text": "moderate-to-severe"}, "action": {"verb": {"text": "manage", "tense": "present"}, "text": "managing", "normalized": "manage"}}, {"subject": {"text": "they"}, "sentence": " \u201cAn unmet need in managing moderate-to-severe UC is sustaining clinical remission,\u201d they wrote.", "object": {"text": "An unmet need in managing moderate-to-severe UC is sustaining clinical remission", "keywords": [{"text": "moderate-to-severe UC"}, {"text": "unmet need"}, {"text": "clinical remission"}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "Patients", "keywords": [{"text": "Patients"}]}, "sentence": " \u201cPatients who achieve this outcome should benefit from improved [quality of life], reduced exposure to corticosteroids , and decreased risk of disease-related complications.\u201d", "object": {"text": "this outcome", "keywords": [{"text": "outcome"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieve", "normalized": "achieve"}}, {"subject": {"text": "Patients who achieve this outcome should benefit", "keywords": [{"text": "outcome"}, {"text": "Patients"}]}, "sentence": " \u201cPatients who achieve this outcome should benefit from improved [quality of life], reduced exposure to corticosteroids , and decreased risk of disease-related complications.\u201d", "object": {"text": "exposure", "keywords": [{"text": "exposure"}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " In a post hoc exploratory analysis of patients with UC in the GEMINI 1 study, researchers assessed the long-term efficacy of vedolizumab in a set of patients who were in clinical remission by week 14 after three induction doses at weeks 0, 2 and 6.", "object": {"text": "the long-term efficacy of vedolizumab", "keywords": [{"text": "long-term efficacy"}, {"text": "vedolizumab"}]}, "action": {"verb": {"text": "assess", "tense": "past"}, "text": "assessed", "normalized": "assess"}}, {"subject": {"text": "They"}, "sentence": " They evaluated clinical remission using two measures; a partial Mayo Score (pMS) of at least 2 with no subscore greater than 1, and a rectal bleeding subscore (RBS) of 0 throughout weeks 14, 26, 38 and 52.", "object": {"text": "clinical remission", "keywords": [{"text": "clinical remission"}]}, "action": {"verb": {"text": "evaluate", "tense": "past"}, "text": "evaluated", "normalized": "evaluate"}}, {"subject": {"text": "They"}, "sentence": " They evaluated clinical remission using two measures; a partial Mayo Score (pMS) of at least 2 with no subscore greater than 1, and a rectal bleeding subscore (RBS) of 0 throughout weeks 14, 26, 38 and 52.", "object": {"text": "two measures", "keywords": [{"text": "measures"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "620 patients prescribed vedolizumab and 149 patients prescribed placebo", "keywords": [{"text": "patients"}, {"text": "placebo"}, {"text": "vedolizumab"}]}, "sentence": " The analysis included 620 patients prescribed vedolizumab and 149 patients prescribed placebo.", "object": {"text": "The analysis", "keywords": [{"text": "analysis"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "included", "normalized": "include"}}], "concepts": [{"text": "Ulcerative colitis", "relevance": 0.961999, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Pharmaceutical industry", "relevance": 0.685763, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Inflammatory bowel disease", "relevance": 0.680988, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Bristol-Myers Squibb", "relevance": 0.642274, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.620865, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Etanercept", "relevance": 0.616935, "dbpedia_resource": "http://dbpedia.org/resource/Etanercept"}, {"text": "Clopidogrel", "relevance": 0.605751, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "The Canon of Medicine", "relevance": 0.539565, "dbpedia_resource": "http://dbpedia.org/resource/The_Canon_of_Medicine"}, {"text": "Pharmacology", "relevance": 0.537183, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Clinical trial", "relevance": 0.529906, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Biogen Idec", "relevance": 0.509781, "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}, {"text": "Medicine", "relevance": 0.489542, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Saxagliptin", "relevance": 0.48, "dbpedia_resource": "http://dbpedia.org/resource/Saxagliptin"}, {"text": "Biotechnology companies", "relevance": 0.476694, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Placebo", "relevance": 0.475445, "dbpedia_resource": "http://dbpedia.org/resource/Placebo"}, {"text": "Crohn's disease", "relevance": 0.468295, "dbpedia_resource": "http://dbpedia.org/resource/Crohn's_disease"}, {"text": "Paclitaxel", "relevance": 0.468181, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Novo Nordisk", "relevance": 0.461193, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}, {"text": "Nocebo", "relevance": 0.456125, "dbpedia_resource": "http://dbpedia.org/resource/Nocebo"}, {"text": "Boehringer Ingelheim", "relevance": 0.455963, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Irbesartan", "relevance": 0.44892, "dbpedia_resource": "http://dbpedia.org/resource/Irbesartan"}, {"text": "Sustain", "relevance": 0.438551, "dbpedia_resource": "http://dbpedia.org/resource/Sustain"}, {"text": "Robarts Research Institute", "relevance": 0.428426, "dbpedia_resource": "http://dbpedia.org/resource/Robarts_Research_Institute"}, {"text": "Certolizumab pegol", "relevance": 0.425389, "dbpedia_resource": "http://dbpedia.org/resource/Certolizumab_pegol"}, {"text": "Dapagliflozin", "relevance": 0.422802, "dbpedia_resource": "http://dbpedia.org/resource/Dapagliflozin"}, {"text": "Clinical research", "relevance": 0.418168, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "TNF inhibitor", "relevance": 0.41693, "dbpedia_resource": "http://dbpedia.org/resource/TNF_inhibitor"}, {"text": "Biotechnology", "relevance": 0.415761, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Medarex", "relevance": 0.412263, "dbpedia_resource": "http://dbpedia.org/resource/Medarex"}, {"text": "John Robarts", "relevance": 0.409106, "dbpedia_resource": "http://dbpedia.org/resource/John_Robarts"}], "categories": [{"score": 0.753615, "label": "/health and fitness/therapy"}, {"score": 0.374478, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.353216, "label": "/health and fitness/disease"}], "relations": [{"type": "hasAttribute", "sentence": "November 6, Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "score": 0.608347, "arguments": [{"text": "Patients", "location": [12, 20], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "ulcerative colitis", "location": [26, 44], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "November 6, Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "score": 0.4219, "arguments": [{"text": "who", "location": [45, 48], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "ulcerative colitis", "location": [26, 44], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "score": 0.480499, "arguments": [{"text": "Patients", "location": [3827, 3835], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "ulcerative colitis", "location": [3841, 3859], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "score": 0.4219, "arguments": [{"text": "who", "location": [3860, 3863], "entities": [{"type": "Person", "text": "Patients"}]}, {"text": "ulcerative colitis", "location": [3841, 3859], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "agentOf", "sentence": "Feagan and colleagues wrote that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab.", "score": 0.934352, "arguments": [{"text": "colleagues", "location": [1990, 2000], "entities": [{"type": "Person", "text": "colleagues"}]}, {"text": "wrote", "location": [2001, 2006], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "\"These findings support the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label,\" they wrote.", "score": 0.992705, "arguments": [{"text": "they", "location": [2352, 2356], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "wrote", "location": [2357, 2362], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "\"- by Alex Young Disclosures : Feagan reports that the is a consultant for Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda,", "score": 0.997761, "arguments": [{"text": "Feagan", "location": [2613, 2619], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, {"text": "reports", "location": [2620, 2627], "entities": [{"type": "EventCommunication", "text": "reports"}]}]}, {"type": "employedBy", "sentence": "\"- by Alex Young Disclosures : Feagan reports that the is a consultant for Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda,", "score": 0.753361, "arguments": [{"text": "Janssen Biotech", "location": [2996, 3011], "entities": [{"type": "Person", "text": "Janssen Biotech"}]}, {"text": "Centocor", "location": [3013, 3021], "entities": [{"type": "Organization", "text": "Centocor", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has received grant and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, and UCB Pharma.", "score": 0.791535, "arguments": [{"text": "Janssen Biotech", "location": [3544, 3559], "entities": [{"type": "Person", "text": "Janssen Biotech"}]}, {"text": "Centocor", "location": [3561, 3569], "entities": [{"type": "Organization", "text": "Centocor", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "\"- by Alex Young Disclosures : Feagan reports that the is a consultant for Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda,", "score": 0.753361, "arguments": [{"text": "Janssen Biotech", "location": [6811, 6826], "entities": [{"type": "Person", "text": "Janssen Biotech"}]}, {"text": "Centocor", "location": [6828, 6836], "entities": [{"type": "Organization", "text": "Centocor", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has received grant and research support from Abbott/AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, and UCB Pharma.", "score": 0.791535, "arguments": [{"text": "Janssen Biotech", "location": [7359, 7374], "entities": [{"type": "Person", "text": "Janssen Biotech"}]}, {"text": "Centocor", "location": [7376, 7384], "entities": [{"type": "Organization", "text": "Centocor", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "\"- by Alex Young Disclosures : Feagan reports that the is a consultant for Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda,", "score": 0.529602, "arguments": [{"text": "JnJ/Janssen", "location": [3024, 3035], "entities": [{"type": "Person", "text": "JnJ/Janssen"}]}, {"text": "Kyowa Hakko Kirin Co Ltd", "location": [3037, 3061], "entities": [{"type": "Organization", "text": "Kyowa Hakko Kirin Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "\"- by Alex Young Disclosures : Feagan reports that the is a consultant for Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda,", "score": 0.529602, "arguments": [{"text": "JnJ/Janssen", "location": [6839, 6850], "entities": [{"type": "Person", "text": "JnJ/Janssen"}]}, {"text": "Kyowa Hakko Kirin Co Ltd", "location": [6852, 6876], "entities": [{"type": "Organization", "text": "Kyowa Hakko Kirin Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "memberOf", "sentence": "He is also on the board of directors for Robarts Clinical Trials Inc. Please see the full study for all other authors' relevant financial disclosures.", "score": 0.742588, "arguments": [{"text": "directors", "location": [3703, 3712], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [3694, 3699], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "memberOf", "sentence": "He is also on the board of directors for Robarts Clinical Trials Inc. Please see the full study for all other authors' relevant financial disclosures.", "score": 0.742588, "arguments": [{"text": "directors", "location": [7518, 7527], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [7509, 7514], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "agentOf", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.994096, "arguments": [{"text": "colleagues", "location": [4182, 4192], "entities": [{"type": "Person", "text": "colleagues"}]}, {"text": "wrote", "location": [4193, 4198], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "\"An unmet need in managing moderate-to-severe UC is sustaining clinical remission,\" they wrote.", "score": 0.992705, "arguments": [{"text": "they", "location": [4445, 4449], "entities": [{"type": "Person", "text": "agents"}]}, {"text": "wrote", "location": [4450, 4455], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "partOfMany", "sentence": "A higher percentage of patients who received vedolizumab achieved remission at week 14 compared with patients who received placebo in terms of both pMS (32.7% vs. 20.1%; difference 12.6%; 95% CI, 5.2-20] and RBS (47.3% vs. 28.9%;18.4%; 95% CI, 10.1-26.7).", "score": 0.567959, "arguments": [{"text": "patients", "location": [5283, 5291], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "who", "location": [5214, 5217], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "partOfMany", "sentence": "Of the patients in remission at week 14, a higher percentage of vedolizumab patients sustained remission compared with placebo (pMS, 66.5% vs. 26.7%; 39.8%; 95% CI, 22.7-56.9; RBS, 56.7% vs. 20.9%; 35.7%; 95% CI, 22.3-49.1).", "score": 0.445182, "arguments": [{"text": "patients", "location": [5445, 5453], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "patients", "location": [5514, 5522], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "hasAttribute", "sentence": "November 6, Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "score": 0.731512, "arguments": [{"text": "Entyvio", "location": [85, 92], "entities": [{"type": "Person", "text": "Entyvio"}]}, {"text": "ulcerative colitis", "location": [26, 44], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "hasAttribute", "sentence": "Patients with ulcerative colitis who received a full induction course of Entyvio and achieved clinical remission by week 14 of therapy had a better chance of experiencing sustained remission, according to research published in Inflammatory Bowel Diseases .", "score": 0.731512, "arguments": [{"text": "Entyvio", "location": [3900, 3907], "entities": [{"type": "Person", "text": "Entyvio"}]}, {"text": "ulcerative colitis", "location": [3841, 3859], "entities": [{"type": "HealthCondition", "text": "ulcerative colitis"}]}]}, {"type": "agentOf", "sentence": "Feagan and colleagues wrote that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab.", "score": 0.590325, "arguments": [{"text": "Feagan", "location": [5794, 5800], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, {"text": "wrote", "location": [5816, 5821], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "Feagan and colleagues wrote that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab.", "score": 0.934352, "arguments": [{"text": "colleagues", "location": [5805, 5815], "entities": [{"type": "Person", "text": "colleagues"}]}, {"text": "wrote", "location": [5816, 5821], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "\"These findings support the guidance that the full standard 3-dose induction course of vedolizumab must be completed before a final decision on clinical benefit is assessed at week 10 or 14, dependent on EU or U.S. label,\" they wrote.", "score": 0.992705, "arguments": [{"text": "they", "location": [6167, 6171], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "wrote", "location": [6172, 6177], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "\"- by Alex Young Disclosures : Feagan reports that the is a consultant for Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, AstraZeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda,", "score": 0.997761, "arguments": [{"text": "Feagan", "location": [6428, 6434], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, {"text": "reports", "location": [6435, 6442], "entities": [{"type": "EventCommunication", "text": "reports"}]}]}, {"type": "educatedAt", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.253327, "arguments": [{"text": "MD", "location": [287, 289], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, {"text": "Robarts Research Institute", "location": [298, 324], "entities": [{"type": "Organization", "text": "Robarts Research Institute"}]}]}, {"type": "educatedAt", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.253327, "arguments": [{"text": "MD", "location": [4102, 4104], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, {"text": "Robarts Research Institute", "location": [4113, 4139], "entities": [{"type": "Organization", "text": "Robarts Research Institute"}]}]}, {"type": "partOf", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.795772, "arguments": [{"text": "Robarts Research Institute", "location": [298, 324], "entities": [{"type": "Organization", "text": "Robarts Research Institute"}]}, {"text": "University of Western Ontario", "location": [332, 361], "entities": [{"type": "Organization", "text": "University of Western Ontario"}]}]}, {"type": "partOf", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.795772, "arguments": [{"text": "Robarts Research Institute", "location": [4113, 4139], "entities": [{"type": "Organization", "text": "Robarts Research Institute"}]}, {"text": "University of Western Ontario", "location": [4147, 4176], "entities": [{"type": "Organization", "text": "University of Western Ontario"}]}]}, {"type": "agentOf", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.994096, "arguments": [{"text": "colleagues", "location": [367, 377], "entities": [{"type": "Person", "text": "colleagues"}]}, {"text": "wrote", "location": [378, 383], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "partOfMany", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.742757, "arguments": [{"text": "Entyvio", "location": [417, 424], "entities": [{"type": "Person", "text": "Entyvio"}]}, {"text": "agents", "location": [404, 410], "entities": [{"type": "Person", "text": "agents"}]}]}, {"type": "partOfMany", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.742757, "arguments": [{"text": "Entyvio", "location": [4232, 4239], "entities": [{"type": "Person", "text": "Entyvio"}]}, {"text": "agents", "location": [4219, 4225], "entities": [{"type": "Person", "text": "agents"}]}]}, {"type": "partOfMany", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.75631, "arguments": [{"text": "Takeda", "location": [439, 445], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "agents", "location": [404, 410], "entities": [{"type": "Person", "text": "agents"}]}]}, {"type": "partOfMany", "sentence": "Brian G. Feagan , MD, of the Robarts Research Institute at the University of Western Ontario, and colleagues wrote that while anti-TNF agents, like Entyvio (vedolizumab, Takeda), have improved the management of UC, data on their ability to sustain remission have been lacking.", "score": 0.75631, "arguments": [{"text": "Takeda", "location": [4254, 4260], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "agents", "location": [4219, 4225], "entities": [{"type": "Person", "text": "agents"}]}]}, {"type": "agentOf", "sentence": "\"An unmet need in managing moderate-to-severe UC is sustaining clinical remission,\" they wrote.", "score": 0.992705, "arguments": [{"text": "they", "location": [630, 634], "entities": [{"type": "Person", "text": "agents"}]}, {"text": "wrote", "location": [635, 640], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "agentOf", "sentence": "Feagan and colleagues wrote that their findings show the clinical remission at week 14 could be a predictor for sustained remission with vedolizumab.", "score": 0.590325, "arguments": [{"text": "Feagan", "location": [1979, 1985], "entities": [{"type": "Person", "text": "Brian G. Feagan"}]}, {"text": "wrote", "location": [2001, 2006], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}], "keywords": [{"text": "clinical remission", "sentiment": {"score": -0.543478, "label": "negative"}, "relevance": 0.909781}, {"text": "patients", "sentiment": {"score": 0.233998, "label": "positive"}, "relevance": 0.555418}, {"text": "Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.447179}, {"text": "sustained clinical remission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438156}, {"text": "vedolizumab", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413536}, {"text": "Synergy Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411873}, {"text": "UCB Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.401017}, {"text": "moderate-to-severe UC", "sentiment": {"score": -0.491278, "label": "negative"}, "relevance": 0.388786}, {"text": "induction course", "sentiment": {"score": -0.595678, "label": "negative"}, "relevance": 0.372896}, {"text": "higher percentage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348739}, {"text": "Robarts Research Institute", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34566}, {"text": "Inflammatory Bowel Diseases", "sentiment": {"score": -0.710112, "label": "negative"}, "relevance": 0.342895}, {"text": "sustained remission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338234}, {"text": "Bristol-Myers Squibb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338159}, {"text": "Brian G. Feagan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335608}, {"text": "Kyowa Hakko Kirin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333067}, {"text": "TNF antagonist treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332182}, {"text": "prior TNF antagonist", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32981}, {"text": "Albireo Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329093}, {"text": "Avir Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328863}, {"text": "hoc exploratory analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328356}, {"text": "antagonist treatment history.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327522}, {"text": "rectal bleeding subscore", "sentiment": {"score": -0.542777, "label": "negative"}, "relevance": 0.326469}, {"text": "partial Mayo Score", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32615}, {"text": "Teva Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325095}, {"text": "Ferring Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325089}, {"text": "Robarts Clinical Trials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32408}, {"text": "Ironwood Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.323773}, {"text": "gICare Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.322665}, {"text": "Baxter Healthcare Corp.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32233}, {"text": "Mesoblast Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321907}, {"text": "Salix Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321612}, {"text": "Sigmoid Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321252}, {"text": "Vertex Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.320808}, {"text": "relevant financial disclosures", "sentiment": {"score": 0.692344, "label": "positive"}, "relevance": 0.320565}, {"text": "Janssen Biotech", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.319472}, {"text": "standard 3-dose induction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318286}, {"text": "Avaxia Biologics Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318215}, {"text": "Given Imaging Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315733}, {"text": "3-dose induction course", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.312917}, {"text": "anti-TNF agents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254499}, {"text": "anti-TNF therapy", "sentiment": {"score": -0.503598, "label": "negative"}, "relevance": 0.237977}, {"text": "unmet need", "sentiment": {"score": -0.491278, "label": "negative"}, "relevance": 0.23716}, {"text": "ulcerative colitis", "sentiment": {"score": -0.595678, "label": "negative"}, "relevance": 0.236652}, {"text": "Western Ontario", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234549}, {"text": "disease-related complications", "sentiment": {"score": -0.608386, "label": "negative"}, "relevance": 0.233836}, {"text": "Boehringer Ingelheim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233789}, {"text": "better chance", "sentiment": {"score": -0.595678, "label": "negative"}, "relevance": 0.232603}, {"text": "Biogen Idec", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231968}]}, "extracted_metadata": {"sha1": "54ee17b54caed4202ddcb062d605c81606caf907", "filename": "1541535968527.zip-9fe0b086ba6ef4b6e7a79a457f232ccc.xml", "file_type": "json"}, "title": "Clinical response within 4 months may predict sustained UC remission with Entyvio", "forum_title": "Gastroenterology News"}]}